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Abstract 
 Cells process a wide range of signals by means of multi-component 
receptors that span the plasma membrane. Our knowledge about the individual 
proteins involved in these signaling cascades has grown considerably over 
recent years. However, critical information about the detailed mechanisms of 
receptor activation, and the quantitative relationships between stimulus and 
biological response, is still missing.  
Here, I used the RET receptor tyrosine kinase (RTK), together with its 
glycosylphosphatidylinositol-coupled co-receptor GFRα3 and their activating 
growth factor artemin (ART), as a model system to investigate the quantitative 
and mechanistic features of receptor activation and signaling. I used a set of anti-
RET agonist antibodies to induce different extents of receptor clustering on the 
cell surface, and studied how this factor affects the amplitude and kinetics of 
membrane-proximal and downstream signaling events, as well as the biological 
response of neurite outgrowth. Using simulations of the RET-GFRα3-ART 
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system, I studied the effect of co-receptor involvement in the activation 
mechanism, as well as the importance of the specific activation pathway for the 
RET system’s response to variations in the expression levels of different 
components. The principal findings of my work include the following: 1) Higher 
order receptor clustering is required for full RET activation, as well as for the 
biological response of neurite outgrowth. 2) The activated forms of the receptor 
brought about by the agonist antibodies and by ART plus GFRα3 are identical 
with respect to the ability to activate the transient extracellular signal-regulated 
kinase (ERK) and Akt responses, but the antibodies show a reduced ability to 
induce sustained activation of ERK, Akt or c-Jun N-terminal kinase (JNK). 3) The 
involvement of GFRα3 co-receptor in the activation mechanism of RET provides 
cells with the ability to regulate their sensitivity to ligand without affecting the 
maximum amplitude of the pRET response. 4) This effect is limited if the co-
receptor GFRα3 is pre-dimerized.  
Overall, my work aims to elucidate broad principles that underlie the 
quantitative relationships between RET activation, signaling, and the resulting 
cellular functional response, that can be applied to other receptor systems. 
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Chapter 1 Understanding cytokine and growth factor receptor activation 
mechanisms 
 
1.1 Introduction 
  Multi-cellular life depends on the ability of each cell to sense and respond 
to its surroundings, so it can coordinate its activities to fulfill the needs of the 
tissue, organ and organism of which it is a part. To achieve this end a 
tremendous volume and variety of information must pass through the cell 
membrane and be integrated and acted upon within the cell. A principal means 
by which this information transduction occurs is through cytokine and growth 
factor receptors, which span the plasma membrane and trigger intracellular 
signals in response to soluble cytokine and growth factor proteins in the 
extracellular milieu. In this chapter we summarize the current state of knowledge 
concerning the molecular mechanisms by which cytokines and growth factors 
engage their cell surface receptors to bring about an activated receptor complex, 
and highlight major questions that remain unanswered.  
Receptors for cytokines and growth factors comprise two or more single-pass 
transmembrane proteins (Figure 1.1A). Each receptor component contains an 
extracellular portion that engages the cytokine or growth factor ligand, a single 
transmembrane-spanning domain, and a cytoplasmic portion that upon receptor 
activation engages with intracellular signaling molecules to initiate the biological 
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response. In the simplest case receptors contain two identical receptor chains, as 
for example in the receptors for epidermal growth factor (EGF), human growth 
hormone (hGH) and erythropoietin (EPO). Other receptors involve more complex 
combinations of components, such as αβ, α3, αβγ, α2β2, or α2β2γ2 (Figure 1.1B).  
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Figure 1.1 Cartoon illustrating the structures and compositions of typical growth factor and 
cytokine receptors. (A) (Left) growth factor receptor, with a kinase domain as an intrinsic part of 
its cytoplasmic structure. (Right) cytokine receptor, with a signaling kinase noncovalently 
associated with its cytoplasmic domain. (B) Examples of stoichiometric compositions that have 
been reported for cytokine and growth factor receptors. Ligands are shown in green and receptor 
proteins (α, β, and γ) are shown in dark or light blue, red, and purple. 
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The variety of stoichiometries displayed by this large and diverse family of 
receptors is further complicated by the fact that, for certain receptors, the binding 
of two separate molecules of the cytokine or growth factor are required to convert 
the receptor to an activated state, as illustrated in Figure 1B. So, for example, the 
activated form of the human growth factor receptor can be represented as L.α2, 
where L represents the bound ligand, whereas for the EGF receptor the activated 
complex has composition L2α2.  
Although the original distinction between cytokines and growth factors was 
based on their biological roles, there are also characteristic structural differences 
in their receptors. Specifically, growth factor receptors typically have a kinase 
domain as part of their cytoplasmic structure, conferring upon them the ability to 
directly phosphorylate intracellular proteins to initiate signaling (Figure 1.1A, left). 
Receptor kinase domains are specific for substrate sites in which 
phosphorylation occurs on a tyrosine residue (receptor tyrosine kinases or 
RTKs), or alternatively on either a serine or a threonine residue (receptor 
serine/threonine kinases). In contrast, cytokine receptors do not contain a kinase 
domain as part of their structure. Instead, the cytoplasmic portion of the receptor 
is non-covalently associated with a cytoplasmic signaling kinase, such as a 
member of the Janus kinase family that comprises Jak1, Jak2, Jak3 and Tyk2 
(Figure 1.1A, right). 
Receptors for growth factors and cytokines involve at least two 
components of the kind described above – that is components that either 
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possess intrinsic kinase activity in their cytoplasmic domains or are noncovalently 
associated with cytoplasmic signaling kinases. However, in addition to these full-
length components other kinds of molecules can be involved in forming the 
activated signaling complex. In some cases, these additional components are 
also transmembrane proteins, but with minimal cytoplasmic structure that does 
not participate in interactions with intracellular proteins. For example, the 
receptor for the cytokine interleukin-2 (IL-2) comprises three polypeptide 
components, IL-2Rα, IL-2Rβ and the common gamma chain γc. Both IL-2Rβ and 
γc have extensive cytoplasmic structure, and associate with the signaling kinases 
Jak1 and Jak3. The IL-2Rα chain, in contrast, has a minimal cytoplasmic domain 
containing only 13 amino acids, which does not directly participate in signaling. 
Thus, only IL-2Rβ and γc are absolutely required for signaling. The role of the 
alpha chain is to further stabilize the complex and to increase the binding affinity 
for IL-2, thereby conferring greater IL-2 sensitivity on cells expressing all three 
receptor components compared to cells expressing IL-2Rβ and γc only. A 
particularly instructive example in this regard is the IL-6 receptor, which becomes 
activated when two IL-6 molecules engage two molecules of IL-6Rα and two 
molecules of gp130 to form a 2:2:2 complex. Like IL-2Rα, IL-6Rα has a relatively 
small cytoplasmic structure. Moreover, cells that express gp130 but not IL-6Rα 
can respond to IL-6 if a soluble form of the IL-6Rα extracellular domain is also 
present [1]. This result shows that IL-6 signaling is principally driven by the gp130 
components of the receptor, and that the role of the IL-6Rα chain is to mediate 
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the interaction of IL-6 with gp130 in order to stabilize the activated signaling 
complex, a function for which IL-6Rα need not be directly tethered to the cell 
membrane.  
In other cases, in addition to two or more full-length signaling components 
a receptor can contain additional polypeptide chains that are not transmembrane 
proteins, but instead are linked to the outer leaflet of the cell membrane by a 
glycosylphosphatidylinositol (GPI) anchor. An example is the receptor tyrosine 
kinase RET, which is activated by members of the GDNF family of growth factors 
but also requires the participation of one of four additional membrane-associated 
components, the GPI-linked co-receptors GFRα1-4 [2]. Each of the four GFRα 
proteins is more or less specific for one of the four GFNF-family growth factors 
that can activate RET. The activated receptor complex comprises two molecules 
of RET plus one molecule of growth factor plus two molecules of the GFRα that 
is specific for that growth factor [3]. Analogous to the situation with IL-6Rα, cells 
that express RET but not any GFRα can be made responsive to GDNF family 
growth factors by inclusion of soluble forms of the appropriate GFRα protein [3]. 
Thus, in the RET system the function of the growth factor in combination with the 
GFRα proteins is principally to bring about the appropriate interaction between 
RET molecules. 
There are also examples of receptors in which non-protein co-factors are 
required for full activation to occur. For example, RET requires Ca2+ to 
productively engage its GDNF family growth factor ligands and GFRα co-
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receptors [4]. Similarly, Zn2+ is required for the high affinity binding of hGH by the 
human prolactin receptor [5]. Other growth factors require participation of 
noncovalently bound carbohydrate molecules to activate their receptor. For 
example, members of the fibroblast growth factor (FGF) family require heparan 
sulfate proteoglycan to interact productively with their receptors [6, 7]. 
Yet some receptors require more than two full-length components to 
achieve signaling. For example, receptors for growth factors from the TGFβ 
family require two alpha and two beta receptor chains for signaling, all four of 
which are receptor serine/threonine kinases [8].  
1.2 Ligand-receptor cross-reactivity 
In the early days of cytokine receptor research it was assumed that each 
cytokine or growth factor acted through its own specific receptor. However, it was 
soon discovered that some receptors could be activated by multiple ligands from 
a given family and, conversely, that some ligands interact with multiple distinct 
but structurally related receptors. Over the course of the 1990s it became clear 
that a degree of cross-reactivity between ligands and receptors is in fact the 
norm rather than the exception. This cross-reactivity takes several forms. In 
some cases a set of structurally related ligands interact with exactly the same 
receptor. For example, the Type I interferon receptor, comprising the two chains 
IFNAR1 and IFNAR2, can be activated by at least 18 different Type I interferon 
ligands [9]. In other cases, however, only one receptor component is common to 
the different ligands. For example, the cytokines IL-2, -4, -7, -9, -15 and -21 all 
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act via receptors that include the common gamma chain, γc, with the additional 
receptor components being cytokine-specific. Other receptor families that use a 
shared component include the receptors for IL-3, IL-5 and GM-CSF, which use 
the common beta chain, βc, the receptors for the ten cytokines of the IL-6/IL-12 
family which use gp130 [10], and the four growth factors of the GDNF family that 
signal through RET, as well as very many cases where a receptor chain is 
shared among two or three receptors. 
One illustrative example of the complexity of ligand-receptor cross-
reactivity is provided by the Erb-B family of receptors. This family comprises four 
receptor chains that interact in different combinations to form a set of homo- or 
heterodimeric receptors that collectively respond to a set of 11 growth factors 
from the EGF family [11]. Further complicating matters, Erb-B2 is incapable of 
binding ligands, and can therefore function only by forming heterodimers with 
ligand-bound forms of the other Erb-B family members. ErbB3, on the other 
hand, can bind some ligands, but lacks an active kinase domain and so again 
can function only through formation of heterodimeric complexes with other Erb-
Bs. Thus, within a small family of structurally homologous receptor chains, we 
see a diversity of homodimeric and heterodimeric activated receptor complexes 
that allow a limited set of receptor components to mediate the distinct biological 
functions of a much larger set of ligands.  Examples of other patterns of ligand-
receptor cross-reactivity include the PDGF/PDGF-R system [12], the TGF-β 
receptor superfamily [13], and the TNF receptor superfamily [14]. 
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1.3 Mechanism of receptor activation 
1.3.1 Value of understanding receptor activation mechanisms 
It might seem unduly esoteric to worry about exactly how a cytokine or a 
growth factor activates its receptor. However, there are very practical reasons 
why it is important for us to understand this phenomenon, both as an important 
aspect of our biological knowledge, and for the effective application of that 
knowledge to medicine and to drug discovery. Specifically, if we wish to 
understand how a given level of stimulus (exposure to a given concentration of 
growth factor for a given time) leads to a particular biological response, a 
mechanistic understanding of the molecular steps involved, including the 
affinities and rates of key steps, is essential. The purely empirical 
characterization of stimulus inputs and biological outputs, treating the system as 
a “black box”, is sufficient to define (though not to understand) the behavior of a 
particular experimental system, but a quantitative, molecular-level understanding 
is required to extrapolate this knowledge to predict or explain behavior under 
different conditions, such as in a different cell type or in vivo. In addition, it is 
becoming increasing recognized that the discovery and development of drugs 
that target growth factor or cytokine receptors or ligands can benefit greatly from 
a thorough and quantitative knowledge of how the receptor functions and how 
the pathology in question is coupled to that function. For example, understanding 
why ligands that induce homotypic receptor complexes - that is complexes that 
contain two copies of the same receptor component - show bell-shaped dose-
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response relationships is important for the rational design of antagonists and 
“super-agonists” through protein engineering [15]. Similarly, it has been shown 
that understanding the activation mechanism of receptors such as IL-4R [16] and 
RET [17] can potentially identify which step in receptor activation is easiest to 
block with an inhibitor, and also which receptor component to target to achieve 
an inhibitor that is competitive versus noncompetitive with respect to ligand. Our 
current understanding of the mechanistic details of receptor activation is, in some 
ways, analogous to the level at which enzymes were understood in the 1960s. 
The biological functions of the molecules involved are empirically quite well 
characterized, but in only a few cases do we have detailed insight into the 
molecular mechanisms involved, and in almost no case do we have a truly 
quantitative understanding of how function derives from the molecular 
mechanisms at work [18]. However, as described below, we are making quite 
rapid advances in our quantitative understanding of receptor function, which, it is 
hoped, will bring benefits to biology and medicine comparable to those that 
resulted from the corresponding advances in enzymology that has occurred in 
previous decades. 
1.3.2 Overview of cytokine/growth factor receptor activation 
If a mutation is introduced into the receptor cytoplasmic domain to 
inactivate or eliminate the associated kinase function, the result is to ablate the 
signaling activity of the mutated receptor. These and other observations, 
involving a wide variety of different receptor systems, show that the key event in 
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receptor activation is the activation of the kinases associated with the receptor 
cytoplasmic regions, and the action of these kinases in phosphorylating specific 
substrate sites on the receptor itself and on cytoplasmic signaling proteins. 
Binding of the cytokine or growth factor to the extracellular portion of the receptor 
triggers this process by inducing the formation of an activated receptor complex 
in which the cytoplasmic regions of the signaling chains are brought into the 
appropriate juxtaposition for this kinase activation to occur (Figure 1.2A). 
Generally, the receptor-associated kinases first phosphorylate each other, which 
converts them to a more active catalytic state. The activated kinases then 
phosphorylate multiple other sites in the receptor cytoplasmic domains, to create 
docking sites for the recruitment of cytoplasmic signaling proteins that contain 
phosphopeptide-specific binding modules such as SH2 and SH3 domains [19]. 
Some of the signaling proteins that bind to the receptor cytoplasmic region 
in this phospho-specific manner are themselves substrates for phosphorylation 
by the receptor-associated kinases. For example, activation of cytokine receptors 
that engage the JAK/STAT signaling pathway begins with trans co-activation of 
the JAK kinases associated with the cytoplasmic domains of the main signaling 
components of the receptor [20]. The activated JAKs then phosphorylate docking 
sites on the receptor, to which STAT proteins from the cytoplasm can bind. The 
JAKs phosphorylate the bound STAT proteins, causing them to dimerize upon 
dissociation from the receptor, and migrate as dimers to the nucleus, where they 
function as transcription factors by binding to promoter sites on DNA to induce 
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the expression of target genes.  Other phosphorylation-induced docking sites on 
receptors serve to recruit additional cytoplasmic kinases to bind to the receptor 
and thereby expand the range of downstream signaling molecules that can 
become activated. For example, Src, Shc1, PKCα and PLCγ are all cytoplasmic 
kinases that can associate with the intracellular portion of the activated EGFR 
through phospho-specific recognition motifs. Other docking sites on receptors 
can bind adaptor proteins that serve to recruit additional signaling molecules into 
a multi-protein complex with the receptor, leading to the initiation of other 
downstream signaling events. For example, activation of many RTKs includes 
phosphorylation of a docking site for the adaptor protein Grb2. Once bound, Grb2 
recruits the guanine nucleotide exchange factor SOS converting it to an active 
conformation. The activated SOS in turn recruits the GTPase Ras into the 
complex, and at the same time promotes the dissociation of GDP from Ras and 
its replacement by GTP from the cytoplasm. The active, GTP-bound form of Ras 
then binds and activates the signaling kinases Raf and PI3K, to initiate signaling 
through, respectively, the MAPK and Akt signaling pathways [20]. Thus, the 
phosphorylation of multiple docking sites on the cytoplasmic domain of cytokine 
and growth factor receptors initiates the assembly of a large multi-protein 
complex centered on the receptor, triggering a complex cascade of intracellular 
signaling events (Figure 1.2A). 
The above discussion addresses only receptor-receptor interactions 
mediated by the extracellular domains of the molecules. However, there is ample 
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evidence that the transmembrane and cytoplasmic portions of receptor proteins 
can also directly participate in receptor-receptor interactions, and in some cases 
these contacts appear to be critical to receptor activation. Using NMR methods, 
direct interactions of the helical TM domains have been observed for ErbB1 
family receptors [21-23]. Evidence for TM-TM interactions has also been 
obtained for the TGFβ receptor [24] from functional studies on chimeric receptor 
constructs transfected into cells, and similar kinds of evidence have 
demonstrated that TM self-association is critical for EPO-R signaling [25, 26]. 
Other receptors for which TM-TM interactions have been proposed to occur 
include FGF-R [27], VEGFR2 [28] and PDGF-Rβ [29]. In many of these cases it 
has been proposed that the TM domain interactions are important in ensuring the 
correct mutual orientation of the receptor components in the activated complex. 
However, the extent to which TM-TM interactions represent a general feature of 
the activation of cytokine and growth factor receptors remains unclear. The 
extent to which interactions between receptor cytoplasmic domains contribute to 
stabilization of the activated receptor complex is even less studied. One 
important exception is a recent study from the Kuriyan group, which showed that 
the EGF-R (ErbB1) kinase domain crystallizes in a form that reveals a direct 
noncovalent interaction [30]. Interestingly, despite the homotypic nature of the 
interaction the complex observed crystallographically was asymmetric, with the 
C-terminal lobe of one EGFR kinase domain contacts the N-terminal lobe of the 
  
 
   
14 
other (Figure 1.2B), very like the manner in which cyclins bind to and activate 
cyclin-dependent kinases (CDKs).  
 
Figure 1.2 Cartoon illustrating the generic mechanism for growth factor receptor signaling. (A) 
Step (I): upon assembly of the activated receptor complex the kinase domains associated with 
the receptor’s cytoplasmic region phosphorylate each other, and then additional sites elsewhere 
on the receptor cytoplasmic domains (added phosphate groups are indicated by red stars). Step 
(II): Cytoplasmic signaling proteins (orange and purple) are recruited to the newly phosphorylated 
docking sites on the receptor, and (Step (III)) are themselves in turn phophorylated. Some of 
these recruited proteins serve as docking sites for additional cytoplasmic signaling proteins (Step 
(IV)), which mediate additional downstream signaling processes, while others dissociate from the 
receptor and then form phosphopeptide-mediated complexes with each other or with other 
transcription factor proteins (Step (V)), after which they migrate to the nucleus where they interact 
with specific promoter sites to modulate the transcription of target genes. (B) Illustration of the 
asymmetric interaction between EGF-R kinase domains that results in kinase activation [30]. 
EGF-R is colored blue or pink, while the bound EGF is colored pale green. The extracellular and 
cytoplasmic domains represent separate experimental crystal structures of these complexes, 
while the connecting segment is drawn arbitrarily. The N-terminal portion of one EGF-R kinase 
domain is colored dark blue, while the corresponding portion of the identical kinase domain from 
the other EGF-R molecule is colored dark red, to highlight the asymmetric nature of the 
interaction. 
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This and other evidence led the authors to propose that, for the full-length 
receptor on cells, the kinase domain associated with one receptor chain binds to 
and allosterically activates the kinase domain on the other EGFR molecule in the 
activated receptor complex, in an asymmetric interaction analogous to how 
cyclins activate CDKs. 
1.3.3 Outstanding questions 
Given the detailed knowledge that has been amassed concerning the structure of 
ligand-receptor complexes, and the phosphorylation, docking and other signaling 
events that receptor activation brings about on the cytopasmic side of the 
membrane, it may come as a surprise to realize how little we know about how the 
binding of ligand actually brings about receptor activation. In particular, it remains 
controversial exactly how the binding of the ligand to the extracellular portion of 
the receptor brings about the necessary juxtaposition between the receptor 
cytoplasmic domains for signaling to occur. In particular, conflicting evidence 
exists concerning whether the resting state of the receptor comprises individual, 
separately diffusing receptor proteins that are brought together into a complex 
only upon the binding of ligand (Figure 1.3A), or whether the resting receptor 
involves the components in a pre-associated complex that is converted to an 
active state by the binding of ligand (Figure 1.3B), or indeed whether some 
receptors function by one of these mechanisms while different receptors employ 
the other. With few exceptions, it is also unclear whether activation of a common 
receptor by different ligands merely represent redundant methods to bring the 
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receptor to a common activated state with a characteristic set of signaling 
properties, or alternatively whether different ligands might induce formation of 
distinct activated states of the receptor that signal differently. In addition to these 
broad uncertainties about fundamental aspects of the activation mechanism, very 
little is known about quantitative aspects of how ligand binding is coupled to 
assembly of the activated receptor complex, or how receptor activation is 
quantitatively coupled to proximal and distal steps in intracellular signaling. Only 
in a handful of cases have a subset of the key rate and equilibrium constants 
been estimated, and this information used to develop a quantitative picture of 
how the receptor functions [17, 31-33]. 
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Figure 1.3 Two possible mechanisms accounting for how ligand binding brings about the 
activation of a dimeric receptor. (A) Ligand-induced receptor dimerization. (B) Allosteric 
rearrangement of a pre-associated receptor dimer. 
 
1.4 Ligand-induced oligomerization versus pre-associated receptors 
Our evolving understanding of how the binding of a growth factor ligand 
brings about an activated state of the receptor can be traced by considering three 
well-studied receptors: EGF-R, hGH-R and EPO-R. In 1987 Schlessinger and co-
workers observed that purified EGF-R formed reversible, non-covalent dimers 
when incubated with EGF, and that this dimerization was accompanied by 
enhanced phosphorylation of the receptor [34, 35]. This report was followed soon 
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after with evidence that EGF induced EGF-R dimerization on living cells [36]. 
These results led Schlessinger et al. to propose that activation occurs when EGF 
binds to EGF-R monomers and induces them to dimerize, bringing the receptor 
cytoplasmic domains together and thereby allowing trans-phosphorylation of the 
receptor kinase domains to initiate signaling (Figure 1.3A). Shortly after this 
seminal work, Wells and co-workers published the co-crystal structure of hGH in 
complex with the extracellular portion of hGH-R, with supporting biophysical and 
biochemical data, showing that one molecule of hGH binds two molecules of 
receptor to form a ternary complex in which the two receptors also make direct 
contact with each other [37]. This study provided the first atomic-level structural 
picture of the interactions involved in a cytokine/receptor complex. It additionally 
showed that each receptor molecule uses essentially the same binding site to 
interact with two quite different surface sites on the hGH ligand, thereby 
establishing that to stabilize a dimeric receptor involving two identical receptor 
chains does not necessarily require a symmetrical ligand. The interaction of EPO 
with EPO-R was found to closely resemble that observed with hGH/hGH-R [38, 
39]. Similarly, for the trimeric cytokines of the TNF family, crystal structures of the 
ligands in complex with soluble forms of their receptor extracellular domains 
invariably show a 3:1 complex, with a receptor chain bound at each of the three 
subunit interfaces in the ligand [40], suggesting a similar mechanism in which 
binding of a single ligand in this case recruits three receptor molecules into a 
complex with 3-fold symmetry [41]. Similar structural and biochemical data 
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establishing the formation of ligand-stabilized receptor oligomers have 
subsequently been reported for multiple other cytokine and growth factor 
receptors. 
1.4.1 Evidence for ligand-induced oligomerization 
In addition to the structural evidence discussed above, an accumulation of 
functional data was invoked to support the ligand-induced dimerization 
mechanism illustrated in Figure 1.3A. Many of these studies used recombinant 
receptor proteins that were truncated to eliminate the transmembrane and 
cytoplasmic portions, giving soluble receptor extracellular domains amenable to 
detailed biophysical and biochemical study using solution-phase methods. Using 
soluble receptor proteins of this kind, together with experimental approaches 
such as size exclusion chromatography, analytical ultracentrifugation and 
dynamic light scattering, it has been shown for multiple systems that a stable 
dimer between soluble receptor extracellular domains is observed only in the 
presence of the cytokine or growth factor ligand. A mechanism of ligand-induced 
dimerization was additionally supported by a great number and variety of cell-
based measurements. For example, Fuh et al. reported that introducing 
mutations into hGH to disrupt its “Site 2” binding site (see above) converted the 
hormone into an antagonist, consistent with the notion that the mutated hormone 
could bind to hGH-R through the unmodified Site 1, but was unable to recruit a 
second receptor molecule to form the termolecular activated complex (Figure 
1.4A) [15]. These investigators additionally showed that hGH mutants in which 
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Site 2 binding affinity was reduced but not eliminated gave a bell-shaped dose-
response curve indicating that they acted as agonists at low and moderate 
concentrations but as antagonists when present at high concentrations (Figure 
1.4B). This finding was interpreted in terms of the mechanism shown in Figure 
1.4C, in which a high concentration of ligand forces the receptor into a dead-end 
state in which each hGH-R molecule is bound by a separate hGH molecule 
through a Site 1 interaction. A bell-shaped dose-response curve has since been 
demonstrated for wild-type hGH-R [42] as well as for many other homotypic 
receptors that bind a single ligand molecule, suggesting that this behavior is a 
general property of such systems. 
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Figure 1.4 Potential explanations for key mechanistic findings in terms of ligand-induced 
dimerization. (A) Thee observation that a ligand that is mutated to inactivate its Site 2 binding 
surface can act as an antagonist of homotyopic receptors such as hGH-R and EPO-R in cellular 
assays can be accounted for if each receptor chain binds a separate ligand molecule through its 
intact Site 1, with no Site 2 interaction to drive recruitment of a second receptor chain into an 
activated ternary complex. (B) Mutants of hGH with reduced but not eliminated Site 2 binding 
show a bell-shaped dose response. Reproduced from [15], with permission. ©American 
Association for the Advancement of Science, 1992. (C) The observation that ligands for 
homotypic receptors such as hGH-R and EPO-R give bell-shaped dose-response relationships in 
cellular assays can be explained if high ligand concentrations drive the receptor to a non- 
signaling state similar to that described in (A). 
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For dimeric receptors involving two different receptor chains, it has 
similarly been shown that mutating the region on the ligand that interacts with the 
second receptor component converts the ligand from an agonist to an antagonist 
(e.g. IL-4) [43], because the mutant growth factor can still bind to and occupy 
receptor chain 1 but cannot recruit receptor chain 2 into a functional complex. For 
a heterotypic receptor a bell-shaped dose response curve such as was shown for 
hGH-R, EPO-R, etc. is not expected, unless the ligand is applied at 
concentrations high enough that even the weaker binding receptor chain 
becomes independently saturated, which typically does not occur at practically 
achievable ligand concentrations. Most heterotypic dimeric receptors involve one 
chain that binds ligand strongly and another that binds ligand alone much more 
weakly, such that the interaction with the second chain can only be observed in 
the ternary complex when all three proteins are present. However, for the 
heterotypic receptor for interleukin-4 (IL-4), which comprises the IL-4Rα chain 
and the common γ chain, an essentially equivalent observation has been 
reported. Specifically, it was shown that an antibody that binds to γc and blocks 
its recruitment into the complex acted as a noncompetitive antagonist of IL-4 
function on cells [16] and also did not block binding of radiolabeled IL-4 to the 
cells, whereas an antibody that binds to IL-4Rα and blocks the binding of the 
cytokine was a competitive antagonist (Figure 1.5A).  
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Figure 1.5 Competitive versus noncompetitive inhibition reveals mechanistic properties of the 
heterodimeric receptor for IL-4. (A) (Left panel) An antibody that binds to the IL-4Rα chain and 
directly blocks ligand binding acts as a competitive antagonist in assays measuring the IL-4 
dependent proliferation of T cells. Antibody concentrations are 0 (circles), 0.41 (squares), 1.23 
(triangles), 3.7 (diamonds), 11.1 (inverted triangles) 33.3 (crossed squares) or 100 (dotted circles) 
µg/mL. Inset plot shows that the concentration of IL-4 required to achieve a 50% maximal 
proliferative response (EC50) increases linearly with the concentration of inhibiting mAb, 
consistent with simple competitive inhibition. (Right panel) antibody that binds to the γc chain and 
blocks its recruitment into the activated receptor complex acts as a noncompetitive antagonist. 
Inset: EC(50) for IL-4 is independent of inhibitor concentration. Figure reproduced from [16], with 
permission.©1998 by the National Academy of Sciences. (B) Scheme illustrating how 
noncompetitive inhibition by anti-γc mAb can be explained in terms of a mechanism of ligand-
induced dimerization, in which IL-4 and the inhibitor bind to distinct and independent receptor 
components, such that the antibody cannot be outcompeted by increasing IL-4 concentration [16].  
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This result is consistent with a mechanism of ligand-induced dimerization, 
because it shows that recruitment of γc into the complex is a separate event from 
the binding of IL-4 to IL-4Rα (Figure 1.5B), and also shows that in the unbound 
state γc and IL-4Rα are far enough apart that binding of a large antibody 
molecule to the extracellular domain of γc does not interfere with the binding of 
IL-4 to IL-4Rα. Such a situation is somewhat difficult (though not impossible) to 
picture if IL-4Rα and γc are intimately associated in a pre-formed complex before 
IL-4 binds, whereas the results are both qualitatively and quantitatively 
accounted for if a mechanism of ligand-induced dimerization is assumed [16]. 
Some of the most compelling evidence for ligand-induced dimerization 
comes from the great variety of ways in which homotypic receptors can be 
activated by dimerizing them through artificial means [44]. The EPO receptor 
provides the best example of this argument [45]. Quite early on it was shown that 
a number of monoclonal antibodies that recognize the extracellular domain of 
EPO-R can act as agonists in cellular assays [46, 47]. Although only a minority of 
anti-EPO-R antibodies possessed agonist activity, the fact that a number of them 
did is consistent with the idea that bringing two receptor molecules together on 
the membrane is a key event in activation. Moreover, the agonist mAbs showed 
a bell-shaped dose-response indicative of a mechanism in which each EPO-R 
chain is bound by a separate antibody molecule at high antibody concentrations 
to give a non-signaling state, showing that receptor activation requires two EPO-
R molecules to be cross-linked by a single mAb. Given the very different 
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structures and sizes of a 150 kDa antibody versus the 21 kDa. EPO molecule, it 
would appear highly unlikely that an agonist mAb can bring two EPO-R 
molecules together in exactly the same orientation observed in the co-crystal 
structure of EPO-R with EPO (Figure 1.7) [48]. Thus, the existence of agonist 
mAbs suggests that receptor activation involves bringing two EPO-R molecules 
together into close proximity, but argues against a requirement for any very 
specific interaction geometry for the extracellular portions of the receptor. Agonist 
mAbs have also been reported for a wide range of other cytokine and growth 
factor receptors [15, 49-59] establishing this as a general phenomenon. 
For EPO-R in particular, it has been established that the receptor can be 
dimerized in a variety of other ways, to form complexes that have a range of 
geometries, to bring about activation and signaling.  These include the following: 
 As mentioned above, it is possible to convert a cytokine such as EPO, hGH 
or IL-4 into an antagonistic by mutating residues that interact with the 
second receptor chain (Site 2), while leaving the regions of the ligand that 
interact with the first receptor chain (Site 1) unchanged. Intriguingly, for EPO 
and for several other cytokines it has been shown that covalently coupling 
such antagonistic variants together results in an agonist [60]. This result 
implies that each of the two antagonist molecules in the engineered ligand 
dimer can engage a separate receptor chain through their unmodified Site 1 
binding sites, and that doing so brings the two receptor chains into a mutual 
orientation that results in activation (Figure 1.6).  
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Figure 1.6 Cartoon illustrating the observation that an antagonistic ligand mutant than can only 
bind monovalently can be converted to an agonist by covalent dimerization. Such agonist activity 
can be explained if each ligand monomer binds a separate receptor chain via the unmutated Site 
1, thereby bringing two receptor chains together due to the covalent tether.  
 
 Clearly, the relative distance and orientation of the two receptor extracellular 
domains must be quite different in this complex compared to the activated 
complex formed upon binding of a single, wild-type cytokine molecule, as 
the crystal structure of EPO bound to EPOR shows that there is not room to 
bind two connected EPO molecules without substantial reorganization of the 
EPO-R extracellular domains [61] (Figure 1.7). 
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Figure 1.7 X-ray crystal structures of the activated form of the EPO-R. The native EPO/EPO-R 
complex showing two molecules of EPO-R (dark and light blue) bound by one molecules of EPO 
(green), as viewed from the side (left image), or from the top  (right image) to show the angle at 
which the two receptor molecules are juxtaposed. Figure reproduced from [61] with permission. 
©1992 by the National Academy of Sciences. 
 
 Furthermore, studies with these dimerized EPO variants have shown that 
their agonistic activity is rather insensitive to the length of the linker tethering 
the two mutant cytokine molecules together [60], implying that the relative 
distance and orientation of the EPO-R extracellular domains compatible with 
receptor activation can vary rather considerably. 
 Chimeric receptors can be constructed, comprising the transmembrane and 
cytoplasmic domains of EPO-R fused to the extracellular domain of a 
different receptor, which when transfected into cells can be activated by 
adding the ligand to the different receptor. In the case of EPO-R, active 
chimeric receptors have been demonstrated using extracellular domains 
from other cytokine receptors such as Prl-R [62], or even receptors from 
quite different structural classes such as EGF-R or cKit [63]. This result 
again implies that receptor activation is not very sensitive to the specific 
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mutual orientation of the extracellular domains brought about by the 
activating ligand. 
 Several mutations have been reported, involving introduction of a cysteine 
residue into the juxtamembrane region of the EPO-R extracellular domain, 
that result in constitutive activation of the receptor through formation of a 
disulfide-linked EPO-R dimer [64, 65]. 
 A few reports describe small molecule (i.e. synthetic organic) agonists for 
cytokine and growth factor receptors [16, 66]. An early example is an 
agonist of the receptor for the cytokine Granulocyte Colony-Stimulating 
Factor (G-CSF). In 1998 Tian et al. reported the small molecule G-CSF-R 
agonist SB247464, which was discovered by screening a compound library 
against a cell-based assay measuring the activation of a reporter gene 
downstream of the G-CSF-R (Figure 1.8) [67].  
 
Figure 1.8 Chemical structure of the small molecules G-CSF receptor agonist SB247464 [67]  
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The small molecule shows a bell-shaped dose-response curve in the 
reporter gene assay, consistent with the notion that the two symmetrically-related 
halves of SB247464 each bind one G-CSF-R molecule to stabilize a receptor 
dimer [16]. Perhaps not surprisingly given the small size of the compound, 
SB247464 appears to bind the receptor not at the G-CSF binding site, but at a 
location in the membrane-proximal region of G-CSF-R where, by analogy to the 
homologous receptors hGH-R and EPO-R, it is expected that the receptor chains 
come close together in the activated complex. For EPO-R itself, it has been 
shown that appending a weak-binding small molecule ligand to a multivalent 
scaffold gave a molecule with agonist activity [68], consistent with the idea that 
ligand-induced clustering of EPO-R brings about activation. Multiple small 
molecule agonists have additionally been reported for TPO-R [69, 70], including 
the FDA-approved drug eltrombopag [71], as well as for the receptor tyrosine 
kinases TrkA, TrkC [72] and TrkB [73, 74]. 
 A number of peptides discovered by phage display - some as small as 13 or 
14 amino acids - were shown to bind to and activate EPO-R on cells [75, 
76]. A crystal structure of one such EPO-mimetic peptides (EMP), called 
EMP1, in complex with the EPO-R extracellular domain [38] showed a 2:2 
complex in which the two EMP1 molecules make contact with each other 
and thereby indirectly mediate contact between the two EPO-R molecules. 
A subsequent study showed that covalently dimerizing EMP greatly 
increased potency [77], and dimeric EMPs with a variety of structures and 
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geometries have been reported [78-80]. The complex of EMP1 with EPO-R 
also showed that the dihedral angle of ~180° between the two EPO-R 
molecules was quite different from the ~120° angle seen for EPO-R bound 
to EPO itself, suggesting that a significant range of mutual orientations 
between the EPO-R extracellular domains can result in activation of the 
receptor. Cytokine mimetic peptides have also been reported for several 
other receptors including the thrombopoietin receptor [81, 82], IL-5 receptor 
[83], and Nerve Growth Factor Receptor TrkA [84].   
The diverse ways in which EPO-R and other receptors can be dimerized to 
bring about receptor activation conclusively establishes that a range of relative 
orientations in the extracellular domain of these receptors is compatible with 
activity. In particular, the observations that monoclonal antibodies and also 
covalently dimerized forms of antagonistic cytokine variants can bring the 
receptor into an active state strongly suggests that quite different geometries of 
the extracellular portions of the receptor can lead to activation of signaling inside 
the cell. 
Importantly, not every means of dimerizing EPO-R results in functional 
activation of the receptor [44]. As mentioned above, only four out of 96 antibodies 
against the EPO-R extracellular domain were found to have agonistic activity 
[46]. Presumably all or most of these mAbs were capable of binding two 
molecules of EPO-R, so this result implies that many antibody-induced EPO-R 
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dimers were inactive. Similarly low percentages of active agonists have been 
reported for mAbs against other receptors too [85, 86].  
A key difficulty in directly comparing results from studies that describe 
different ways to activate EPO-R or other receptors is that often different forms of 
the protein were used in the different experiments. For example, eight out of 14 
monoclonal antibodies raised against the extracellular domain of hGH-R were 
able to activate a chimeric protein containing the extracellular domain of GHR 
fused to the transmembrane and intracellular domains of GCSF-R, but none 
activated full length hGH-R on FDC-P1 cells (though two of the eight showed 
weak agonist activity against full-length hGH-R on BaF-B03 cells) [85]. 
Interpreting what we can conclude about requirements for receptor activation 
from data on dimerization of EPO-R or other receptors by different means thus 
becomes even more complicated when the magnitude and the nature of the 
functional response that is achieved is considered. We still do not have a 
definitive explanation for the quantitative and qualitative differences in activation 
of the same receptor via distinct dimerizing agents. For example, the four 
monoclonal antibodies that were reported as eliciting EPO-R activation showed 
much lower efficacy compared to EPO in a functional assay measuring erythroid 
colony stimulation in primary cells [47]. Furthermore only one of the antibodies 
promoted differentiation, which suggests that they activated EPO-R in a different 
way from EPO. Such differences in agonist activities were addressed in a recent 
study by Moraga and co-workers. 
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The authors showed that EPO-R could be efficiently dimerized by a set of 
four diabodies, but the different ligands showed markedly different efficacies to 
activate the receptor, ranging from full to very weak partial agonism [87]. The 
different activation efficiencies of the agonists were evident in their ability to bring 
about EPO-R and pSTAT phosphorylation, as well as to trigger cell proliferation 
and CFU-E colony formation. X-ray crystal structures of the EPO-R complexed 
with there of the diabodies revealed that the different ligands dimerized the ECD 
portion of the receptor in very different orientations. In fact, one of the diabodies 
(DA10) brought two EPO-R molecules in a “head-to-toe” orientation, which is 
difficult to imagine for the membrane-tethered receptor. In additionally to the 
dihedral angles, the two EPO-R molecules were at different distance from each 
other in the different complexes. Moreover, activation of EPO-R by the Friend 
virus gp55 protein results in different JAK/STAT phosphorylation pattern from 
that achieved with EPO [44]. Lodish et al. determined the activity of mutated 
forms of EPO-R that had 1, 2, 3 or 4 alanine residues inserted into an alpha-
helical segment of their juxtamembrane cytoplasmic domains, that resulted in the 
rotation of the downstream kinase domain of the receptors relative to one 
another by about 109° per inserted alanine [88].  The results clearly showed that 
the wild type and the 3xAla mutant elicited similar levels of cell proliferation, 
which were much higher than the levels achieved by the 1xAla, 2xAla or 4xAla 
mutants. Interestingly, the 1xAla mutant was still able to trigger proliferation when 
exposed to much higher ligand concentrations, even though its affinity for binding 
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EPO was no different from that of wild type EPO-R and the 3xAla mutant. 
Moreover, the level of JAK2 phosphorylation upon stimulation with EPO was 
higher for the less active 1xAla mutant than for the wild type or the 3xAla mutant, 
but EPO-R phosphorylation was undetectable for the former and almost the 
same for wild type and 3xAla. These results suggest that both the extent and the 
nature of EPO-R signaling are critically dependent of the mutual orientation of the 
receptor cytoplasmic domains. Moreover, like several of the other studies 
described above, this work amply illustrates the difficulty in interpreting the 
significance of the experimental observation that a given manipulation causes 
receptor “activation” in an experimental system. 
1.4.2 Evidence for a pre-associated receptor mechanism 
For a number of years it was generally assumed that essentially all growth 
factor and cytokine receptors were activated through a mechanism of ligand-
induced oligomerization, based on evidence such as that described above, but 
encompassing also many other well-studied receptor systems [89, 90]. However, 
in the late 1990s evidence began to emerge for an alternative activation 
mechanism, in which receptors exist as a preassembled dimers or oligomers 
before ligand binds. In this alternative mechanism, the ligand activates the 
receptor by inducing a conformation change in this pre-associated receptor 
complex that brings the receptor cytoplasmic domains into the required mutual 
orientation (Figure 1.3B). Evidence supporting this mechanism came from both 
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structural and functional studies. The literature on EPO-R and EGF-R again 
provides a good illustration of the evolution of these ideas. 
In 1999 Livnah et al. reported the X-ray crystal structure of the 
extracellular domain of EPO-R in the absence of ligand [91]. In this structure, the 
EPO-R molecules are arranged in pairs, with each pair held together by a 
relatively extensive contact interface encompassing many of the same regions of 
EPO-R that are involved in binding to EPO itself (Figure 1.9). 
 
Figure 1.9 X-ray crystal structures of the activated and inhibited forms of the EPO-R. The 
antiparallel dimer seen for the unbound EPO-R (A) [91] and the native EPO/EPO-R complex (B) 
with the residues that make direct contact with EPO colored in red in both images, showing that 
the same regions of the receptor proteins that contact EPO also mediate receptor/receptor 
contact in the crystal of the unbound EPO-R. Figure reproduced from [92].  
 
This structure addressed a major gap in our knowledge, in that to gain 
structural insight into the mechanism of receptor activation it is necessary to 
consider the structures of both the resting and activated states of the receptor. 
However, interpreting X-ray crystal structures of unligated receptors it raises the 
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problem of how to distinguish which crystallographically-observed contacts reflect 
interactions that occur in the native, full-length receptor on cells, and which result 
from characterizing an artificial receptor construct packed at high density into a 
crystal. In this particular case the structural report was accompanied by a second 
paper providing strong functional evidence that EPO-R can pre-associate on 
cells (see discussion of Remy et al., below), and so the authors felt justified in 
proposing that the EPO-R homodimer seen in the crystal structure might 
represent an inactive but pre-associated form of EPO-R that could exist on cells. 
One notable problem with the interpretation of this structure is that, as the 
authors point out, the dimer interface seen in the crystal occludes the binding site 
for the ligand, making it difficult to conceive of a compelling mechanism for how 
EPO might bind to this proposed pre-associated form of the receptor to convert it 
to an activated state. 
Among the best functional data to support a pre-associated receptor 
mechanism also involves the EPO receptor. As a companion to the 
crystallographic paper described above, Remy et al. reported an elegant set of 
experiments in which complementary fragments of the enzyme dihydrofolate 
reductase (DHFR) were fused to the cytoplasmic portion of various EPO-R 
constructs resulting, indirectly, in a fluorescent read-out when the receptor 
cytoplasmic domains were close enough together to directly associate. Only if 
two complementary DHFR fragments came together to reconstitute the active 
enzyme would a signal result [93]. The authors showed that EPO-R/DHFR-
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fragment constructs containing a short linker showed ligand-dependent induction 
of DHFR complementation, but that constructs containing a longer linker gave a 
dimerization signal even in the absence of EPO or the peptide agonist EMP1. 
The authors concluded that EPO-R exists as a dimer in the absence of EPO, but 
in the resting state the cytoplasmic domains are held apart, and that binding of 
the cytokine induces a reorganization of the pre-associated receptor dimer to 
bring the cytoplasmic domains into close contact thereby initiating signaling. 
Multiple reports have appeared in recent years suggesting that other 
receptors also exist on cells as pre-associated dimers or oligomers in the 
absence of bound ligand [94-96]. For EGF-R in particular, the recent literature 
contains a multitude of studies addressing the possible existence of preformed 
dimers or oligomers, of which the following references represent just a sample 
[97-102]. Many of these reports involve imaging studies of one kind or another in 
which receptors on cells are labeled with fluorescent tags or by other means, and 
are shown to be clustered even when no ligand is present. However, some 
studies of pre-associated receptors also involve functional data. An obvious 
potential weakness of studies that rely on labeled receptors is the possibility that 
modification of the receptor protein to introduce the label has altered its self-
association properties. Moreover, any study that involves recombinant 
expression of a modified receptor introduces the possibility that artificially high 
expression levels might induce self-association that would not occur at 
endogenous levels. Nevertheless, many of the above studies take careful 
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account of these possible artifacts, and control for them very convincingly. For 
example, recent studies of EGF-R expressed at endogenous levels has shown 
that receptor monomers and dimers exist in equilibrium prior to ligand binding, 
using quantum dot-based optical measurements of single molecules [103]. Upon 
stimulation with EGF the receptor molecules appeared to form clusters of three 
or more monomers. The dimeric state always preceded activation/clustering, but 
both monomers and dimers bound soluble ligand. Binding of ligand to a kinase-
null mutant or a mutant that lacked the dimerizing arm from its extracellular 
domain did not stabilize the dimer form. Recently, Freed et al. showed that at 
physiologically relevant expression levels the analogue of hEGFR in C. Elegans, 
LET-23, is constitutively dimerized on the cell surface and that the contacts 
between two receptor molecules mediated through the extracellular domains 
provide sufficient affinity to account for this interaction [104]. Biophysical 
characterization of the interaction between the receptor and its ligand, LIN-3, 
revealed subtle structural rearrangement within the dimer, but no further receptor 
clustering. However, the authors showed that when the self-association was 
weakened by mutations in the extracellular domain, the system exhibited 
behavior typical for ligand-induced dimerization.  
Receptors from the TNF-R superfamily have also been proposed to 
function by a pre-associated receptor mechanism. These studies exemplify some 
of the complexities and apparent contradictions that make definitive conclusions 
on this point so difficult to reach. A crystal structure of the extracellular domain of 
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the p55 TNF receptor has been reported that shows two different types of 
receptor dimers possessing extensive interaction interfaces [105]. As was the 
case with EPO-R, described above, these authors too proposed that the 
crystallographically observed dimers might reflect the structure of an inactive 
state of the receptor that exists under physiological conditions. Furthermore, the 
notion that TNFRp55 is pre-associated on the cell surface is supported by a 
compelling set of functional studies conclusively demonstrating that, on H9 
lymphoma cells, full-length TNFRp55 predominantly exists as a pre-associated 
trimer in the absence of its TNFα ligand [106]. The trimeric structure is consistent 
with the 3-fold symmetry of the 3:1 complex that TNFRp55 forms with the trimeric 
ligand TNFβ (Figure 1.10) [40]. Experiments using truncated or mutated variants 
of TNFRp55 showed that self-associate is mediated by a so-called Pre Ligand-
Binding Assembly domain (PLAD) near the N-terminus of the receptor. Similar 
pre-association behavior was seen for the other TNFR superfamily members 
TNFRp75, Fas, CD40 and DR4. However, notwithstanding the compelling nature 
of the data that establish TNFR receptor pre-association, its incorporation into a 
plausible mechanism for how ligand binding brings about receptor activation 
remains problematic. First, it is hard to reconcile the functional data of Chan et al. 
with the structure observed by Naismith et al. In the former case the data show 
the receptor to be pre-associated essentially exclusively as a trimer, whereas the 
crystal structure just as clearly indicates that a dimer is the observed oligomeric 
state. Moreover, the PLAD domain, which comprises residues 1-56 in TNFRp55 
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[106] does not appear to participate in the self-association that is observed 
crystallographically. Even if the X-ray structure is dismissed as a crystal artifact, 
thereby resolving the above discrepancies, the functional data supporting pre-
associated receptors are difficult to reconcile with the known properties of 
TNFRp55/TNFα binding. For example, the crystal structure of the complex of 
TNFβ with the extracellular domain of TNFRp55 [40] as well as corresponding 
complex structures for other PLAD-containing TNFR family members [106], 
clearly shows that the N-terminal domain of the receptor is not involved in binding 
to the ligand. And yet deletion of the PLAD domain from TNFRp55 was shown to 
abolish ligand binding [106]. Moreover, if the resting state of the receptor is a 
trimer connected via the N-terminal PLAD domains, forming a termolecular, 
cage-like structure on the membrane, then how does the ligand enter this cage to 
adopt the complex structure observed crystallographically (Figure 1.10).  
 
Figure 1.10 Scheme illustrating the difficulty in reconciling TNF-R pre-association via the PLAD 
domains with the known structure of the ligand-receptor complex. The extracellular portion of the 
TNF-Rp55 comprises four cysteine-rich domains (CRDs). The cartoon shows three molecules of 
TNF-Rp55 (blue) pre-associated via their N-terminal PLAD motifs, illustrating the difficulty in 
accounting for how the large TNF ligand (green) gains access to the interior of this three-fold 
cage. The experimental structure on the right shows the relative sizes TNFβ (green) and the 
CRDs 2 and 3 of TNF-Rp55 (blue) [40]. Figure reproduced from [92]. 
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The dimensions of the TNFRp55 molecule are such that the 55 kDa TNFα 
trimer appears far too big to squeeze through the small gaps that would exist 
between the pre-associated receptor chains. Thus, as was the case for EPO-R, 
the evidence for receptor pre-association of TNF-Rp55 and these related 
receptors appears strong, and yet does not easily lend itself to a plausible 
molecular mechanism for how the binding of ligand to such a pre-associated 
state could induce formation of the activated receptor complex. 
Thus, the receptor systems that provide the strongest evidence for a pre-
associated receptor mechanism are largely the same ones, including EPO-R, 
hGH-R, Prl-R, EGF-R and TNFRp55, that were originally used to formulate and 
establish the concept of ligand-induced dimerization or oligomerization. Thus, we 
are in the uncomfortable position that the very same, well characterized receptor 
systems appear to provide contradictory information about the mechanism by 
which they function. 
1.4.3 Critical analysis of arguments for ligand-induced oligomerization 
versus pre-associated receptors 
In the examples cited above, and for cytokine and growth factor receptors 
in general, the interaction between receptor proteins in the activated complex is 
strictly noncovalent. Thus, as for any other noncovalent complex, there is no 
question that any given receptor can in principle exist either as dissociated 
monomers or as pre-associated oligomers, and which of these are observed will 
depend on the concentration of receptors on the cell surface relative to the 
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dissociation constant for self-association. Thus, rather than being entirely distinct 
mechanisms, as is typically portrayed, ligand-induced oligomerization and the 
pre-associated receptor mechanism represent two extremes of a mechanistic 
continuum (Figure 1.11). In circumstances where receptor components are 
expressed at low levels compared to the KD for their interaction in the absence of 
ligand (KD1 in Figure 1.11), the unactivated receptor will exist predominantly as 
dissociated monomers. But if at least one of the receptor components is 
expressed at a high level compared to KD1, in its unactivated state the receptor 
will predominantly exist as oligomers. It should be noted that when we speak of 
the expression level or concentration of a receptor protein on the cell membrane, 
we must think in terms of moles per unit area, not per unit volume; the KD for 
interactions between membrane proteins also has “two-dimensional” units of 
moles per unit area (often more conveniently expressed as molecules/µm2) [16, 
17, 107-110]. These units are appropriate because the separate, membrane-
associated molecules are constrained to diffuse in the two dimensions of the cell 
membrane, and thus it is the dispersion of these species across the available 
membrane surface and not their distribution in the total volume of the 
experimental system that governs the change in free energy that occurs when 
they associate noncovalently into complexes [110]. Importantly, it is the local 
receptor density rather than the average density across the whole cell surface 
that governs the position of the binding equilibrium [17]. The contextual and 
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dynamic nature of receptor self-association has received growing attention of late 
[17], especially for the case of the EGF receptor [98, 99, 101, 103, 111, 112]. 
Other important advances in this area include the recognition that 
interactions with other species might be involved in governing the monomer-
dimer-oligomer equilibrium for EGF-R [113] and that the impact of EGF-R dimer 
formation on the affinity for binding ligand can be affected by the receptor 
phosphorylation state [114]. Notwithstanding the increasing sophistication of our 
investigation of the quantitative coupling of ligand binding to receptor 
dimerization that is implied by the mechanistic scheme in Figure 11, work of this 
kind is still in its infancy, and very great advances in this area can be anticipated 
over the next decade or so. 
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Figure 1.11 The mechanistic continuum that connects the ligand-induced dimerization and pre-
associated receptor mechanisms. The scheme reflects the fact that any receptor with even a 
weak tendency to self-associate will form pre-associated dimers if present at local concentrations 
on the membrane that exceed KD2’. Conversely, even strongly self-associating receptors will 
predominantly exist as independently diffusing monomers if the local expression density falls 
below KD2’. Thus, which mechanism is followed is not an intrinsic property of a particular receptor, 
but rather is a contextual function of expression level and of other factors that effect membrane 
localization or interaction affinity of the receptor components. 
 
The above considerations lead to several conclusions concerning what we 
can say, from the available evidence, about whether a given receptor is activated 
by a mechanism of ligand-induced oligomerization versus pre-associated 
receptors: 
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1.5 Conclusions 
 Much of the mechanistic evidence that has been used to support one or 
the other of the candidate mechanisms of ligand-induced dimerization 
versus pre-associated receptors is less conclusive than is commonly 
believed. 
In the case of the evidence supporting a pre-associated receptor mechanism, the 
following criticisms can be made: 
• The fact that a receptor dimer or oligomer can be observed 
crystallographically, or by other biophysical or biochemical methods that 
require high protein concentrations, is not by itself evidence that such 
complexes will occur to any significant degree on cells. Even if the 
crystallographically-observed interface looks “real”, in the sense that it 
shares structural characteristics of known protein-protein interfaces, the 
structure alone cannot tell us whether the binding affinity between the 
proteins is sufficient to drive substantial association at the levels of receptor 
expression that are present on any given cell. 
• For the same reason, experiments in which recombinant receptor proteins 
are heterologously expressed on cells can show spurious self-association if 
the protein is expressed at levels higher than would be seen physiologically. 
Studies that measure receptor complex formation using endogenous 
receptors on untransfected cells are rare, due to the technical difficulties 
involved. Consequently, most functional experiments have involved 
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recombinant expression of receptor proteins engineered to include a 
reporter module of some kind, such as the cytoplasmic domain of a different 
receptor, a fluorescent protein fusion partner, or complementary enzyme 
fragments. The observation of ligand-independent receptor pre-association 
by methods such as these must be interpreted with extreme caution, unless 
careful controls are done to show that the effect is seen at physiologically-
relevant receptor expression levels, and also that the reporter module does 
not itself promote spurious self-association. 
• The observation that a fraction of receptors exist in pre-associated clusters 
on cells, as is undoubtedly true in many cases, does not prove that the 
receptor is activated by a pre-associated receptor mechanism. To draw this 
conclusion it must additionally be shown that these pre-associated dimers or 
clusters are on the reaction pathway for receptor activation, and do not just 
represent an inactive “depot” state of the receptor. In this regard, the 
crystallographically-observed ligand-free dimers that have been reported for 
EPO-R [91] and TNFRp55 [105] are troubling, because in both cases the 
ligand binding site is occluded by the self-association interface seen in the 
crystal structure, and so it is not clear how ligand would bind to either 
complex to bring about its conversion to an active state. In these cases, for 
the observed complexes to represent the resting state of the receptor it is 
necessary to propose either (i) that ligand first binds to the receptor through 
a different and as-yet undiscovered binding site that remains available in the 
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pre-associated receptor complex, and in so doing induces a change in the 
mutual orientation of the receptors allowing the ligand to subsequently 
migrate in a separate step to occupy the final binding site observed in the 
intact ligand-receptor complexes; or alternatively (ii) that for ligand to bind, 
the pre-associated receptors must first spontaneously dissociate to reveal 
the ligand binding site. In this latter case the ligand is actually binding to 
monomeric receptor and activating it by ligand-induced oligomerization. This 
is not merely a semantic distinction; a receptor with a resting state 
comprising off-pathway dimers or oligomers is anticipated to display many of 
the functional properties expected for ligand-induced dimerization rather 
than a pre-associated receptor mechanism. An alternative possibility is that 
the pre-associated receptor dimers involve additional interactions between 
the cytoplasmic and/or transmembrane portions of the receptor proteins, 
such that the extracellular domains can come apart to reveal the ligand 
binding site without entirely dissociating the receptor dimer. However, 
complexes observed for receptor extracellular domains are irrelevant to 
such a mechanistic hypothesis - receptors could pre-associate through their 
cytoplasmic domains either with or without any interaction between the 
extracellular domains - and so crystallographically observed complexes 
between receptor extracellular domains, such as those reported for EPO-R 
and TNFRp55, provide no evidence either for or against such a mechanism. 
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Much of the evidence that has been used to argue for a mechanism of ligand-
induced dimerization, when examined closely, can be seen to be similarly 
inconclusive. Specifically: 
• As is widely recognized, the observation of ligand-receptor co-crystal 
structures in which the ligand appears to bring together two or more receptor 
proteins, which provided some of the early evidence supporting ligand-
induced dimerization, does not rule out a pre-associated receptor 
mechanism. Such structures do not tell us anything about the oligomeric 
state of the receptor before ligand binds, which is the key distinction 
between these two mechanisms. 
• Biophysical or biochemical studies showing that a soluble form of the 
receptor can be induced to dimerize or oligomerize in solution upon adding 
ligand cannot be taken as proof that the receptor functions by ligand-
induced dimerization in a cellular context. There are several reasons for this. 
Clearly, if the transmembrane or cytoplasmic domains of the receptor 
participate in self-association, then any study that uses engineered receptor 
constructs that lack these domains will miss or underestimate the tendency 
of the receptors to self-associate in the cellular context. Moreover, any 
experiment in which a receptor is studied in solution rather than on the 
membrane will alter the thermodynamics of binding in ways that are difficult 
to account for in any quantitative manner [110, 115], so that it is effectively 
impossible to say whether the degree of self-association that is seen in 
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solution resembles that which would be observed on the membrane. Thus, 
two receptors that are predominantly self-associated when present on the 
cell might interact so weakly in solution that this interaction is missed, 
leading the investigator to incorrectly assume that oligomerization only 
occurs in the presence of ligand. Similarly, experiments in which receptors 
are artificially captured on a solid surface or other matrix will not recapitulate 
the situation that exists on a cell membrane [115], and so cannot be 
assumed to accurately indicate the degree of self-association that would be 
observed on cells. 
• The observation that a ligand can be mutated to abolish its “Site 2” 
interaction with the second receptor chain, thereby converting the ligand 
from an agonist to an antagonist, is consistent with a mechanism of ligand-
induced dimerization but does not prove this mechanism. The effect of such 
mutations can equally well be explained in terms of a pre-associated 
receptor mechanism, in which the mutated ligand can bind to one receptor 
chain but cannot make the productive contacts with the additional receptor 
chain that are needed to stabilize the activated conformation of the receptor 
complex (Figure 1.12A). 
• Similarly, the observation of a bell-shaped dose-response when a 
homodimeric receptor such as hGH-R or EPO-R is activated by its natural 
ligand or by a monoclonal antibody is again perfectly consistent with ligand-
induced dimerization, but does not prove this mechanism. Assuming trivial 
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explanations such as cytotoxicity or rapid down-regulation of the receptor at 
high ligand concentrations can be ruled out, formally speaking the 
observation of self-inhibition at high ligand indicates that binding of one or 
more additional ligand molecules converts the activated receptor into a 
“dead-end” (non-signaling) state [17]. In a ligand-induced dimerization 
mechanism this dead-end state would involve each monomeric receptor 
chain being occupied by a separate ligand molecule, as shown in Figure 
1.4C. However, this result can be explained equally well in the context of a 
pre-associated receptor mechanism, where the dead-end state might 
involve a receptor complex in which an additional ligand molecule binds to 
induce a state in which each receptor chain is again occupied by a separate 
ligand molecule as shown in Figure 1.12B. A similar caveat applies to the 
observation, for a heterotypic receptor, that antagonists that bind to receptor 
chain two and block its interaction with chain one are noncompetitive with 
respect to ligand [16]. 
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Figure 1.12 Potential explanations for key mechanistic findings in terms of pre-associated 
receptors. (A) The observation that a ligand that is mutated to inactivate its Site 2 binding surface 
can act as an antagonist of homotyopic receptors such as hGH-R and EPO-R in cellular assays 
(see Figure 1.6) can be accounted for if each receptor chain in the pre-associated receptor dimer 
can bind a separate ligand molecule through its Site 1 binding surface, with no activating 
structural reorganization. (B) The observation that ligands for homotypic receptors such as hGH-
R and EPO-R give bell-shaped dose-response relationships in cellular assays can similarly be 
accounted for by high ligand concentrations driving the receptor to a non-signaling state similar to 
that described in (A). 
 
 Because ligand-induced dimerization and receptor pre-association 
represent extremes of a mechanistic continuum, there is in any case no 
reason to suppose that one or the other of these mechanistic alternatives 
  
 
   
51 
will apply to all cytokine and growth factor receptors, or even to the same 
receptor under different conditions. 
It is quite likely that some receptors will be found to act by one mechanism 
while other receptors use the other. Indeed, some receptors might function by 
either mechanism depending on the cellular context: i.e. using ligand-induced 
dimerization on cell types where the receptor is expressed at low levels 
compared to KD2’ (Figure 1.12), but by a pre-associated receptor mechanism on 
other cell types in which the receptor is expressed at higher levels. This behavior 
would lead to the interesting and potentially biologically significant result that two 
different cells expressing the same receptor might respond quite differently when 
exposed to the same concentration of ligand. It is even possible that some 
receptors will be found to use both mechanistic pathways, in parallel, on the 
same cell. A receptor that is expressed at a level comparable to KD2’ will have a 
fraction of molecules present as pre-associated oligomers and the remainder as 
monomers, such that some receptors might be activated by ligand binding to pre-
associated receptor oligomers while activation of the remainder requires ligand 
binding to induce them to associate. A heterogeneous distribution of receptors 
between monomeric and pre-associated states has been invoked to account for 
the observation of two affinity classes for the EGF-R on cells [116], though it 
should be noted that many other phenomena can lead to binding data that give 
nonlinear Scatchard plots, and so such interpretations must be treated with great 
caution. Given the tendency of nature to use similar molecules in different ways, 
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it would not be surprising if examples of all of these mechanistic variations were 
to eventually be shown to exist for different receptors in different cellular 
contexts. This diversity of mechanistic possibilities for a given receptor might 
account for some of the conflicting results that have been reported concerning 
the activation mechanism of particular receptors, though the intrinsic difficulty in 
performing unambiguous experiments in this area undoubtedly contributes as 
well. 
 The extent to which a given receptor will self-associate in the absence of 
ligand is not an intrinsic property of the receptor, but instead is highly 
contextual, depending as it does on local receptor expression levels. 
The contextual nature of the receptor activation mechanism constitutes an 
important and underappreciated aspect of the biology of these systems. It 
potentially provides a means for cells to dynamically regulate their 
responsiveness to a given growth factor [17], either by up- or down-regulating the 
expression of one or more receptor components, or by dynamically regulating 
how uniformly or heterogeneously the receptor is distributed on the cell 
membrane, by elevating local receptor density by induction into membrane 
microdomains such as lipid rafts [117]. This contextual plasticity in receptor 
activation mechanism, if it occurs, could potentially have important 
consequences for the relationship of stimulus to response in cytokine and growth 
factor signaling processes. To address this question will require that we cease to 
assume that a given receptor functions by a particular activation mechanism as 
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an unchanging characteristic, and instead move towards a more nuanced picture 
in which the sequence of steps by which a cytokine or growth factor activates its 
receptor is governed by the equilibrium and kinetic behavior of molecules in a 
particular cellular situation. 
Despite the enormous amount of work that has been done on this 
problem, what we can say for sure, at the present time, about which of these two 
mechanistic possibilities applies to a given cytokine or growth factor receptor is 
rather limited. We can say that, for a number of receptors at least, pre-associated 
receptor clusters exist in the absence of ligand. However, the exact number of 
receptors involved and the role of these clusters in receptor activation remains 
unclear, although important recent advances of the sort described in the 
preceding sections are bringing us closer to a definitive answer. We can also say 
that receptor activation is a multi-step process, with the first step involving 
binding of the ligand to one receptor chain, followed by recruitment or re-
organization of the remaining receptor chains to form the activated receptor 
complex. But we generally cannot say whether the later steps involve recruitment 
of freely diffusing receptor chains or structural reorganization within a pre-formed 
receptor complex. We can say that in many cases there is considerable plasticity 
in the mutual orientation of the receptor extracellular domains that can bring 
about receptor activation, but currently we do not understand in detail which 
orientations are productive and why. Without developing the experimental 
methods and theoretical insights required to achieve definitive answers to these 
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questions for a given system of interest – in the same way that, in the arena of 
enzymology, current methods allow us to achieve a quantitative description of the 
mechanism of action of essentially any enzyme of interest – our quantitative 
understanding of signaling and inter-cellular communication will remain severely 
limited. 
1.6 Other key unanswered questions concerning receptor activation and 
signaling 
This chapter has focused primarily on the longstanding controversy over 
whether various well-studied receptors are activated by a mechanism of ligand-
induced oligomerization versus a pre-associated receptor mechanism. 
Consideration of this question illustrates both the relative paucity of definitive 
mechanistic knowledge concerning how cytokine and growth factor receptors 
function, and also the technical challenges associated with trying to perform 
definitive experimental work in this difficult area. However, this is the only 
important unresolved question in this field. Indeed, there are many other aspects 
of the quantitative and mechanistic behavior of cytokine and growth factor 
receptors about which we know even less. Below, we briefly summarize some 
other major areas in which our knowledge and understanding of these systems is 
currently lacking. 
1.6.1 The role of higher-order receptor clustering 
When we consider the structure of an activated receptor complex, as it 
exists on cells, we tend to think of the smallest structural unit in which all binding 
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sites on both the ligand and the receptor are satisfied. In this, we are 
undoubtedly influenced by crystallographic studies of receptor-ligand complexes, 
in which the unit cell typically contains only one or two such assemblages, and by 
solution-phase biophysical studies in which formation of small complexes of this 
type dominates the observable behavior. There is, however, substantial evidence 
to indicate that formation of small, prototypical complexes of this kind is, for many 
receptor systems, insufficient to trigger a full biological response. Instead, in 
these cases the complexes that are formed when growth factor binds to one or 
two receptor chains is an intermediate state that goes on to aggregate into larger 
clusters that represent the active form of the receptor. The ligand-induced 
formation of large clusters is well established for immune receptors such as the T 
Cell Receptor [118], the IgE Receptor [119], and also for Eph receptor tyrosine 
kinases [120], where it was shown that the ratio of trimers and higher-order 
clusters was correlated with cell response [121]. 
Formation of higher order clusters is not commonly considered as an 
essential part of the activation mechanism of cytokine and growth factor 
receptors, however, partly due to the technical limitations in characterizing 
receptor interactions on cells that are discussed in detail in previous sections, 
and partly because such behavior has not often been directly looked for. 
Nevertheless, evidence exists for several receptors such as EGFR [97, 122], IL-
5R [123], leptin receptor [124], and several TNF family receptors [125] that higher 
order oligomers can form concomitant with receptor activation. Hsieh and co-
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workers showed computationally that Grb2 might associate with active EGFR 
clusters with a longer half-life compared to its association to EGFR dimers [126] 
and Kozer et al. showed Grb2 binding to EGFR tetramers in Baf/3 cells [127]. We 
have yet to integrate this phenomenon of receptor clustering, however, into a 
complete and coherent mechanistic picture of how ligand binding brings about 
receptor activation. 
1.6.2 Differential activation of a common receptor by different cytokine or 
growth factor ligands 
As we have described in the preceding sections, for many receptors it 
appears that there is considerable plasticity in the mutual orientation of the 
receptor extracellular domains that can bring about receptor activation, but 
currently we do not understand in detail which orientations are productive and 
why. Moreover, there is considerable uncertainty about the extent to which these 
structural differences in the orientation of the extracellular domains are 
transmitted to the cytoplasmic portions of the receptor [128], and the 
consequences for the quality of the signaling response that results. This issue 
has important implications in the many cases in which a receptor can be 
activated by two or more different ligands. 
Different ligands that activate a common receptor typically have different 
biological activities in vivo, as has been well established for example through 
genetic knock-out experiments in mice. In general, however, it is unclear to what 
extent these different in vivo activities are due simply to the different times, 
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places and levels at which each ligand is expressed, versus to biochemical 
differences in how the ligands engage their common receptor. One possibility is 
that different ligands represent essentially redundant ways to achieve a common 
activated state of the receptor, as if the receptor is analogous to a light switch 
that has a single “on” state regardless of how activation is brought about. 
Alternatively, different ligands might induce activated receptor complexes with 
quite different conformations, causing geometrically distinct interactions between 
the receptor cytoplasmic domains. If this is the case – that is, if the receptor is 
more analogous to a joystick than to a simple light switch – then it is possible that 
different ligands will induce distinct patterns of intracellular signals leading to 
distinct biological responses. Qualitative analysis generally shows that different 
ligands activate the same set of signaling pathways downstream of a given 
receptor. However, in relatively few cases have such ligands been compared 
using quantitative methods that could identify differences in the levels, timing and 
durations of the various downstream signaling events. Moreover, we know very 
little about the functional consequences that such quantitative differences in the 
quality of the signal might bring. One instructive exception to this paucity of 
knowledge is provided by the work of Schreiber, Piehler and their co-workers and 
collaborators on the activation of the Type I Interferon Receptor by interferon 
IFNβ versus IFNα2. Both of these homologous cytokines are used as drugs, but 
they can have quite distinct activities in certain disease states leading, for 
example, to the use of IFNβ as a treatment for multiple sclerosis, a condition for 
  
 
   
58 
which IFNα2 is not beneficial. In an elegant series of studies, Schreiber and 
Piehler showed that the different biological activities of these two ligands results 
from the different kinetic lifetimes of the activated receptor complexes that each 
forms with their common receptor, which in turn results from the higher affinity of 
IFNβ versus IFNα2 for binding to the IFNAR1 receptor component that is 
recruited into the complex in the second step in receptor activation [31-33]. 
Notwithstanding this and a small number of other studies of this aspect of 
receptor signaling, as a general rule we are largely ignorant of the biological 
implications of the very widely observed phenomenon of ligand-receptor 
promiscuity. 
1.6.3 The link between pathway and function 
The great variety of stoichiometric compositions that are observed for 
cytokine and growth factor receptors from different protein families (Figure 1.1B) 
implies that there are a variety of different molecular mechanisms for receptor 
activation. That is, the number and sequence of steps by which the initial binding 
of the ligand to the first receptor chain leads sequentially to the assembly of the 
activated receptor complex must clearly differ depending on the number of 
receptor components involved, and the sequence in which these components 
undergo the requisite association events and conformational changes. The more 
components are involved, the greater the number of possible activation 
mechanisms that exist (Figure 1.13A). One example of a receptor comprising 
more than two receptor components for which a detailed mechanism has been 
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proposed is the activation of RET by artemin (ART) in conjunction with the GPI-
linked co-receptor GFRα3 [17]. The activated RET receptor complex includes two 
copies of RET, two copies of GFRα3 and one copy of the covalently-dimeric 
ligand, ART. In this study the authors measured how the level of RET 
phosphorylation varied in response to independent manipulation of the ART 
concentration and the level of available GFRα3 on the cell. The results were 
qualitatively and quantitatively consistent with a mechanism in which ART first 
binds to one molecule of GFRα3, followed by recruitment of the first RET 
molecule, followed by binding of the second molecule of GFRα3, followed by 
recruitment of the second RET molecule to give the activated complex (Figure 
1.13B). Alternative pathways, for example in which GFRα3 exists as a preformed 
dimer, or in which the second GFRα3 is recruited into the complex before the first 
RET molecule, were incompatible with the experimental data. Importantly, the 
results were used to develop a quantitative model to account for the relationship 
between the level of stimulation by ART and the resulting level of activated RET 
on the cell, and to elucidate the roles that individual steps in the activation 
mechanism govern the functional coupling of input to output in this system 
(Figure 1.13C) [17]. Remaining unresolved is whether activation of RET by any of 
its three other activating ligand/co-receptor combinations – GDNF/GFRα1, 
neurturin/GFRα2 and persephin/GFRα4 – use the same mechanism, or whether 
in some of these cases the receptor complex might assemble by a different 
sequence of steps, and if so what the consequences would be for the functional 
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relationship between ligand concentration and activated RET levels on the cell. 
The general question of how receptor complexes assemble on the cell, how the 
choice of assembly mechanism affects the function and regulation of receptor 
signaling, and therefore what is the reason why nature has evolved the many 
different structures and stoichiometries of receptor complexes illustrated in 
Figure 1.1B, represent yet another aspect of receptor signaling about which we 
remain largely ignorant. 
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Figure 1.13 Proposed mechanism for the activation of RET by ART plus GFRα3, and its link to 
function [17]. (A) Reaction tesseract illustrating potential pathways by which binding of ART to 
different possible resting states of the receptor (green squares) could lead to assembly of the 
activated receptor complex (pink square with bold red outline). The proposed pathway is 
indicated by the black equilibrium arrows. (B). The proposed mechanism for the activation of RET 
by ART plus GFRα3. (C) Simulations showing how the activation mechanism shown in (B), 
together with the experimentally determined values for KD1’-KD4’ predicts how the different species 
on the activation pathway will vary with ART concentration, for NB41A3-mGFRα3 cells 
expressing RET and GFRα3. The filled circles show experimental measurements of phosphoRET 
levels on NB41A3-mGFRα3 cells stimulated with different concentrations of ART, normalized to 
the same y-axis scale. Figure reproduced from [17] with permission. ©2006, Rights Managed by 
Nature Publishing Group.  
 
1.7 Summary 
Our understanding of the detailed mechanism of action of cytokine and 
growth factor receptors – and particularly our quantitative understanding of the 
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link between structure, mechanism and function – lags significantly behind our 
knowledge of comparable functional protein classes such as enzymes, G protein-
coupled receptors, and ion channels. In particular, it remains controversial 
whether such receptors are activated by a mechanism of ligand-induced 
oligomerization, versus by a mechanism in which the ligand binds to a pre-
associated receptor dimer or oligomer, which becomes activated through 
subsequent conformational rearrangement. A major limitation to progress has 
been the relative paucity of methods for performing quantitative mechanistic 
experiments on unmodified receptors expressed at endogenous levels on live 
cells. New approaches and techniques have led to rapid recent progress in this 
area, however, and the field is poised for major advances in the coming years, 
which promises to revolutionize our understanding of this large and biologically 
and medically important class of receptors. 
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Chapter 2 Probing the RET activation mechanism using anti-RET 
monoclonal antibodies 
 
2.1 Introduction  
A large proportion of growth factor receptors can be activated by two or 
more distinct ligands [9-14]. However, it remains largely unresolved whether 
these different ligands represent redundant ways to convert the receptor to a 
common activated state with fixed signaling and functional properties, or 
alternatively whether each ligand induces a unique activated receptor complex 
that signals in a distinct way. Activation of a given receptor by different ligands 
generally engages the same set of downstream signaling pathways. But few 
studies have addressed whether activation of a growth factor receptor by 
different ligands might result in quantitative differences in the absolute or relative 
amplitudes or timing of the various signaling events downstream of the receptor. 
This question has been definitively answered in the case of the Type 1 Interferon 
Receptor, a cytokine receptor that signals primarily through the JAK/STAT 
pathway [31-33]. Some data also exist for the Epidermal Growth Factor Receptor 
(EGFR) system, suggesting that different phenotypical outcomes may results 
from high- and low-affinity interactions of the receptor with different ligands, from 
variations in ligand-induced receptor dimerization kinetics, or from differential 
ligand-dependent receptor internalization [129-131]. However, to our knowledge 
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there is very little definitive information available on this question for any other 
growth factor receptor. 
In addition to activation by their natural ligands, receptors for cytokines 
and growth factors can sometimes be activated in artificial ways, such as by 
introducing cysteine residues that mediate formation of covalent receptor dimers 
[64, 65], or by monoclonal antibodies that bind to the receptor extracellular region 
[15, 46, 47, 49-59, 132], by synthetic peptide [76, 77, 81, 82, 84, 87] or small 
molecule agonists that bind to the extracellular portion of the receptor [16, 66, 
67], by covalently linking two monovalently binding antagonist molecules [60], or 
by dimerizing the kinase domains via a chimeric protein that binds to a bivalent 
small molecule [133-135]. Agonist monoclonal antibodies (mAbs), in particular, 
have been reported for a number of cytokine and growth factor receptors [15, 46, 
47, 49-59, 132], and interest has been expressed in them as potential 
therapeutics [136-138]. The key question of whether agonist mAbs signal 
identically to the receptor’s natural ligand has rarely been addressed in detail, 
however. A notable exception was the study of the signaling characteristics of a 
set of diabodies (covalently linked dimeric antibody VH/VL variable domain 
fragments, possessing two binding sites) against the EPO-R [87]. The authors 
studied the effect of the relative orientation of two EPO-R molecules, bridged by 
different diabodies, on proximal and distal signaling, as well as on the cellular 
response of cell proliferation. Their analysis revealed that the EPO-R could be 
activated to different extents by different diabodies, and that the amplitude of the 
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response correlated well with the distance, as well as the rotation angle, between 
the ERO-R molecules within a dimer. More fundamentally, analysing how the 
quality of the signaling response is affected when the receptor is activated by 
different natural or artificial means has the potential to shed light on the extent to 
which the activated receptor can exist in a variety of states with distinct signaling 
properties. Few quantitative, systematic studies of this question have been 
reported. 
The receptor tyrosine kinase RET is a good system for the investigation of 
this question for several reasons. RET is expressed on certain subsets of 
neuronal cells, and is important in kidney development and in the development 
and maintenance of the nervous system [2, 139]. Loss of function mutations in 
RET causes abnormal development in the enteric nervous system, which leads 
to Hirschprung’s disease, while gain of function mutations result in several types 
of cancer [140, 141]. RET serves as the receptor for a family of four neurotrophic 
growth factors, glial cell-line derived neurotrophic factor (GDNF), neurturin, 
artemin (ART) and persephin, each of which additionally requires the 
participation of one of four glycosylphosphatidylinositol (GPI)-anchored co-
receptors GDNF Family Receptor alpha chain (GFRα)1-4 [139, 140, 142, 143] 
(Figure 2.1).  
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Figure 2.1 Cartoon representation of the RET receptor system and key downstream signaling 
pathways. The activated receptor complex consists of one disulfide-linked dimeric ligand 
molecule (purple), two GFRα co-receptors (green), and two RET receptors (dark blue). Upon 
complex formation, the kinase domains of RET undergo autophosphorylation on multiple tyrosine 
residues that serve as docking sites for adapter proteins or directly for substrates that are then 
phosphorylated by the activated RET kinase domain.    
 
At least some of these co-receptors can also function in trans – that is, as soluble 
co-ligands rather than as cell associated co-receptors [143, 144]. Knock-out 
mice, in which the different ligands and co-receptors have been genetically 
deleted, show distinct phenotypes [145-151], raising the possibility that the four 
ligand/co-receptor pairs might activate RET in different ways. However, it is 
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equally possible that the observed phenotypic differences result simply from 
differences in tissue distribution of the different RET ligands and co-receptors 
and in the timing of their expression during development. One study has reported 
that two RET ligands, GDNF and neurturin, gave distinct signaling responses in 
NG108-15 cells that express RET plus GFRα1 [152]. This difference might, 
however, have resulted from the weak cross-reactivity of neurturin with GFRα1, 
compared to its preferred co-receptor GFRα2 [153]. Finally, RET is a proto-
oncogene, and can undergo point mutations in its extracellular or cytoplasmic 
domains, leading to the development of Multiple Endocrine Neoplasia type 2A or 
2B (MEN 2A or MEN 2B) [154]. It has been reported that the autophosphorylation 
sites on RET in MEN 2A and MEN 2B expressing cells differ [155-157], and that 
phosphorylation sites on RET in MEN 2B differ from those in the wild-type protein 
[155, 157, 158], providing evidence that the RET cytoplasmic domain can adopt 
a distinct activated state under certain circumstances. 
Here we describe the activation of RET by two different monoclonal 
antibodies, mAb1 and mAb2, that bind to the extracellular domain of the receptor. 
We compare the ability of these mAbs to activate receptor autophosphorylation, 
to induce activation of the key downstream signaling effectors ERK and Akt, and 
to support the functional cellular response of neurite outgrowth, with the 
corresponding activity of ART plus GFRα3. Both of the mAbs were raised by 
immunizing hamsters with recombinant rat RET extracellular domain, and have 
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been reported previously (US Patent 6861509; [153]). However the agonist 
properties of these mAbs have not previously been characterized in detail.  
2.2 Materials and Methods 
2.2.1 Materials 
2.2.1.1 Chemicals, Antibodies and Recombinant Proteins 
All salts, NP-40, phenylmethanesulfonyl fluoride (PMSF), bovine serum 
albumin, sulfuric acid, Dulbecco’s PBS, and 3,3’,5,5’-tetramethylbenzidine 
dihydrochloride (TMB) were purchased from Sigma-Aldrich (St. Louis, MO) or 
Fisher (Waltham, MA). Rat artemin (ART) [159] and the Armenian hamster anti-
rat RET antibodies [153] were gifts from Biogen (Cambridge, MA). Goat anti-
Armenian hamster IgG (H + L) (cat. #127-005-160), Alexa Fluor 488-conjugated 
goat anti-mouse IgG (115-545-062), and Alexa Fluor 647-conjugated donkey 
anti-goat IgG (705-605-003) were purchased from Jackson Immonoresearch 
Laboratories, Inc (West Grove, PA). Rabbit anti-RET monoclonal antibody 
(ab134100), biotinylated goat IgG isotype control (ab37376) and Armenian 
hamster IgG monoclonal isotype control (ab18479) were purchased from Abcam 
(Cambridge, MA). PE-conjugated anti-Amernian hamster IgG (sc-3733), was 
from Santa Cruz Biotechnology (Dallas, TX). Mouse anti-phosphotyrosine IgG-
HRP (037720) was from Invitrogen (Minneapolis, MN). PathScan® phospho-Akt 
(Thr308) sandwich ELISA antibody pair (7144) and PathScan® phospho-p44/42 
MAPK (Thr202/Tyr204) sandwich ELISA antibody pair (7246) were purchased 
from Cell Signaling Technology (Danvers, MA).  
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2.2.1.2 Cell Lines and Tissue Culture Reagents 
The murine neuroblastoma cell line NB41A3, which expresses RET, was 
purchased from ATCC (Manassas, VA). The NB41A3-mGFRα3 cell line was 
derived from NB41A3 by stably transfecting the cells with mouse GFRα3 as 
described previously [160], and was a generous gift from Biogen Idec 
(Cambridge, MA). Both cell lines were maintained in DMEM (Life Technologies, 
Grand Island, NY or Sigma Aldrich, St. Lois, MO) supplemented with 10% fetal 
bovine serum (Atlanta Biologicals), in a humidified incubator at 37 °C with 5% 
CO2 and passaged using a standard EDTA protocol [161].  
2.2.2 Methods 
2.2.2.1 RET Phosphorylation (KIRA) ELISA 
NB41A3-mGFRα3 cells were plated in 24-well plates (Santa Cruz, Dallas, 
TX) overnight at a density of 3 x 105 cells/well in 500 µL of growth medium 
(DMEM, supplemented with 10% FBS) per well. Cells were stimulated by adding 
the desired concentration of mAb1, mAb2 or artemin in 300 µL DMEM, and 
incubated for the desired time. For dose-response experiments cells were 
incubated with mAb1 or mAb2 (0, 0.05, 0.14, 0.41, 1.23, 3.70, 11.1, 33.3, 100 or 
300 nM), or with 4 nM ART as a positive control, for the specified time. For time-
course experiments cells were incubated with 10 nM mAb2, 100 nM mAb1 or 4 
nM ART for 0, 2, 5, 10, 20, 40, 60 or 90 min. For experiments testing the effect of 
pre-clustering the anti-RET agonist antibodies, mAb1 or mAb2 was pre-incubated 
for 15 min at room temperature with the indicated molar ratio of goat anti-
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Armenian hamster polyclonal IgG (typically a 2-fold molar excess of anti-hamster 
IgG), and then the cells were stimulated by adding the pre-clustered anti-RET 
antibody. In all experiments, at the end of the cell stimulation period the reaction 
was stopped by washing each well once with 300 µL ice-cold Dulbecco’s 
phosphate buffered saline (DPBS) and then adding 150 µL lysis buffer (10 mM 
Tris, 0.5% NP-40, 0.2% sodium deoxycholate, 50 mM NaF, 0.1 mM Na3VO4, 1 
mM PMSF, pH 8.0) and incubating on ice for 30 min with vigorous shaking. 
Assay plates were prepared by coating a 96-well ELISA plate (Santa Cruz, 
Dallas, TX) with 0.523 µg/mL rabbit monoclonal anti-RET IgG (ab134100, 
Abcam, Cambridge, MA) in 100 µL/well DPBS per well and incubating overnight 
at 4 °C. Excess capture antibody was removed by washing the wells three times 
with 300 µL PBS containing 0.05% Tween-20 (PBST), and then the wells were 
blocked for one hour with 300 µL KIRA blocking buffer (3% BSA, 1% FBS in 
PBST) at room temperature with gentle shaking. To measure pRET levels in the 
cell lysate, samples the plate was washed with PBST, and 110 µL of cleared cell 
lysate was added to each well. The plate was incubated with the lysate for 2 
hours at room temperature with gentle shaking, washed three times with PBST, 
and incubated with 100 µL of 1.5 µg/mL HRP-conjugated mouse anti-
phosphotyrosine monoclonal antibody in blocking buffer for one hour at room 
temperature with gentle shaking. Unbound detection antibody was removed by 
washing three times with PBST, and the signal was developed by adding 100 µL 
of the HRP substrate 3,3’,5,5’-tetramethylbenzidine dihydrochloride (TMB) to 
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each well. After allowing the color to develop over a period of approximately 3-4 
min, the reaction was quenched with 100 µL of 1 M sulfuric acid, and absorbance 
at 450 nm was measured using a SpectraMax M5 microplate reader (Molecular 
Devices, Sunnyvale, CA).  
2.2.2.2 ERK and Akt Phosphorylation ELISAs 
Cells were treated and lysates prepared as described above for the RET 
phosphorylation ELISAs, except that cells were lysed using 300 µL pERK/pAkt 
lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-
100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 50 mM NaF, 1 
mM Na3VO4, 1 mM PMSF, pH 7.5). A 96-well ELISA plate was coated by adding 
to each well 100 µL of a 100-fold dilution of stock solution of anti-ERK or anti-Akt 
capture antibody in PBS, and incubating overnight at 4 °C. On the following day 
the plates were washed three times with 300 µL PBST per well and blocked for 
one hour with 300 µL pERK/pAkt blocking buffer (1% BSA in PBST) per well. 
After clearing the cell lysates by centrifuging at 10000g for 5 min, 110 µL was 
added to each of two wells on the assay plate, one for measurement of pERK 
and the other for Akt. The plates were incubated for two hours at room 
temperature with gentle shaking, after which the wells were washed three times 
with PBST.  Next, 100 µL of a 100-fold dilution of the stock mouse anti-
phosphoERK or anti-phosphoAkt detection antibody in blocking buffer was added 
to the wells, and the plate was incubated for one hour at room temperature with 
gentle shaking. After washing the wells three times with PBST to remove excess 
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detection antibody, 100 µL of a 1000-fold dilution of the stock of the HRP-
conjugated anti-mouse IgG was added for 30 min. The plate was washed three 
times with PBST, 100 µL of TMB solution was added, and the plate was 
incubated for 7-9 min until the color developed. The reaction was quenched by 
adding 100 µL of 1 M sulfuric acid to each well, and the absorbance at 450 nm 
was measured using a SpectraMax M5 microplate reader (Molecular Devices, 
Sunnyvale, CA). The anti-phospho44/42 MAPK rabbit capture antibody 
recognizes ERK1/2 when dually phosphorylated at Thr202/Tyr204 in ERK1 or at 
Thr185/Tyr187 ERK2, or when singly phosphorylated at Thr202 in ERK1 or at 
Thr185 in ERK2, as described by the manufacturer 
(http://www.cellsignal.com/products/elisa-kits/7246). The anti-phospho-Akt rabbit 
capture antibody recognizes Akt1 phosphorylated at Ser308 
(http://www.cellsignal.com/products/elisa-kits/7144).  
2.2.2.3 Clustering mAb1 and mAb2 with anti-Armenian hamster polyclonal 
antibody 
Solutions of different concentrations of mAb2 and goat anti-Armenian 
Hamster IgG (H + L) were prepared in DMEM and incubated for 15 min at room 
temperature, after which they were added to the cells (300 µL per well).  
2.2.2.4 Antibody binding to cell-surface RET at equilibrium 
Binding of mAb1 and mAb2 to RET expressed on NB41A3-mGFRα3 cells 
was measured using flow cytometry. Cells were lifted from their tissue culture 
plates using 20 mM EDTA in PBS solution, pelleted, and resuspended at a 
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density of 2x105 cells/mL in 1 mL FACS buffer (PBS, 2% FBS, 0.1% BSA, 0.1% 
sodium azide). The anti-RET antibody was added to the desired final 
concentration (0, 0.05, 0.14, 0.41, 1.23, 3.70, 11.1, 33.3, 100 or 300 nM for 
mAb1, and 0, 0.01, 0.02, 0.05, 0.14, 0.41, 1.23, 3.70, 11.1 or 33.3 nM for mAb2), 
followed by incubation for 30 min on ice. The cells were washed once with 1 mL 
FACS buffer and resuspended in 100 µL of 2.5 µg/mL phycoerythrin-conjugated 
anti-Armenian hamster (H + L) antibody in FACS buffer. The samples was 
incubated for 30 min on ice in the dark, then washed twice with 1 mL FACS 
buffer and resuspended in 200 µL FACS buffer. The fluorescence intensity of 
cells was measured using a FACSCalibur flow cytometer (BD Biosciences, 
Billerica, MA). The data were analyzed using FlowJo software (FlowJo LLC, 
Ashland, OR). Binding of clustered mAb1 and mAb2 to RET was detected using 
Alexa Fluor 488-conjugated goat anti-mouse IgG that cross-reacts with hamster 
antibodies. 
2.2.2.5 Unclustered mAb2 binding to adherent cells at 10 min 
Cells were plated in 24-well plates at a density of 3x105 cells per well in 
500 µL DMEM supplemented with 10% FBS and allowed to attach overnight. 
Cells were washed with 1 mL FACS buffer and incubated with different 
concentrations of pre-clustered or unclustered mAb2 in 300 µL FACS buffer for 
10 min or 60 min. The unbound mAb2 was removed by washing with 2 mL FACS 
buffer, and the cells were incubated with 5 µg/mL PE-conjugated anti-Armenian 
hamster IgG for 5 min. Unbound detection antibody was removed by washing 
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with 2 mL FACS buffer, and the fluorescence intensity of cells was measured 
using a FACSCalibur (BD Biosciences, Billerica, MA). The data were analyzed 
using FlowJo software (FlowJo LLC, Ashland, OR). The binding data obtained by 
incubating the cells with mAb2 for 60 min was fitted to a rectangular hyperbola 
and the maximum signal from the fit was used as the signal at 100% RET 
occupancy.  
2.2.2.6 Clustered mAb2 binding to adherent cells at 10 min 
A stock solution of 300 nM mAb2 pre-clustered with 600 nM polyclonal 
anti-Armenian hamster IgG for 15 min at room temperature was prepared in 
FACS buffer. Pre-clustered mAb2 solutions of concentrations 33.3, 11.1, 3.70, 
1.23, 0.41, 0.14, 0.046 and 0.015 nM were prepared by serial dilutions of the 
stock solution. NB31A4-mGFRα3 cells plated in 24-well plates were washed with 
2 mL FACS buffer, and then incubated with the pre-clustered mAb2 solutions for 
10 min. The unbound agonist was removed by washing with 2 mL FACS buffer, 
and the cells were lifted with gentle pipetting. The samples were centrifuged at 
300g for 5 min and the cells pellets were resuspended in 100 µL FACS buffer 
containing 2.5 µg/mL Alexa Fluor 488-conjugated anti-mouse IgG and incubated 
for 20 min on ice. Unbound detection antibody was removed by washing with 2 
mL of FACS buffer. Fluorescence intensity was measured using FACSCalibur 
(BD Biosceinces, Billerica, MA) and the data were analyzed using FlowJo 
software (FlowJo LLC, Ashland, OR). The data were fitted to a four-parameter 
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equation and the maximum signal from the fit was set as the signal at 100% RET 
occupancy.  
2.2.2.7 Activation of ERK and Akt by FAB2 
Cells were treated with 0, 0.22, 0.67, 2.0, 6.0 or 18 nM FAB2 or 4 nM ART 
for 10 min. The activation of ERK and Akt was measured exactly as described for 
the pERK and pAkt ELISAs. 
2.2.2.8 FAB2 Competition ELISA 
NB41A3-mGFRα3 cells were plated in 24-well plates overnight at a 
density of 3x105 cells/well. Cells were incubated with 0, 1.23, 3.70, 11.1, 33.3 or 
100 nM Fab2 prepared in 300 µL DMEM. The supernatant was aspirated, and 
300 µL DMEM containing the same concentrations of Fab2 in combination with 1 
nM mAb2 was added to the cells for 5 min. The result for treatment with 0 nM 
Fab2 and 4 nM ART was used as a positive control. Stimulation was stopped by 
washing the cells once with 300 µL PBS and lysing them with ERK/Akt lysis 
buffer. The levels of pERK and pAkt were measured by the appropriate ELISAs. 
2.2.2.9 Neurite Outgrowth Assay 
NB41A3-mGFRα3 cells were seeded in 24-well plates overnight at a 
density of 4000 cells per well in 500 µL growth medium. On the next day the cells 
were treated by replacing the growth medium with serum-free DMEM containing 
mAb2, mab2 with goat anti-Armenian hamster IgG (H + L), mAb2 with goat IgG 
isotype control, Armenian hamster monoclonal IgG isotype control and anti-
Armenian Hamster IgG (H + L), ART, or with DMEM alone. The plate was 
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incubated for 5 days in a humidified incubator at 5 % CO2 and 37 °C. The DMEM 
was aspirated and replaced with 500 µL fresh DMEM. Cells were fixed at 37 °C 
with 500 µL of a warm solution of 8% paraformaldehyde (PFA), 8% sucrose in 
PBS added directly to the DMEM for 15 min [162]. Cells were washed twice with 
1 mL PBS and incubated for 15 min in 500 µL PBS containing 0.1% v/v Hoechst 
stain (Sigma Aldrich, cat # 861405). Cells were rinsed again, left in 500 µL PBS 
and imaged using a fluorescent inverted microscope (Olympus IX70, Center 
Valley, PA). 5-9 fields of view were acquired per well, and the number of nuclei 
was determined using ImageJ software (National Institutes of Health, Bethesda, 
MD). Cells bearing a total neurite length of at least one cell diameter were 
counted as positive. The experiment was repeated three times on different days 
using independently prepared treatment solutions.  
2.2.2.10 SPR characterization of mAb2 binding to RET 
To test if mAb2 binds to more than one site on the RET extracellular 
domain, we performed a surface plasmon resonance (SPR) experiment, using 
Biacore 3000 (GE Healthcare Bio-Sciences, Pittsburgh, PA). 2.5 µg/mL mouse 
GFRα3-Fc solution (Biogen), prepared in 10 mM acetate buffer, was covalently 
immobilized to a Biacore sensor chip (GE Healthcare Bio-Sciences) using 
EDC/NHS (GE Healthcare Bio-Sciences) covalent coupling. A solution of 50 nM 
ART and 200 nM RET was flown over the chip surface for 17.5 min to form the 
ART-GFRα3/Fc-RET(ECD). Without a washing step, 10 nM mAb2 solution was 
flown over this complex and the mAb2 binding was allowed to reach equilibrium. 
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Due to the very different binding kinetics of ART and RET to the GFRα3/Fc on 
the chip, we were able to calculate the response units that corresponded to RET 
binding alone. Based on the amount of bound RET, we calculated the expected 
response units for mAb2 binding and a comparison of this predicted value with 
the experimental result supported the interpretation that there was no more than 
one mAb2 binding site in the RET extracellular domain.  
2.3 Results and Discussion  
2.3.1 Dose-dependent phosphorylation of RET, ERK and Akt by mAb1 and 
mAb2 in comparison to natural ligand ART 
To test whether RET can be activated with monoclonal antibodies we 
treated NB41A3-GFRα3 cells, which endogenously express mouse RET and are 
stably transfected with GFRα3, for 10 minutes with different concentrations of the 
two Armenian hamster anti-RET monoclonal antibodies mAb1 and mAb2. At the 
end of the incubation period the cells were lysed, and the lysates were assayed 
by KIRA ELISA to determine the relative concentrations of phospho-RET.  As a 
positive control we used 4 nM ART stimulation, which has been shown to induce 
66% of the maximal possible level of RET activation at 10 min [163].  We 
observed dose-dependent activation of the receptor by both antibodies, with 
pRET levels reaching saturation and exhibiting hints of a bell-shaped curve 
(Figure 2.2A). Both antibodies triggered ≤20% of the response seen with 4 nM 
ART.  
  
 
   
78 
 
Figure 2.2 Activation of RET upon stimulation of cells for 10 min with mAb1 or mAb2. (A) 
NB41A3-mGFRα3 cells were incubated with various concentrations of mAb1 (blue squares), 
mAb2 (red circles) or with 4 nM ART for 10 min. The reaction was stopped by lysing the cells, and 
phosphorylated RET (pRET) levels were measured by ELISA. The data points are averages of 
three independent experiments and the error bars are standard deviations. (B) Equilibrium 
binding curves for mAb1 (blue squares) and mAb2 (red circles) measured by flow cytometry. 
NB41A3-mGFRα3 were incubated with various concentrations of mAb1 or mAb2 for 60 min. The 
data were fitted to a rectangular hyperbola, and the maximum signal from the fit was defined as 
100% RET occupancy. 
 
Upon stimulation with its natural neurotrophin, RET becomes 
phosphorylated on multiple tyrosine residues [164, 165]. Thus, the maximal 
pRET levels measured for the two antibodies could be interpreted in two ways: 
There could be fewer activated receptors, or all receptors could be 
phosphorylated but on fewer Tyr residues. To distinguish between these 
possibilities, we performed a similar ELISA where cells were stimulated with the 
same concentrations of mAb1, but instead of measuring total phosphorylation, 
we detected phosphorylation using an antibody specific for Tyr1062 in the 
intracellular domain of RET. If fewer receptors per cell were activated by 
treatment with the agonist antibodies compared to by stimulation with ART, and 
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the receptors were phosphorylated on the same tyrosine residues, we would 
expect the signal amplitude elicited by the antibodies to be the same fraction of 
the ART induced pRET level regardless of whether pRET is measured using a 
total pTyr antibody or the pTyr1062-specific antibody. If, however, stimulation 
with the antibody agonists resulted in the activation of the same number of 
receptors as treatment with ART did, but the receptors were phosphorylated on 
fewer tyrosine residues, it is likely that the two methods for detecting RET 
phosphorylation would yield different relative pRET amplitudes for stimulation 
with the antibodies versus with ART.  
Figure 2.3 shows that mAb1 was able to induce Tyr1062 phosphorylation 
at levels that were only about 20% of that observed for treatment with 4 nM ART. 
This fraction was identical to the relative pRET amplitude that we measured 
when we detected total phosphorylation of RET in the same experiment. This 
result shows that the mAb1 was indeed able to activate, at most, ~20% of the 
RET receptors that could be activated by 4 nM ART. The antibody mAb2 was 
used as the capture antibody in the Tyr1062 RET ELISA, which made the assay 
unsuitable to measure the activation of RET at this tyrosine residue upon 
stimulation with mAb2. However, our data for mAb1 strongly suggests that the 
antibodies only manage to activate ≤ 20% of the available receptors, rather than 
activating larger number of RET molecules but with phosphorylation at fewer 
sites. 
  
 
   
80 
  
Figure 2.3 Activation of RET by mAb1, measured by total phosphorylation or by phosphorylation 
on tyrosine 1062. Cells were treated with different concentrations of mAb1 or 4 nM ART for 10 
min. The stimulation was stopped by lysing the cells, and the levels of phosphorylated RET were 
measured using antibodies that recognize all phosphorylated tyrosines or pY1062 only. 
  
 We measured the ability of our agonist antibodies to trigger activation of 
two key signaling molecules downstream of RET, ERK and Akt. NB41A3-
mGFRα3 cells were treated in the same way as for measuring pRET, but 
assayed for levels of phosphorylation of ERK and Akt by ELISA. Both agonist 
mAbs gave dose-dependent phosphorylation of both ERK and Akt showing that 
the activated RET receptors they induce were able to engage in downstream 
signal transduction (Figure 2.4).  
The levels of phosphorylation for both ERK and Akt were again lower than 
was observed upon treating the cells with 4 nM ART. The maximum Akt 
activation was 30-50% and that of ERK was 60-70% of the level achieved with 
ART/GFRα3, with mAb2 being the more potent agonist. The higher amplitude of 
the pERK and pAkt responses relative to that of pRET suggested that there was 
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significant amplification of the signal as it was propagated downstream of the 
RET receptor.  
 
Figure 2.4 Activation of ERK and Akt upon stimulation of cells for 10 min with mAb1 or mAb2. 
NB41A3-mGFRα3 cells were incubated with various concentrations of mAb1 (blue squares), 
mAb2 (red circles), or 4 nM ART for 10 min. The reaction was stopped by lysing the cells, and 
phosphorylated ERK (A) and Akt (B) levels were measured from the same lysates by ELISA. The 
data points are averages of three independent experiments and the error bars are standard 
deviations. 
  
To rule out the possibility that the pRET, pERK, and pAkt we measured upon 
treatment of cells with the antibody agonists actually resulted from a weak 
autocrine signaling by ART, we measured the pERK and pAkt responses to 
stimulation with mAb1 and mAb2 on parental NB41A3 cells.  This cell line 
expresses only RET and not GFRα3, and thus does not respond to stimulation 
with ART (data not shown). Treatment of NB41A3 and NB41A3-mGFRα3 cells 
with 100 nM mAb1 or 33 nM mAb2 for 10 min gave similar levels of ERK and Akt 
phosphorylation (Figure 2.5), showing that RET activation was indeed triggered 
by the antibody agonists.  
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Figure 2.5 Activation of ERK and Akt by mAb1 and mAb2 on NB41A3 and NB41A3-mGFRα3 
cells. NB41A3 cells were seeded at 3 x 105 cells per well in a 24-well plate. Cells were treated 
with a solution of 100 nM mAb1 (A) or 33 nM mAb2 (B), and the pERK and pAkt levels were 
measured using the appropriate ELISAs. The results are presented as fold change in the 
absorbance of stimulated NB41A3 cells (solid bars) or NB41A3-mGFRα3 (patterned bars) at 450 
nm over control cells that were treated with assay buffer only. The solid bars represent the results 
for NB41A3 cells from a single experiment. The patterned bars show the fold change in 
absorbance of NB41A3-mGFRα3 cells, treated with the same concentrations of mAb1 (A) or 
mAb2 (B), and were taken from our dose-response experiments shown in Figure 2.4. Plotted is 
the average of three independent experiment and the error bars represent standard deviations. 
 
 The results described above reveal a number of differences between the 
signaling activities of the agonist mAbs versus that observed upon stimulation of 
the same cells with ART acting in conjunction with GFRα3. Most notably, even at 
maximally effective concentrations the mAbs induced only relatively low levels of 
pRET. This observation could be the result of a difference in the ability of the 
antibodies and ART to activate RET, of variations in the signaling properties of 
the activated RET complexes that are formed, or from a combination of the two. 
2.3.2 Efficiency of RET, induced by mAb1, mAb2, or ART, to activate 
transient responses for ERK and Akt 
To compare the intrinsic signaling properties of the activated RET complexes 
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formed by a given agonist mAb versus ART/GFRα3, it was necessary to first 
factor out effects that result from differences in the ability to activate RET at all. 
This was done by comparing the amplitudes of the pERK or pAkt signalling 
responses produced by different agonists, but measured at agonist 
concentrations that produce identical levels of pRET. We have previously 
reported that, upon activation by ART/GFRα3, RET shows peak receptor-effector 
coupling ratios of pERK/pRET ~ 150 and pAkt/pRET ~ 50, with these coupling 
ratios gradually decreasing as the pRET response becomes saturated [163]. 
Figure 2.6 shows the pERK and pAkt responses at 10 min after stimulation, from 
Figures 2.4A and B, plotted as a function of the pRET levels seen for each 
treatment condition (from Figure 2.2A). Also shown are the corresponding 
relationships for stimulation of the same cells with ART, which we have described 
previously [163]. Figure 2.6A shows that, for both mAb1 and mAb2, pERK 
increases linearly with increasing pRET, and that the data for the two mAbs fall 
on the same line. Thus, although the two mAbs bind RET with different affinities 
(Figure 2.2B), and show substantial differences in potency for activating RET and 
its downstream signaling effectors (Figures 2.2A and 2.4), the activated RET that 
is formed by each mAb appears to be identical in its ability to induce a transient 
pERK response. This finding suggested that the lower signaling capabilities of 
the antibody agonists compared to ART/GFRα3 resulted from their reduced 
ability to bring about RET activation per binding event and not from a reduced 
ability of the activated RET to effectively engage the transient pERK and pAkt 
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signaling responses.  
 
Figure 2.6 pERK and pAkt levels as a function of pRET levels for mAb1, mAb2, and ART.  A 
replot of the data shown in Figures 2.2 and 2.4. pERK (A) and pAkt (B) levels are plotted against 
pRET levels for cells stimulated with various concentrations of mAb1 (blue squares) or mAb2 (red 
circles) and ART (green triangles). ART dose-responses for pRET and pERK are from [163], and 
the dose-response for pAkt was measured separately. The green curve for ART was generated 
by plotting the four-parameter fits describing the pERK and pAkt dose-responses against that for 
the pRET dose-response. 
 
2.3.3 Incubation of cells with mAb2 leads to effective dimerization of RET at 
10 min 
 One possible explanation for the relatively poor ability of the antibodies to 
trigger RET phosphorylation would be if they don’t effectively bring about RET 
dimerization, but instead bind RET predominantly in a 1:1 complex. For an 
antibody to bind two RET molecules, to form a 1:2 mAb/RET2 complex in which 
each arm of the agonist mAb binds a separate RET molecule, requires a two-
step binding mechanism (Figure 2.7). In the first step, an antibody molecule from 
solution binds a RET molecule on the cell surface to form a 1:1 complex, and in 
the second step this complex recruits a second RET molecule to form the final 
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mAb/RET2 complex [166]. At relatively low mAb concentrations, most of the 
receptors will be in a 1:2 mAb/RET2 complexes, since the interaction of the 
second antibody arm with a free RET molecule adds binding energy to the 
complex at a relatively low entropic cost, assuming that there is no strain in the 
complex, or will be unbound. At very high concentrations of antibody, the 
monovalent binding interaction between the antibody and the receptor becomes 
significant and a larger fraction of the receptors exist in a 1:1 mAb/RET complex. 
  
Figure 2.7 Schematic representation of the two-step mechanism for antibody binding to receptors 
expressed on the cell surface. In the first step an antibody molecule from solution binds 
monovalently to a single receptor. Subsequently, this complexed mAb binds a second receptor 
molecule. At antibody concentrations much lower than the affinity of the monovalently bound 
mAb:receptor complex, most of the receptors are either unbound or in 2:1 complex with antibody 
molecules. At very high antibody concentrations, the monovalently bound antibody becomes 
thermodynamically favored and a larger fraction of the receptors exist in 1:1 complex with the 
mAb. 
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However, at early times after the addition of the agonist mAb, before 
binding equilibrium is established, the ratio of monovalently to bivalently bound 
mAb will also be determined, in part, by the relative rates of formation of these 
two complexes. If the rate of recruitment of a second RET molecule to the 1:1 
mAb/RET complex (step 2 in Figure 2.7) is fast compared to the rate of initial 
binding of an antibody molecule from solution to a single RET, most of the mAb 
that binds from solution in Step 1 will rapidly convert to bivalently cross-link two 
RET molecules, resulting in a predominance of bivalently bound antibodies. 
These conditions are most likely to be met at low antibody concentrations, when 
the first binding step is at its slowest. However, at high mAb concentrations the 
rate of antibody binding from solution to a single RET will increase, because the 
rate of the initial binding event is first-order in mAb, and could compete with the 
recruitment of a second RET molecule, leading to a temporary accumulation of 
1:1 complexes. Such 1:1 complexes can be kinetically trapped, unless koff is fast 
compared to the incubation period of the experiment. Thus, the likelihood that the 
agonist mAbs will form predominantly the 1:2, bivalent complexes that we 
assume are required to bring about RET activation, can depend on both 
equilibrium and kinetic factors. The low signaling capabilities of our mAbs could 
be attributed to such kinetically-trapped one-arm bound mAb complexes [167].  
To measure the extent of one-armed bound mAb2 accumulation under the 
conditions of our dose-response experiments, we used Fab fragment of mAb2 
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(Fab2) as a mimic for monovalently bound mAb2. Fab2 will recognize and bind to 
the same site on RET as mAb2. However, Fab2 can form only a 1:1 complex 
with RET. Thus, differences in the binding levels of Fab2 and mAb2 will reflect 
the occurrence of the second step in the mechanism for mAb2 association with 
surface RET, leading to the accumulation of bivalent mAb-RET2 complexes.   
 Fab2 displayed no agonist activity, as determined by measuring pERK 
and pAkt laves after incubation of cells with various concentrations of Fab2 for 10 
min (not shown). Moreover, pre-incubation of the cells with Fab2, to occupy 
some or all of the RET molecules, was able to almost completely inhibit the initial 
activation of ERK and Akt by intact mAb2, measured at 5 min after the mAb2 was 
added, with excess Fab2 present in solution (Figure 2.8). These results show 
that mAb2-bridged RET dimers are indeed required for signaling.  
 
Figure 2.8 Blocking of mAb2-dependent activation of ERK and Akt by pre-incubation of cells with 
Fab2. NB41A3-mGFRα3 cells were pre-incubated with different concentrations of Fab2 for 30 
min, and subsequently treated with 1 nM mAb2 for 5 min in the continued presence of Fab2 at the 
original concentration. The data represent averages from three independent experiments. Error 
bars are standard deviations.   
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To directly compare the binding of mAb2 and Fab2 at 10 min, we 
determined binding curves for mAb2 and Fab2 to RET on cells plated in 24-well 
plates at a density of 3 x 105 cells/well (the same conditions used for all RET, 
ERK and Akt activation measurements), at both 10 and 60 min, by detaching the 
cells and measuring the bound mAb2 or Fab2 using flow cytometry. We kept the 
incubation time of cells with the secondary detection antibody to 5 min, to prevent 
significant Fab2 dissociation. The apparent KD that we measured for Fab2 at 
equilibrium was 18 ± 2 nM (n = 2) and for mAb2 was 0.20 ± 0.0001 nM (n = 2). 
The binding curves for Fab2 at 10 min and 60 min were identical (not shown), 
indicating that binding had reached equilibrium in <10 min. The binding curve for 
mAb2 at 10 min exhibited a slight shift to the right relative to the binding curve 
measured at 60 min, suggesting that at 10 min, binding of mAb2 had not quite 
reached equilibrium (Figure 2.9). 
  
Figure 2.9 Binding curves for mAb2 and Fab2 at 10 or 60 min of incubation. NB41A3-mGFRα3 
cells were seeded in 24-well plate overnight at a density of 3x105 cells/well. Cells were washed 
with warm FACS buffer and incubated with various concentrations of mAb2 (blue squares and red 
circles) or Fab2 (green triangles) for 10 min (red circles and green triangles) or 60 min (blue 
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squares). The unbound ligand was removed by washing with 1 mL FACS buffer, and then cells 
were incubated with 200 µL of a solution of 10 µg/mL PE-conjugated anti-Armenian hamster IgG 
for 5 min. Unbound detection antibody was removed by washing with 2 mL FACS buffer, and the 
cells were detached from the wells by gentle pipetting. The fluorescence intensity of the cells was 
measured using flow cytometry. Data shown represent the average from two independent 
experiments. Error bars (mostly too small to be seen) are the variation between the 
measurements.   
 
Based on our assumption that Fab2 is a mimic of monovalent mAb2, we 
would expect that if each mAb2 molecule bound to a single RET, its binding 
curve would look identical to that of Fab2 and that any additional binding 
measured for the intact mAb2 could be attributed to the formation of the more 
stable bivalent antibody-RET2 complex. Thus, the difference in the amplitude of 
binding between mAb2 and FAB2 could be interpreted as the lower limit of 
bivalent mAb2 binding to RET.  A comparison between the mAb2 binding curve 
at 10 and the Fab2 binding curve at equilibrium in Figure 2.9 indicates that, at 
least for concentrations of the mAb2 < 3.7 nM, there is not significant 
accumulation of monovalently bound mAb2.  
To get an estimate of the relative magnitudes of kon1, kon2 and koff from the 
model for mAb2 binding shown in Figure 2.6, we first used the binding data for 
mAb2 at 10 and 60 min to construct a family of binding time-courses, consisting 
of time points at 0, 10 and 60 min for each concentration of mAb2 tested (0, 
0.015, 0.046, 0.14, 0.41, 1.2, 3.7, 11, 33, 100, and 300 nM mAb2). Using Dynafit 
[168], we performed a global curve fit of the 11 time-courses (Figure 2.10) to the 
kinetic model for mAb2 binding described in Figure 2.7. 
  
 
   
90 
 
Figure 2.10 Global fit of the binding time-courses for 11 concentrations of mAb2 to the kinetic 
binding mechanism for mAb2 binding. Using the mAb2 binding data at 10 and 60 min, shown in 
Figure 2.6, we constructed time-course binding curves, consisting of 0, 10 and 60 min time points 
for each concentration of antibody tested. These time-courses were globally fitted to the kinetic 
model for mAb2 binding, shown in Figure 2.4. Best-fit values for kon1 and kon2 were derived from 
the global fitting analysis, and koff was constrained to equal 18 x kon1. 
 
Assuming that the first binding step in the mAb2 binding mechanism is identical 
to the binding of Fab2 to a single RET, we used the Fab2 equilibrium dissociation 
constant, measured in Figure 2.9, to constrain koff in the fitting process. For Fab2 
binding, the following relationship between the kinetic constants kon1, koff, and the 
equilibrium dissociation constant, KD, must be satisfied 𝐾D(Fab2) = !off!on1,  
so we fixed the value of koff in our model to be equal to KD.kon1. The global fitting 
analysis returned the following values for the kinetic constants: kon1 = 0.067 ± 
0.007 nM-1min-1, koff = 1.2 min-1, and kon2 = 2.5 ± 0.7 x 105 nM-1min-1. Using the 
value of koff obtained from the global fit, we calculated the half-life, t1/2, of the 
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monovalently bound mAb2 to be 0.56 min. Such a short half-life, combined with 
kon2 being 3 x 106 times larger than kon1, argues strongly against the likelihood of 
a significant fraction of kinetically trapped 1:1 mAb2/RET complexes 
accumulating during the 10 min stimulation time used in our KIRA ELISA 
experiments, at concentrations at which the monovalently bound mAb2 is not 
thermodynamically favored. 
 In the pRET dose-response experiments shown in Figure 2.2A, we 
observed a decrease in the levels of RET phosphorylation at concentrations 
above 33 nM, which we interpreted as accumulation of monovalently bound 
mAb2. To test if our model of mAb2 binding, combined with the kinetic constants 
we obtained from the global fits of the 11 time-courses, supports this 
interpretation, we simulated the monovalent, bivalent, and total bound mAb2 at 
10 min for a wide range of antibody concentrations (Figure 2.11). The shaded 
region in Figure 2.11 shows that, at [mAb2] = 33 nM, the fraction of bivalently 
bound antibody (red curve) starts to decrease from its peak levels, and the 1:1 
mAb/RET complex (green curve) begins to accumulate, which coincides with the 
antibody concentrations in our dose-response experiment, at which we measured 
decrease in the pRET response (Figure 2.2A).    
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Figure 2.11 Simulated mAb2 binding curves showing monovalent, bivalent, and total mAb2-bound 
RET at 10 min of incubation at different concentrations of antibody. Using the mAb2 binding 
mechanism shown in figure 2.4 and the kinetic constants kon1, kon2 and koff obtained form the 
global fitting analysis of the mAb2 binding time-courses, we simulated the amount of 1:1 (green 
curve) and 1:2 (blue curve) mAb2-RET complexes. The total amount of bound RET (blue curve) 
was obtained by adding the amounts of 1:1 and 1:2 complexes. 
 
The above analysis shows that, for concentrations of mAb2 up to 11 nM, it 
is unlikely that a significant fraction of RET molecules exists in a 1:1 complex 
with mAb2 under the conditions used in the pRET, pERK, and pAkt dose-
response experiments shown in Figures 2.2A and 2.4. Our simulations predict 
that at the concentrations of agonist antibody used in these experiments, almost 
all of the bound mAb2 cross-links two RET molecules in 1:2 mAb2/RET 
complexes. At concentrations of 33 nM and higher the accumulation of 
monovalently bound mAb2 starts to increase, and in cells incubated with 300 nM 
antibody (the highest concentration used in the dose-response experiments in 
Figures 2.2A and 2.4) about 20% of the bound RET receptors exist in 1:1 
complexes with the antibody. However, the same fraction of 1:1 RET/mAb2 
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complexes is observed in our simulations under equilibrium conditions (not 
shown), suggesting that at concentrations of mAb2 higher than 33 nM the 
increase in the amount of monovalently bound antibody is thermodynamically 
favored, and does not represent a kinetic artifact of the time chosen for our dose-
response experiments. 
2.3.4 Time-dependent signal evolution and decay for RET, ERK, and Akt. 
Having established that at 10 min of stimulation, mAb1 and mAb2 exhibit 
significantly lower activities for activating RET, but the pRET, brought about by 
the two agonist antibodies, has the same ability to activate the ERK and Akt 
response, compared to ART plus GFRα3, we investigated how the activation of 
the same molecules at later time points compared between the three agonists. 
We measured time-courses for the phosphorylation of RET, ERK, and Akt in 
response to stimulation with mAb1 or mab2 concentrations that gave maximal 
activation in the dose-response experiments at 10 min, or with 4 nM ART (Figure 
2.12). We stimulated NB41A3-mGFRα3 cells with 100 nM mAb1, 10 nM mAb2, 
or 4 nM ART for 90, 60, 40, 20, 10, 5, 2, or 0 minutes, lysed the cells, and 
measured the relative amount of phosphorylated RET, ERK, and Akt in the lysate 
using the appropriate ELISA. As shown previously [163], the time-course for RET 
activation by 4 nM ART showed a peak signal at 10 min, with subsequent decline 
to about 60% of that value over the next 80 min. Stimulation of the cells with the 
two antibodies also showed a steep increase in pRET levels in the first 10 min, 
but then the signal remained roughly constant throughout the remaining time of 
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the experiment. Treatment with 4 nM ART resulted in a transient ERK response 
that peaked at 10 min, and then decreased to sustained response at about 60% 
of the transient peak level. Both mAb1 and mAb2 showed a transient pERK peak 
at 10 min, comparable to that of ART (50-75%), and also some sustained 
signaling, although 3-4-fold lower than that seen for ART. The inability of the two 
antibodies to support robust sustained signaling was even more pronounced in 
the Akt response. Both mAb1 and mAb2 triggered a prominent transient Akt 
response at 5 min (at least 40% of that seen for 4 nM ART) but a more than 5-
fold lower sustained response that returned to basal levels by 90 min, a time at 
which ART could supported signaling. 
 
Figure 2.12 Time-courses for activation of RET, ERK, and Akt by mAb1, mAb2, or ART.Cells 
were incubated with 100 nM mAb1 (blue squares), 10 nM mAb2 (red circles), or 4 nM ART (green 
triangles) for the indicated times. The reaction was stopped by lysing the cells, and the levels of 
pRET (A), pERK (B), and pAkt (C) were measured using the appropriate ELISA. The data are 
averages of three independent experiments and error bars are standard deviations. 
 
  
 
   
95 
2.3.5 Effect of clustering mAb1 and mAb2 with a polyclonal secondary 
antibody  
The current model for RET activation suggests that the active signaling 
unit consists of two RET molecules brought together in the correct orientation by 
two co-receptor molecules (GFRα) bound to a single bivalent ligand [3, 17].  We 
wanted to test whether higher order oligomers might play a role in signaling. In 
particular we wanted to see if receptor clustering can enhance the signaling 
achieved by our agonist antibodies, to make their activities more similar to that of 
the natural ligand ART. To cluster mAb1 and mAb2, we used polyclonal anti-
Armenian hamster IgG. To find the optimal molar ratio of clustering-to-agonist 
antibody we incubated fixed concentrations of mAb1 or mAb2 with varying 
concentrations of anti-Armenian hamster IgG for 15 min, then treated NB41A3-
mGFRα3 cells with the clustered antibodies for 10 min, and measured the levels 
of pRET, pERK, and pAkt using the appropriate ELISA. Aggregating mAb1 and 
mAb2 with the anti-IgG caused marked effects on their ability to trigger RET 
activation indicated by the enhanced phosphorylation of all three signaling 
molecules (Figure 2.13).  
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Figure 2.13 Effect of pre-clustering mAb2 on agonist activity measured by RET, ERK, and Akt 
transient activation. 3 nM (blue squares) or 0.3 nM (red circles) mAb2 was pre-incubated with 
different concentrations of anti-Armenian hamster polyclonal antibody (anti-IgG), and the resulting 
mixtures were added to cells for 10 min. pRET (A), pERK (B) and pAkt (C) were measured using 
the appropriate ELISA. The data represent the average of three independent experiments, and 
the error bars are standard deviations. 
 
All anti-IgG dose-response curves were clearly bell-shaped, suggesting 
that too great a proportion of anti-IgG favored the formation of clusters that were 
not optimal for signaling.  We determined that pre-incubation of the agonist 
antibodies with a 2-fold molar excess of the clustering anti-IgG polyclonal 
antibody resulted in the greatest enhancement of signal. To characterize the 
signaling properties of the clustered mAb1 and mAb2, we directly compared their 
full dose-response curves to those of the unclustered antibodies (Figure 2.14).  
The enhancement in the mAb2 agonist activity upon clustering was most 
pronounced for the antibody’s ability to induce RET phosphorylation. Treatment 
of cells with 11.1 nM clustered mAb2 resulted in pRET levels that were about 
85% of those measured upon stimulation of cells with 4 nM ART, and 
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represented approximately 5-fold increase in RET phosphorylation compared to 
the same concentration of unclustered antibody (Figure 2.14A).  
Clustering also significantly increased the transient phosphorylation of 
ERK and Akt. pERK levels reached 100% of those achieved with 4 nM ART, and 
pAkt levels increased to about 70% of those measured upon stimulation with the 
natural ligand. However, the sensitivity of the responses (EC50) for all three 
measured molecules was essentially unchanged, compared to the sensitivity of 
the responses to stimulation with unclustered mAbs.  
To test whether the enhancement in signaling observed upon pre-
clustering the agonist mAbs can be explained by an increased binding affinity of 
the clustered mAb, we directly measured the binding of monomeric and clustered 
mAb2 by flow cytometry. We pre-formed the mAb2/anti-IgG complexes and 
incubated NB41A3-mGFRα3 cells with them, or with monomeric mAb2, for 1 
hour on ice in the presence of 0.1% NaN3 to block receptor internalization (Figure 
2.13D). The bound mAb2 was detected with Alexa Fluor 488-conjugated goat 
anti-mouse IgG that cross-reacts with hamster antibodies. The apparent KD for 
the binding of the clustered mAb2 was 0.54 ± 0.075 nM – slightly higher than the 
0.12 ± 0.06 nM KD measured for monomeric mAb2. This unexpected result can 
be explained if some of the mAb2 molecules within a cluster are not able to bind 
to RET. The same KD value for binding of mAb2 clusters to RET was obtained 
from experiments where we detected the bound clustered mAb2 through the 
clustering antibody, rather than through the mAb2, using Alexa Fluor 647-
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conjugated donkey anti-goat IgG (data not shown). This result, together with the 
lack of shift in the EC50 in the pRET, pERK and pAkt dose-response curves for 
the clustered mAb2, suggested that the enhanced signaling observed for the 
complexed mAb2 does not stem from increased affinity due to avidity effects, but 
is instead indicative of more effective signaling per mAb2 bound.  
 
Figure 2.14 Comparison of clustered and unclustered mAb2 dose-responses for transient RET, 
ERK, and Akt activation, and binding to cell surface RET. NB41A3-mGFRα3 cells were 
stimulated with various concentrations of mAb2 (blue squares), mAb2 pre-clustered with 2-fold 
molar excess of anti-IgG (red circles), or 4 nM ART for 10 min. The cells were lysed, and pRET 
(A), pERK (B,) and pAkt (C) levels were measured using the appropriate ELISA. (D) 2x10
5
 cells 
were incubated in suspension with various concentrations of unclustered or clustered mAb2, in 
FACS buffer, for 1 hour, on ice. The bound mAb2 was detected with Alexa Fluor 488-conjugated 
anti-mouse polyclonal antibody. Plotted is the average of three independent experiments. The 
error bars represent standard deviations. 
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2.3.6 Efficiency of RET, activated by clustered mAb1, clustered mAb2, or 
ART, to activate the transient responses for ERK and Akt 
The increased levels of ERK and Akt phosphorylation achieved with the clustered 
mAbs raised the question whether the form of pRET induced by the clustered 
mAbs engaged in downstream signaling more efficiently than the pRET form 
achieved with the unclustered agonist antibodies. To compare the efficiency of 
RET, that has been activated by the two clustered antibodies or by ART/GFRα3, 
to activate transient ERK and Akt signaling, we plotted the level of activated ERK 
and Akt as a function of active RET, for clustered mAb1 and mAb2 and for 
ART/GFRα3, similar to the plots for unclustered mAbs shown in Figure 2.6. 
Figure 2.15 shows that, at 10 min after stimulation, the clustered antibodies 
activated the same number of ERK and Akt per RET as was seen for 
ART/GFRα3 or for the unclustered antibodies.  
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Figure 2.15 Comparison of the efficiency of RET, activated by clustered mAb1, clustered mAb2, 
or ART/GFRα3, to trigger transient ERK and Akt activation. The pERK (A) and pAkt (B) levels 
from the dose-response data shown in Figure 2.11 B and C were plotted as a function of the 
pRET levels, shown in Figure 2.11 A, measured upon stimulation of cells with the same 
concentration of clustered mAb1 (blue squares) or clustered mAb2 (red circles). The data for 
stimulation of cells with ART plus GFRα3 (green triangles and dashed curves) are described in 
Figure 2.5. 
 
The results shown Figures 2.4, 2.5, 2.11, and 2.15 show that the limited 
ability of the unclustered mAb1 and mAb2 to induce RET, ERK, and Akt 
activation, compared to ART plus GFRα3, cannot be attributed to differences in 
phosphorylation state of the receptor, to insufficient RET occupancy, or to the 
inability of a large fraction of pRET to participate in downstream signal 
propagation.  
2.3.7 Higher order clustering may be required for the full activation of RET 
The result that clustering mAb1 and mAb2 led to pronounced increase in 
the RET phosphorylation levels (Figure 2.14A), but did not affect the ability of the 
phosphorylated RET to activate transient ERK and Akt signaling (Figure 2.15), 
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led us to hypothesize that clustering may be a required step in the activation 
mechanism of the system.  
More specifically, we considered that the low level of RET activation that 
we measured upon stimulation of cells with the unclustered antibodies could be 
due to self association of two or more RET dimers, and not to phosphorylation 
occurring within antibody-bridged RET dimers, as we had previously assumed 
(Figure 2.16, Unclustred mAb). If so, then the dissociation constant for the dimer-
dimer interaction must be high relative to the available mAb2-RET2 density on 
the cell surface to account for the low levels of activation of RET even under 
conditions of saturated RET occupancy by mAbs.  
In the case of stimulation with clustered mAb, the requirement for self-
association is obviated, if this multivalent form of the agonist brings together at 
least 4 RET molecules upon binding (Figure 2.16, Clustered mAb). In addition to 
the differences in the amount of RET activation seen upon stimulation of cells 
with unclustered and clustered mAbs, the hypothesis of RET-mediated receptor 
contacts also accounts for the observation made, by us and other researchers, 
that overexpression of RET leads to constitutive activation [169], (Chapter Four).  
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Figure 2.16 Proposed mechanism for RET activation by unclustered and clustered mAb2. The 
unclustered mAb2 (top) binds to RET to form dimers that have very weak propensity to self-
associate into active clusters. Clustered mAb2 (bottom) by-passes the requirement for dimer-
dimer binding and directly brings about RET activation upon binding. 
   
If this hypothesis is correct and, for example, clustering of two RET dimers 
is required for receptor activation, we would predict the amount of pRET to vary 
with the square of the fraction of mAb-bound RET when the cells are treated with 
monomeric mAb, but to be linearly proportional to bound RET when cells are 
stimulated with clustered mAbs. To test this prediction, we looked the relationship 
between the level pRET and the fraction of RET bound by mAb2 for different 
agonist antibody concentrations at 10 min. We had already determined the 
binding curve for unclustered mAb2 at 10 min (Figure 2.6, red circles) at the 
concentrations of mAb2 used in our pRET dose-response experiments. To 
measure the binding curve for clustered mAb2, we pre-incubated NB41A3-
mGFRα3 cells, seeded in 24-well plates, with various concentrations of pre-
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clustered mAb2 for 10 min and detected the bound mAb2 clusters with Alexa 
Fluor-conjugated anti-mouse IgG, using flow cytometry.   
The plot of pRET vs. bound RET for unclustered mAb2 showed upward 
curvature and fitted well to the equation pRET = a*[RET]2 (Figure 2.17A), 
consistent with a mechanism for RET activation, in which the association of two 
mAb2-bridged dimers is required for receptor phosphorylation. At the same time, 
the plot of pRET vs bound RET for the clustered antibody was a linear (Figure 
2.17B), suggesting that every binding event of the clustered mAb2 leads to RET 
activation. This finding supports the hypothesis that RET activation requires an 
additional clustering step after the receptor dimerization by mAb2, and that the 
need of this step is obviated when RET molecules are brought together in a 
higher-order complex by the pre-clustered form of mAb2.  
 
Figure 2.17 Quantitative relationship between RET activation and the fraction of RET bound by 
mAb2 for stimulation of cells with unclustered and clustered mAb2. (A) Replot of the mAb2 dose-
response for pRET shown in Figure 2.2 A versus the fractions of RET bound by unclustered 
mAb2 at 10 min, shown in Figure 2.6. The blue solid line represents the fit of the data to the 
equation p[RET] = a*[RETbound]2. (B) A plot of the levels of pRET phosphorylation (from Figure 
2.11 A) versus the fraction of RET bound by clustered mAb2 at 10 min. The red solid line in 
represents the fit of the data to a linear equation, [pRET] = a*[RETbound] 
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It is worth noting that for the analysis of the unclustered mAb2, we 
included only data that we obtained for concentrations of antibody that do not 
give significant accumulation of monovalently bound species, allowing us to 
interpreted all measurable binding as bivalent (see Section 2.3.3). More thorough 
analysis is required to quantify small amounts of monovalent antibody binding 
that would represent a form of mAb2-RET complexes that would not lie on the 
pathway of activation proposed here, and should thus be subtracted from the 
total measured receptor occupancy. Such 1:1 mAb2-RET complexes are more 
likely to accumulate at higher mAb2 concentration (see discussion in Section 
2.3.3) and, for example, we would expect that if 1:1 mAb2-RET complexes form, 
they will represent a higher fraction of the bound receptor at 11 nM mAb2 than at 
the lower antibody concentrations tested. This phenomenon would cause the plot 
in Figure 2.16A to have even more pronounced curvature.  As a result, the 
curvature in the pRET vs Bound RET plot that we observed should be interpreted 
as a lower limit to the curvature that would result from plotting the fraction of 
strictly bivalent mAb2 interactions with RET. Thus, we could conclude that 
formation of pRET required a minimum of two RET dimers had to interact, but we 
cannot exclude the possibility that higher-order clustering is required for full RET 
activation.   
2.3.8 Ability of agonist mAbs to induce neurite outgrowth 
The above results indicated that the unclustered and clustered forms of 
mAb2 activate RET through different pathways, and we therefore tested which of 
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these alternative ways of activating the receptor leads to a functional cell 
response.  We have shown previously that long-term treatment of NB41A3-
mGFRα3 cells with ART results in cell differentiation that can be quantified using 
a neurite outgrowth assay [163]. To test whether the unclustered and clustered 
agonist antibodies can mimic this functional effect of ART treatment, we 
determined the neurite outgrowth activity of unclustered and clustered mAb2 and 
compared it to that of ART. NB41A3-mGFRα3 cells were incubated with 10 nM of 
either mAb2, 10 nM mAb2 + 20 nM anti-hamster IgG, or 4 nM ART, for 5 days in 
serum-free DMEM. At the end of the treatment the cells were fixed, and 
differentiation was quantified by counting the cells that had neurite extensions 
with length totaling more than one cell diameter. ART and clustered mAb2 each 
elicited a strong neurite outgrowth response, with the clustered mAb2 showing a 
slightly smaller effect. In contrast, the cells treated with monomeric mAb2 
showed no differentiation at all (Figure 2.18).  
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Figure 2.18 Ability of clustered and unclustered mAb2 to induce neurite outgrowth in NB41A3-
mGFRα3 cells. Cells were incubated with assay buffer, 20 nM anti-IgG, 10 nM mAb2, 10 nM 
mAb2 + 20 nM anti-IgG, or 4 nM ART, for 5 days in serum free medium. On the last day, the cells 
were fixed and imaged. Cells bearing neurites with a total length exceeding one cell body 
diameter were counted as positive. Total cell number was determined using ImageJ software. 
The data are averages of three independent experiments, and the error bars are standard 
deviations. The asterisks indicate statistically significant differences from the untreated sample (p 
< 0.05), from a one-tailed student’s t-test. 
 
The fact that clustering mAb2 was able to rescue the ability of the antibody 
to trigger cell differentiation suggested that there is some difference in signaling 
between the unclustered and clustered forms of the agonist antibody that is 
important for this cellular response. There are a number of reports in the 
literature about the importance of pERK activation for neurite outgrowth [170, 
171], suggesting that we should focus our attention on this downstream pathway. 
Specifically, sustained pERK signal levels have been shown to be critical for 
neuronal cell differentiation [172-174]. For example, nerve growth factor (NGF) 
and the epidermal growth factor (EGF) both lead to the activation of ERK in 
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PC12 cells. However, NGF, which supports sustained ERK activation, leads to 
neuronal differentiation, while stimulation with EGF, which only elicits transient 
ERK phosphorylation, results in a proliferative response in this cell line [172-174]. 
In one study the upregulation and activation of c-fos, a transcription factor 
implicated in the neuronal cell differentiation response, was measured in PC12 
cells when sustained ERK signaling was stimulated by treatment of cells with 
NGF, but when the same cells were treated with EGF, no c-fos accumulation was 
detected [174]. The lower ability of unclustered mAb2 to support sustained pERK 
signaling might, therefore, explain why stimulation of cells with this form of the 
agonist did not result in neurite outgrowth. We have already shown that pre-
clustered mAb2 gives a higher amplitude for the transient pERK and pAkt 
signals, compared to the unclustered mAb2. One possibility is that pre-clustering 
mAb2 might give a concomitant increase in the sustained pERK amplitude, which 
could explain the neurite outgrowth activity of the clustered mAb. 
Another possibility that we considered was that, in our system, perhaps 
the neurite outgrowth is under the regulation of a different signaling pathway 
downstream of RET, which we didn’t measure. For example, we found reports in 
the literature that sustained c-June N-terminal Kinase (JNK) signaling might be 
involved in neuronal differentiation in PC12 cells [175].  Thus, it is possible that, 
in our cell line, differences in the amplitude and duration of JNK signaling are 
responsible for the distinct neurite outgrowth outcomes that we measured with 
unclustered and clustered mAb2. 
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2.3.9 Clustered mAb2 does not support high levels of ERK, Akt and JNK 
signaling  
 To test if the neurite outgrowth response that we observed in cells treated 
with clustered mAb2 could be explained by an increased ability of this form of the 
agonist to support sustained signaling through RET, we measured time-courses 
of RET, ERK and Akt activation by the same dose of pre-clustered mAb2 that we 
used in our neurite outgrowth experiment. We pre-formed the clusters by 
incubating 10 nM mAb2 (a saturating concentration for both binding and 
activation) with 20 nM of the polyclonal anti-hamster IgG for 15 min, and 
stimulated cells for different periods of time. The pRET time-course (Figure 
2.19A) seen for the clustered mAb2 resembled that of ART more closely than 
mAb2 alone did, exhibiting a peak signal at 10 min that decreased to about 50% 
of the peak level over the subsequent 80 min of the experiment. However, the 
pERK and pAkt time-courses more closely resembled the signal achieved with 
the unclustered mAb2 than that seen with ART (Figure 2.19B and C). In 
agreement with our results from the dose-response experiment at 10 min, 
clustering had a pronounced effect on the amplitude of the transient response. 
However, we observed almost no effect on sustained signal levels.  
To test our hypothesis that cell differentiation might be triggered by 
sustained signaling of the JNK pathway, we also measured a time-course for the 
activation of the c-Jun N-terminal Kinase (JNK) (Figure 2.19D). ART stimulation 
resulted in a lag in JNK activation of about 5 min, followed by an increase in 
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signal that peaked around 20min after stimulation and then declined to about 
50% of the positive control value after 90 min. Both unclustred and clustered 
mAb2 triggered the peak in signal– at 20 min after stimulation. Consistent with 
our results for ERK and Akt, unclustered mAb2 elicited a much weaker pJNK 
transient response, reaching only 30% of the levels seen for the ART control at 
20 min. The unclustered mAb2 also failed to support sustained JNK activation, 
with the signal decreasing to 10% of the positive control in the remaining 70 min 
of the time course. Treatment with clustered mAb2 produced the same level of 
pJNK at 20 min, as that measured upon stimulation with ART. However, unlike 
ART, the clustered mAb2 failed to support significant JNK activation at 60 min 
and later times, with the signal decreasing to about 10% of peak.  
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Figure 2.19 Time-course activation of RET, ERK, Akt, and JNK by unclustered mAb2, clustered 
mAb2, or ART. NB41A3-mGFRα3 cells were incubated with 10 nM monomeric mAb2 (blue 
squares), 10 nM mAb2 pre-clustered with 20 nM anti-IgG (red circles), and 4 nM ART (green 
triangles) for the indicated periods of time. At the end of the treatment the cells were lysed, and 
the levels of phosphorylated RET (A), ERK (B), Akt (C), and JNK (D) were measured using the 
appropriate ELISA. The data in panels A, B, and C represent averages of three independent 
experiments, and the error bars are standard deviations. The data in panel D are averages of two 
independent experiments, and the error bars are the variations between the two measurements. 
 
A sustained response of JNK had also been shown to contribute to 
neuronal differentiation [175]. However, our results argued against the possibility 
that sustained JNK compensated for the lack of prolonged ERK activity when 
cells were stimulated with clustered mAb2. Our findings showed that the transient 
signal amplitude of all three tested pathways was the only feature of the 
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activation profiles that positively correlated with whether the cells commit to 
differentiation or not (Table 2.1).  
Table 2.1 Summary of the qualitative differences in the amplitudes for pRET, pERK, pAkt, and 
pJNK, and the neurite outgrowth response for cells stimulated with unclustered mAb2, clustered 
mAb2, or ART. 
 
 
2.4 Conclusion 
We have shown for the first time outside the patent literature that the RET 
receptor tyrosine kinase can be activated by anti-RET monoclonal antibodies. 
Both mAbs are weak agonists with respect to RET phosphorylation, but pre-
clustering them with a secondary polyclonal anti-IgG allows full receptor 
activation, as well as the functional cellular response of neurite outgrowth. Based 
on these findings, and the observation that activation of RET was cooperative 
with respect to receptor occupancy, we propose a mechanism for RET activation 
by the agonist antibodies, in which receptor autophosphorylation does not occur 
within the antibody-bridged RET dimers, but instead requires the self-association 
of two or more such dimers into a higher order complex. This higher order 
clustering step must be characterized by a low affinity compared to the 
concentration of RET dimers on the cells at any given mAb concentration, so that 
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even at full RET occupancy by the antibodies only 20% of the receptors are 
recruited in functional clusters. 
Whether this clustering is important in the activation of the system by its natural 
ligand/co-receptor pairs remains to be elucidated, however, it seems highly 
unlikely that this step would be required for both of the antibody agonists that we 
tested and yet be irrelevant for the natural systems. The fact that ART, in 
conjunction with GFRα3 was able to activated essentially all RET receptors on 
the cells, but the antibodies only activated 20% of the RET, suggests either that 
ART is able to produce receptor dimers that were better suited for 
oligomerization than the ones formed by our antibodies, or that additional 
contacts between GFRα3/ART dimers might increase the clustering affinity of 
RET/GFRα3/ART complexes. Another possible factor affecting clustering is that 
RET/GFRα3/ART complexes are recruited in lipid rafts [144, 176], which may 
cause their local concentration to be much higher than that of freely diffusing 
mAb-bridged dimers. Thus, even if the self-association affinity for the RET dimers 
is an intrinsic property of the RET molecules and is not affected by the other 
components of the complex, the clustering could still be more efficient in the 
native system due to the higher local RET-dimer concentrations. In either case, it 
is possible that weakening the affinity of individual RET dimers to self-aggregate 
by inhibiting all or some of the binding interactions may be sufficient to decrease 
RET activation by its native ligands bellow the threshold level required for cellular 
response. The low intrinsic affinity for receptor self-aggregation, that we 
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measured upon stimulation with the antibodies, also suggests that this step of the 
activation mechanism may be a good target for inhibition of RET signaling. 
The observation that all forms of activated RET were equally efficient in 
activating transient downstream signaling, at first suggested that there is a single 
form of the activated receptor, and the amplitude of the downstream response 
depends only on the ability of the agonists to bring about this activated RET 
species. However, the similarities in RET signaling efficiency among the different 
agonists did not hold at longer times of stimulation, suggesting that even though 
all agonists produced the same form of phosphorylated RET at 10 min, they 
differed in their ability to trigger potential feed-back regulatory pathways. The 
difference in the ability of the different agonists to trigger cell differentiation, 
suggested that it is possible to achieve different biological outcomes with 
different stimulation conditions. This finding can be instructive in a future study of 
RET activation by two or more of its natural ligands/GFRα pairs.  
One prominent regulatory pathway in RTK signaling is the internalization 
of activated receptors in vesicles. It has been shown that upon internalization 
receptors remain active, as long as they stay associated with their ligands [177]. 
Zhang et al. reported different biological responses to activation of the TrkA by its 
ligand NGF in PC12 cells, and showed that neurite outgrowth is specifically 
triggered in cells, in which active TrkA receptors were internalized in vesicles, 
suggesting that the cellular compartmentalization of the activated receptors plays 
a crucial role in biological response [178]. A subsequent study reported that 
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trafficking of active receptors into late endosomes is, indeed, required for neurite 
outgrowth triggered by TrkA/NGF, in PC12 cells and BDNF/TrkB, in hippocampal 
neurons [179]. Based on the findings discussed above, we speculate that 
receptor internalization and trafficking could also be important for the cellular 
response of neurite outgrowth in the RET system, and that differences in the 
ability of unclustered and clustered mAb2 to trigger pRET internalization may 
account for the difference in their ability to support neuronal differentiation. Such 
differences in induction of receptor trafficking remain to be elucidated.  
 Our results suggest that the amplitude of the transient pRET, pERK, pAkt, 
and pJNK is important for neurite outgrowth, since the two agonists, which 
supported neuronal differentiation (clustered mAb2 and ART), both induced high 
levels of transient signals for all of the above molecules, whereas the unclustered 
mAb2 showed reduced ability to induce activation of either pathway. However, 
we acknowledge the possibility that, in our cell system, the neurite outgrowth 
response might be driven by a pathway downstream of RET that we didn’t 
examine in this study, and that some property of this unidentified signaling 
cascade could be an important determinant of whether RET activation will lead to 
a neurite outgrowth response.  
 Agonist monoclonal antibodies have been reported for a number of RTK 
systems. The ability of monoclonal antibodies to activate cytokine and growth 
factor receptors has historically been interpreted as evidence for a ligand-
induced dimerization mechanism for receptor activation (see Chapter 1). 
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However, potential quantitative differences in the extent of receptor and 
downstream molecules activation by the natural and unnatural ligands, at 
different doses and times of stimulation, have rarely been studied. An 
outstanding question about activation of RTKs with agonist antibodies is whether 
the activated forms of the receptor, brought about by the agonist mAbs and the 
natural ligand(s), are functionally the same with respect to activation of 
downstream signaling cascades and cellular response. The lack of detailed 
quantitative characterization of the agonistic properties of mAbs has made it 
difficult to compare them to natural agonists.  
 In this study, we quantified the extent of receptor and downstream 
molecules transient activation, triggered by treating cells with one of two agonist 
antibodies, which were unclustered or pre-clustered with polyclonal anti-IgG, or 
the natural ligand for RET, ART, in conjunction with its preferred co-receptor 
GFRα3. This approach allowed us to establish that all agonists induced forms of 
the activated receptor that were identical in their abilities to activate the transient 
ERK and Akt signaling responses. However, the different agonists showed 
differences in their ability to support sustained ERK and Akt activation, as well as 
to trigger the cellular response of neurite outgrowth, suggesting that the activated 
RET receptor signaled in distinct ways, depending on the agonist that was used 
to bring about receptor activation. Furthermore, the quantitative differences in the 
extent of transient receptor and downstream signaling activation, upon 
stimulation of cells with unclustered or pre-clustered agonist mAbs, suggested a 
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role for higher order receptor clustering in the activation mechanism of RET, 
which has not been proposed for the RET system before. Such mechanism was 
supported by the quantitative relationships between the levels of pRET and the 
fraction of RET bound by unclustered or clustered mAb2, at various agonist 
antibody doses. We believe that the activation pathway of RET by its native 
ligands in conjunction with GFRα may also involve such higher-order clustering 
step.  
The findings presented here, elucidate key aspects of the activation 
mechanism for RET, and also illustrate the general importance of quantitative 
characterization of agonist ligands for RTKs, as means to study the activation 
mechanism of such systems, as well as to elucidate the features of the signaling 
responses that are important for biological function. 
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Chapter 3 Role for the involvement of GFRα3 and the importance of Its 
oligomeric state for the regulation of ART signaling through the RET 
Receptor Tyrosine Kinase 
 
3.1  Introduction 
Many receptor systems, including RET, require additional membrane-tethered 
co-receptor molecules to function. These co-receptor proteins bind the ligand, but 
typically have no other signaling abilities. In the case of the RET-GFRα3-ART 
system, the functional complex involves ligand-induced dimerization of both the 
GFRα3 and RET [17]. Presumably, the involvement of a co-receptor in the 
activation mechanism of RET makes the system better suited to fulfill its 
biological functions in some way, and was thus selected for during evolution over 
a simplified homodimeric receptor system in which RET binds its ligand directly, 
despite the energetic cost for the cell to synthesize additional proteins. However, 
the biological benefits of co-receptor involvement have not been systematically 
investigated, for RET or for any other receptor, mainly due to the difficulty of 
designing an experimental system in which the co-receptor can be eliminated 
from the activation pathway without affecting other aspects of the receptor’s 
activity. Thus, it is unclear what unique functional characteristics are available to 
the native RET-GFRα3-ART system that are not present in a simpler hypothetical 
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RET-ART system, or how these characteristics play a role in the biological 
function of the receptor.  
The simplest explanation for why the RET receptor is activated by its ligand via 
involvement of a co-receptor, and doesn’t instead bind the ligand directly, may 
come from the fact that RET is shared among four GFLs – GDNF, Neurturin, 
ART and Persephin. Since each of the four different co-receptors is more or less 
specific for one of the four ligands [139, 142], the requirement for their 
involvement dictates which ligand is able [151] to activate the receptor on a given 
cell, based on which co-receptor molecules are present. It has not been 
established, however, whether activation of the system by the four ligands results 
in different biological outcomes. Studies with mutant mice in which the genes for 
different GFLs were knocked out showed distinct phenotypes [145-150, 180], but 
it remains unclear whether these differences stemmed from differential tissue 
expression of the disrupted signaling pathway, differential RET activation by the 
different ligands that led to intrinsically different signaling, or from a combination 
of the two. 
Here we explore the role of the co-receptor in RET function using a 
computational approach. We use the RET-GFRα3-ART system, for which the 
activation pathway and the affinities of the individual binding events have been 
determined experimentally [17]. Using a quantitatively well-described system 
such as RET-GFRα3-ART, we were able to simulate the response of the system 
to ligand at various expression levels of GFRα3 and RET. The results provide 
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insight into the distinct roles that these two different receptor components play in 
determining how stimulation of the cells with ART relates to levels of RET 
phosphorylation. Additionally, we simulated the response of the system to 
variations in RET and GFRα3 concentrations for several alternative activation 
pathways. The results illuminate the functional importance of the sequence of 
binding steps by which a multi-component receptor becomes activated.   
3.2 Materials and Methods  
3.2.1 Simulations of ART dose-responses at different RET and GFRα3 
expression levels 
We used the ART-GFRα3-RET activation pathway proposed by Schlee et al. 
(Figure 3.1) and the equilibrium dissociation constants that the authors 
determined (Table 3.1) [17] to simulate the pRET response at different RET 
expression levels, using the software DynaFit (BioKin, Ltd) [168]. We assumed 
the same cell number, number of GFRα3 receptors per cell (65000 molecules per 
cell), assay volume and molar response coefficient as in the system described by 
Schlee et al. and used ART concentrations ranging from 0.01 to 1000 nM. For all 
simulations the activation of RET was identical as the formation of the ART- 
GFRα2-RET2 [17]. 
  
 
   
120 
Table 3.1 Values of equilibrium dissociation constants K1-4 and the molar response coefficient 
determined by Schlee et al. for the activation mechanism of ART-GFRα3-RET system [17]. 
 
To simulate the pRET response at different expression levels of GFRα3 
we used the parameters shown in Table 3.1, and calculated the molar 
concentration of co-receptor assuming the same number of cells, expression 
level of RET (6000 RET molecules per cell), and volume as in the original 
experimental system described by Schlee et al. [17].  
3.2.2 Assessment of the ability of a hypothetical homodimeric receptor 
system to replicate the pRET response to ART at different RET and GFRα3 
expression levels 
 To test how a hypothetical simpler homodimeric activation mechanism 
affects the properties of the system, we took the simulated results obtained using 
the native RET activation mechanism, and performed a global fit to the 
hypothetical homodimeric receptor mechanism shown in Figure 3.5. The goal 
was to see how well this simple mechanism could reproduce the observed 
dependencies of signal amplitude and signal sensitivity, as a function of ART, 
RET and GFRa3 levels. We first tested how well the simple homodimeric 
mechanism can reproduced the differences in the ART dose-responses at 
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varying levels of RET. To do that, we globally fitted the simulated results 
obtained from the native RET activation mechanism, at different RET expression 
levels, to the hypothetical simpler pathway shown in Figure 3.5. The expression 
level of GFRα3 was kept constant at the value of 65000 molecules per cell, which 
was determined for the experimental system described by Schlee et al., and was 
used in our simulated dose-response curves at various RET expression levels for 
the native RET activation pathway. This expression value of GFRα3 translated 
into a molar concentration of 0.2 nM, when cell number and the volume of the 
original experimental system were taken into account [17]. Using the above 
parameters for the assay conditions, under which the native activation pathway 
was determined, we also converted each tested RET expression level into molar 
concentration, and used this calculated molar concentration in the global fitting 
process. The equilibrium dissociation constants K1 and K2 were optimized in the 
fit.   
 To test how the same simpler homodimeric activation mechanism (Figure 
3.5) fits the data at varying expression levels of GFRα3, we performed a global fit 
of the results obtained with the native RET activation mechanism to the 
hypothetical homodimeric receptor system. The molar response coefficient was 
fixed to the values used for the original simulations of the pRET response and 
equilibrium dissociation constants K1 and K2 were allowed to vary. In the native 
activation mechanism the different dose-response curves were characterized by 
the different levels of GFRα3 expression. However, in the simpler pathway, we 
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could not retain this characteristic, since GFRα3 was eliminated from the 
mechanism. We, therefore, allowed the RET concentrations to vary for each 
curve to return the best fit.   
3.2.3 Effect of activation pathway on the ART dose-response at varying 
expression levels of RET and GFRα3. 
To test how pre-dimerziation of GFRα3 or of RET affects the ART dose-
response at different expression levels of these two components, we again used 
the simulated results for the ART does-responses for original RET system, and 
globally fitted them to an alternative activation mechanism involving either pre-
dimerized GFRa3 (Figure 3.15) or pre-dimerized Ret (Figure 3.18).  
To investigate the effect of pre-dimerzation of GFRα3 on the pRET 
response to ART, we set the total number of molecules of GFRα3 per cell equal 
in the two mechanisms. Thus, the concentration of GFRα3 dimers in the pre-
dimerized GFRα3 mechanism was half of the total concentration of GFRα3. The 
equilibrium dissociation constants K1 and K2 were optimized by the fit, while K3 
was fixed at the value of K4 from the original RET activation mechanism, since it 
described identical binding events in both (compare the last steps in Figures 3.5 
and 3.15). 
To test the effect of pre-dimerization of RET on the pRET response to 
ART, we kept the total RET expression for each curve the same across 
pathways, so that the final concentration of the RET dimers was half of the total 
concentration used in the native RET pathway. The equilibrium dissociation 
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constants K2 and K3 for the pre-dimerized RET pathway (Figure 3.18) were 
optimized in the fit, but K1 was fixed at the same value as in the original RET 
pathway (417 nM) [17], since it described the same binding event in both 
mechanisms (compare the first step in Figures 3.5 and 3.18).  
All DynaFit script files used to perform the simulations are shown in 
Appendix 3.  
3.3 Results and Discussion 
3.3.1 Effects of varying the expression levels of RET and GFRα3 on the 
ART dose-response for RET phosphorylation. 
The activation mechanism of RET-GFRα3-ART on cells has previously been 
established (Figure 3.1) and the numerical values for the four equilibrium binding 
constants determined (Table 3.1) [17].  
 
Figure 3.3.1 RET activation pathway proposed by Schlee et al. RET and GFRα3 are monomeric 
in the absence of artemin. In the first step of the mechanism artemin (purple) from solution binds 
to a monomeric GFRα3 (red). In the second step, the ART-GFRα3 complex binds to a free RET 
(blue) on the cell membrane. This trimeric complex binds a second molecule of GFRα3. The 
ART-GFRα32-RET complex binds a second molecule of RET to form the activated pentameric 
ART-GFRα32-RET2 complex [17]. The activation of RET is indicated by the red lighting bolt. All 
binding constants are equilibrium dissociation constants. 
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We used the above mechanism and values for the binding constants to perform 
simulations, using DynaFit (BioKin, Ltd) [168], in which we varied the expression 
levels of either RET or GFRα3 and calculated how pRET values varied as a 
function of the stimulating ART concentration.  
Comparison of the ART dose-response curves simulated for different RET 
levels showed that increasing the amount of surface RET strongly increased the 
amplitude of the signal, and also slightly increased the sensitivity of the system to 
ART, as defined by the concentration of ART that elicited 50% of the maximum 
pRET response (EC50) (Figure 3.2). 
 
Figure 3.3.2 Simulated ART dose-response curves at different RET concentrations. The curves 
were generated by simulating the response of the system as measured by the levels of RET 
phosphorylation using the activation pathway, equilibrium dissociation constants and GFRα3 
expression level (65000 molecules per cell) established by Schlee et al. [17]. Each curve 
represents the ART dose-response at the indicated RET expression level. The x-intercept of the 
dashed lines indicates the EC50 for each dose-response. 
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To test the effect of modulating GFRα3 concentration on the ART dose-
response for RET activation, we again used the experimentally determined 
equilibrium dissociation constants from Table 3.1 and simulated the ART dose- 
responses at different expression levels of the co-receptor. The results show that 
variations in available surface GFRα3 levels are predicted to have different 
effects on the ART dose-response for pRET, depending on the relative 
abundance of the co-receptor and RET. When GFRα3 is in excess compared to 
RET, decreasing its levels strongly affects the sensitivity of the system to ART, 
as measured by the EC50 of the response, but had minimal effect on the 
maximum amplitude of the RET response. When GFRα3 became 
stoichiometrically limiting in comparison to RET, further decreasing its 
abundance continued to decrease the sensitivity of the response, though less 
sharply, but also caused a strong decrease in the maximum amplitude of the 
signal (Figure 3.3). 
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Figure 3.3.3 Simulated ART dose-response curves at different GFRα3 concentrations. The 
curves were generated by simulating the response of the system as measured by phosphorylated 
RET using the activation pathway, equilibrium dissociation constants and RET concentration 
(6500 molecules per cell) established by Schlee et al. [17], but using different amounts of GFRα3. 
Each curve represents the ART dose-response at the indicated co-receptor expression level. The 
x-intercept of the dashed lines indicates the EC50 for each dose-response. 
 
The simulations on Figures 3.2 and 3.3 suggest that involvement of a co-receptor 
in the RET system provides cells with the capability to function in four different 
regimes that are characterized by the amplitude and sensitivity of the response 
and their susceptibility to change upon changing GFRα3 expression levels: 
(Figure 3.5): 
1. GFRα3 < RET: At very low expression levels of GFRα3, the ART dose-
response is characterized by low maximum amplitude and low sensitivity. 
Increasing co-receptor expression on the cells modestly increases the 
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sensitivity to ART stimulation (EC50), but produces a large increase in the 
maximum amplitude of the response (Figure 3.4 unshaded area).  
2. GFRα3 ~ RET: At stoichiometrically equivalent levels of GFRα3 and RET 
(Figure 3.4 vertical dashed line), the ART dose-response is characterized 
by a high maximum amplitude, but relatively low sensitivity. Both 
amplitude and EC50 are relatively sensitive to variations in GFRα3 
expression levels, with the amplitude being more sensitive to decreasing 
co-receptor while the sensitivity of the response is affected more strongly 
by increasing GFRα3. 
3. GFRα3 > RET: When GFRα3 is present on the membrane in 
stoichiometric excess relative to RET (Figure 3.4 blue-shaded area), the 
maximum amplitude of the response is high (and becomes limited by how 
much RET is present to become activated), and the sensitivity of the 
system to ART is high. Further increasing the expression levels of GFRα3 
has no effect on the maximum amplitude of the response, but 
proportionately increases the sensitivity to ART. 
4. GFRα3 >> RET: At very high GFRα3, binding of ART to GFRα3 is so 
strongly favored that essentially all ART molecules present in the system 
will be bound to RET as part of an ART-GFRα3-RET complex, provided 
there is a free RET to bind. Under these conditions, EC50 reaches a lower 
limit that corresponds to half the molar concentration of RET, reflecting the 
number of ART molecules required to titrate the RET to 50% occupancy. 
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Thus, at very high GFRα3 levels, both the amplitude and the sensitivity of 
the response become insensitive to further increases in co-receptor 
expression level. The numerical value of the minimum achievable EC50 
value, in molar units, will depend on the number of cells and the volume of 
the fluid by which the cells are surrounded, as we have discussed in a 
different context [163].  
 
Figure 3.3.4 Plot of the maximum pRET amplitude and the sensitivity to ART (EC50), as a function 
of GFRα3 expression levels, at 6000 RET molecules per cell, showing the three regimes of cell 
response defined by the relative abundance of the co-receptor. The unshaded region of the plot 
represents conditions of low GFRα3 expression relative to RET, where the response is 
characterized by very low amplitude and low sensitivity to ART (high EC50). Under these 
conditions, variations in the expression levels of the co-receptor have a strong effect on the 
amplitude but not the sensitivity of the response. The region shaded in blue represents conditions 
where GFRα3 expression is high relative to RET, and the response is characterized by a high 
maximum amplitude (limited by [RET]) and low EC50 (high sensitivity). Variations in the 
expression levels of GFRα3 affect strongly the sensitivity, but not the magnitude of the response. 
The vertical dashed line represents conditions where GFRα3 ~ RET, where the cells are able to 
achieve almost full maximum amplitude, but only at high ART concentrations. Modulation of 
GFRα3 expression levels in this region affects both the amplitude and the sensitivity of the 
response. 
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3.3.2 Mimicking the ART dose-response at different RET and GFRα3 
expression levels with a hypothetical homodimeric receptor system 
 As part of our analysis of the individual roles of RET and GFRα3 in 
determining the relationship between the dose of ART and the RET 
phosphorylation response, we wanted to see if there is a set of parameters that 
describe a simpler homodimeric receptor system that can replicate the response 
of RET (signal amplitude and sensitivity) to stimulation with different ART 
concentrations. To test this question, we took the simulated ART dose-response 
curves determined at different RET expression levels (Figure 3.2), and fitted 
them to a model, in which RET binds directly to ART without any involvement of 
GFRα3 (Figure 3.5). This simpler activation mechanism resembles that proposed 
for a number of cytokine receptors (see Chapter 1). 
 
Figure 3.3.5 Activation mechanism for a hypothetical homodimeric receptor. A bivalent ligand 
(purple) binds sequentially to two identical receptor molecules (blue). K1 and K2 are equilibrium 
dissociation constants. 
 
During the fitting process, the equilibrium dissociation constants K1 and K2 were 
allowed to vary to provide the best fit. The model returned good fits (Figure 3.6 
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dashed lines), and achieved very similar dose-response relationships to those 
seen for the RET-GFRα3-ART system when the expression levels of the receptor 
were varied (Figure 3.6 solid lines). The global fit returned an optimized value for 
K1 in the simple homodimeric mechanism of 24 ± 0.89 nM. This value was about 
20-fold lower than the reported value of 417 nM reported by Schlee et al. for K1 
in the native RET activation mechanism. K2 was 4.8 ±0.17 x 10-4 nM, only twice 
as large as the affinity for the binding of the second RET molecule in the 
pentameric complex (2.2 x 10-4 nM). The results of this simulation suggest that 
the response of the system to variations in receptor expression level are broadly 
similar with or without participation of a co-receptor, if appropriate binding 
affinities for the various steps in activation can be achieved. Thus, any unique 
functional properties imparted by the involvement of a co-receptor do not appear 
to relate either to the shape of the ligand dose-response curve, or to how this 
dose-response relationship might be regulated by modulating receptor 
expression. 
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Figure 3.3.6 Fit of the simulated ART dose-responses for RET phosphorylation at varying RET 
expression levels in the RET-GFRα3-ART system, to a hypothetical homodimeric receptor model 
that does not involve a co-receptor. Solid lines represent the response of the RET-GFRα3-ART 
system. Each curve is the ART dose-response at the indicated RET expression levels. The 
dashed lines represent the best global fit to this data set obtained for the simpler homodimeric 
receptor system, after optimization of the values of K1 and K2. 
 
 In the simplified homodimeric receptor model, illustrated above, 
modulating the receptor expression level affected both the amplitude and the 
sensitivity of the response in a coupled manner. A feature of the RET activation 
mechanism is that the expression levels of both RET and GFRα3 affect the 
response. We therefore hypothesized that a unique characteristic that 
involvement of a co-receptor contributes to the system is the ability of the cell to 
separately regulate the amplitude and sensitivity of the response by differentially 
regulating receptor and co-receptor expression levels. Based on this hypothesis, 
we would expect, that for a homodimeric system, there would be no combination 
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of parameters that would reproduce the effects on the ART dose-response that, 
in the more complex mechanism, are seen upon varying expression of the co-
receptor. 
To test this question, we used the simulated ART dose-responses from 
Figure 3.3, and fitted these simulated results to the simpler homodimeric system 
shown in Figure 3.5, allowing K1 and K2 to vary to return the best global fit to the 
data. The results show that the simple homodimeric receptor model returned 
poor fits (Figure 3.7 dashed lines) and could not recapitulate the effect of varying 
the GFRα3 expression levels, observed in the native RET activation mechanism, 
on the maximal pRET amplitude or the sensitivity of the response to ART (Figure 
3.7 solid lines). This simulation therefore supports our hypothesis that a simple 
homodimeric receptor cannot achieve the independent regulation of signal 
amplitude and signal sensitivity that is seen for the RET system, because 
attempts to modulate the response EC50 by varying receptor expression has 
substantial concomitant effects on the maximum amplitude of the response 
(Figure 3.7 dashed lines).  
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Figure 3.3.7 Fit of the simulated RET-GFRα3-ART responses to varying concentrations of ART at 
different concentrations of GFRα3, to a simple homodimeric receptor model that does not involve 
a co-receptor. Solid lines represent the response of the RET-GFRα3-ART system. Each curve is 
the simulated ART dose-response at the indicated GFRα3 expression levels 6000 RET 
molecules per cell. The dashed lines represent the best global fit to the simpler homodimeric 
receptor system, after optimization of the values of K1 and K2 
  
Under biologically relevant conditions, the RET system likely functions at 
very low ligand concentrations [163]. Under these circumstances, the number of 
available ART molecules in solution, rather than the number of RET or GFRα3 
molecules present on the cell, might limit the amplitude of the response [163] 
showed that formation of only 200 – 250 RET-GFRα3-ART receptor complexes 
was enough to elicit the cellular response of neurite outgrowth in mouse 
neuroblastoma cells [163]. Thus, in evaluating the effect of variations in GFRα3 
and RET expression levels on the responsiveness of the cells to ART, it is 
probably more relevant to determine the concentration of ART required to 
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produce 250 activated receptors (EC250pRET), rather than the EC50 or the 
maximum pRET response. We therefore used the model from Figure 3.1 to 
determine the EC250pRET for simulated ART dose response curves at different 
GFRα3 and RET concentrations. Figure 3.8 shows how the ART concentration 
required for the activation of 250 RET molecules per cell varies as a function of 
the expression levels of RET (Figure 3.8A) and GFRα3 (Figure 3.8B). 
The results show that varying RET and GFRα3 expression levels have the 
same effect on the EC250pRET; the ART concentration required to induce 250 
pRET molecules increases with the square of the expression level of RET and 
also of GFRα3. So it seems that, even though varying the expression levels of 
RET and GFRα3 have quite distinct effects on the amplitude and sensitivity of the 
full ART dose-response, they show equivalent effects on the ligand concentration 
required to elicit a threshold number of activated receptor complexes required for 
a biological response. Thus, participation of a co-receptor confers upon the 
receptor system two orthogonal means to regulate the functional sensitivity of the 
cell to stimulation by the activating ligand: by modulating the expression level of 
the signaling receptor component, or of the co-receptor. 
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Figure 3.3.8 Dependence of 
the EC250pRET on the 
expression levels of RET and 
GFRα3. The ART 
concentration required to 
bring about activation of 250 
RET receptors (EC250pRET) 
was determined by simulating 
ART dose-response curves at 
different levels of RET (A) or 
GFRα3 (B), using the model 
from Figure 3.1. The linear 
part of the double logarithmic 
plots were fitted to y = a*xz + 
b. In (A) each curve shows 
the result of varying RET 
expression at indicated fixed 
expression levels of GFRα3, 
while the reverse is true in 
(B). 
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3.3.3 Evidence for regulation of GFRα3 expression levels during 
development 
Based on the above results, several reasons can be envisioned for why 
the RET system requires the involvement of a co-receptor in its activation 
mechanism. The dependence of signaling on the recruitment of GFRα converts 
the system into a three-input logic “AND gate”, where a cellular response 
requires the simultaneous satisfaction of three conditions: a given level of 
stimulus (concentration of and time of exposure to ligand); expression of an 
appropriate level of RET; and expression of an appropriate level of co-receptor. 
The contingency of the response on the presence and recruitment into a 
signaling complex of three different components offers a means for more 
stringent regulation than would be available to a simpler system where a co-
receptor is not involved [110]. 
Another possible advantage of participation of a co-receptor is that it 
allows the system to regulate its sensitivity to ligand while maintaining the ability 
to produce a signal of high amplitude through the receptor. In the case of RET, 
one can speculate that signaling in response to different GDNF family ligands 
(GFLs) might have posed evolutionary pressure for the receptor to be able to 
modulate its responsiveness to one ligand, while maintaining the capability to 
signal in response to the presence of a given concentration of another ligand. It is 
clear that expressing the preferred co-receptor for a given ligand enables cells 
that are exposed to a mixture of stimuli to “choose” which RET ligand to respond 
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to. Such an ability could be particularly important if signaling by different GFLs 
results in qualitatively distinct biological responses. However, our results 
additionally show that a cell can quantitatively tune its responsiveness to different 
GDNF family ligands by modulating the expression of the different GFRα co-
receptors. Thus, a cell could be simultaneously responsive to two or more 
different GDNF family members, but with quite different and readily controllable 
sensitivities. 
The strong effect of GFRα3 expression levels on the sensitivity of the 
system’s response may be a means to determine which among a set of nearby 
cells will respond when exposed to the same concentration of ART. A cellular 
response is elicited only when a certain threshold number of RET receptors 
become activated. If adjacent cells express the similar levels of surface RET, the 
amplitude of the response will be determined by the expression level of GFRα3. 
At low levels of co-receptor the sensitivity of the RET response will be low, and 
the number of receptors engaged in activated complexes may not reach the 
threshold level required for the cellular response. However, cells that express 
higher levels of GFRα3 will exhibit higher sensitivity for ART, leading to activation 
of a greater number of RET molecules at the same ligand concentration (Figure 
3.9).  
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Figure 3.3.9 Diagram illustrating the responsiveness of cells with different GFRα3 expression 
levels to different concentrations of ART. When cells express low levels of GFRα3, their 
sensitivity to ART is low and a cellular response would not be elicited at relatively low doses of 
ligand. The same cells will respond to ART at higher concentration. If, however, cells express 
high levels of GFRα3, their sensitivity to ART will also be high. These cells will response to low 
and high ART concentrations.  
 
Another way in which regulation of signaling by modulating the expression 
level of a co-receptor could be critical for biological activity is if quantitative 
differences in signaling levels can lead to distinct biological outcomes. Our 
simulations show that cells with different cell-surface GFRα3 expression levels 
exposed to the same concentration of ART result in different levels of RET 
activation, which could translate into different cell fates (Figure 3.10). By 
dynamically regulating its co-receptor expression levels, an individual cell may 
also respond differently to the same levels of stimulus at different times. This 
type of gradient signaling has been shown for morphogenetic factor receptors 
during embryonic development, such as BMP [181, 182], which utilizes a co-
receptor [183, 184]. However, whether RET has morphogenetic characteristics 
remains to be elucidated.  
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Figure 3.3.10 Diagram illustrating the effect of different GFRα3 expression levels on the cellular 
response at a fixed concentration of ART. Stimulation of cells expressing different levels of 
GFRα3 with a fixed concentration of ART will result in different amplitudes of the RET response. 
This quantitative difference in signaling could affect the biological outcome of RET signaling.  
 
The speculations that we described above imply that the expression of 
GFRαs should differ in distinct subsets of cells. To look at the expression of the 
different components of the RET receptor system during mouse development we 
used the Allen Developing Mouse Brain Atlas, which is a collection of gene 
expression data measured by the abundance of mRNA using In Situ 
Hybridization (ISH) [185]. The levels of expression of each gene are shown by 
colored spheres, where each sphere represents a small cross sectional area of 
the mouse embryo (Figure 3.11A). Relatively low expression level (per cell) of 
the gene of interest in a given area is indicated by green color, while high 
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expression level is represented by red color (Figure 3.11B). The size of the 
spheres is proportional to the area occupied by cells that express the gene 
normalized to the total area represented by the sphere. Thus, if only a few cells 
in the studies area express the gene of interest, this section will be represented 
by a relatively small sphere. 
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Figure 3.3.11 Example of the analysis of the data presented in the Allen Developing Mouse Brain 
Atlas.(A) Representation of RET system gene expression from the Allen Developing Mouse 
Embryo Atlas. A picture of a sagittal cross-section of mouse embryo at developmental stage E 
13.5 is shown in the right panel. The overlaid colored spheres represent expression of RET 
mRNA. The physical area represented by a single selected sphere (green) is shown in the bottom 
left area of the left panel. The middle picture in the left panel shows the same area relative to the 
whole embryo. (B) Example of the representation of different average relative expression levels 
per cell by different colors on a green-red scale and fraction of studied area covered with cells 
expressing the gene of interest by different size of the spheres. A picture of the mouse embryo at 
E 11.5 stage is shown in the right panel. The overlaid colored spheres represent RET expression. 
Different color and size spheres are shown in the right panel. On the green-red scale green 
represents relatively low expression and red represents relatively high levels of expression of 
RET. The relative size of different spheres indicates the fraction of the area within each sphere 
covered by cells that stained positive for RET mRNA. 
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At the earliest tested stage of development (E 11.5), both RET and 
GFRα3 show expression in localized areas of the embryo (Figure 3.12). The 
different colors describing the expression of GFRα3 indicate that the co-receptor 
is expressed at different copy number per cell in distinct regions. The observation 
that, in vivo, different subsets of cells express different levels of GFRα3 supports 
our hypothesis that regulation of the responsiveness of individual cells to ligand, 
by means of modulating cell surface expression GFRα3 levels, may be 
biologically important. 
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Figure 3.3.12 RET, GFRα3, GFRα1, and GFRα2 expression in the developing mouse embryo at 
E11.5, measured by In Situ Hybridization (ISH). A sagittal cross-section of the embryo is shown in 
the first panel, and is excluded from the other images for clarity. The relative expression levels of 
the RET receptor components are represented by the color of the spheres. On the green-red 
scale, green indicates low expression, and red high expression. Levels of expression, indicated 
by different colors can only be compared within the same gene expression profile. 
 
 Interestingly, at this stage of development the expression of both GFRα1 
and GFRα2 is low (Figure 3.12), suggesting that RET signals primarily via 
activation by GFRα3/ART, or alternatively through a GDNF family ligand-
independent pathway, which has been observed in vivo, during postnatal stages 
of development [186]. 
At development stage E 13.5, the overall expression of GFRα3 has 
decreased, while RET expression has increased dramatically in the brain and 
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throughout the spinal cord (Figure 3.13).  At the same time, expression of GFRα1 
and -2 is high in several places, including sites where GFRα3 has become low 
but RET remains high, suggesting that the receptor may be activated through 
these other ligand/co-receptor pairs during this developmental stage (Figure 
3.13). The changes in GFRα3 expression in several regions of the embryo, 
between these two stages of development, supports our hypothesis that 
individual cells can regulate their expression of GFRα to vary their sensitivity and 
responsiveness to ligand stimulation at different times. Also, comparison of the 
expression levels and areas of GFRα1 and GFRα2 indicates that at this stage of 
development the two co-receptors are expressed at different levels and in 
partially overlapping areas of the embryo (Figure 3.13). This observation 
supports the idea that neighboring cells may selectively respond to different 
ligands by regulating the expression levels of the respective co-receptor.  
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Figure 3.3.13 RET, GFRα3, GFRα1, and GFRα2 expression in the developing mouse embryo at 
E 13.5, measured by In Situ Hybridization (ISH). A sagittal cross-section of the embryo is shown 
in the first panel and is excluded from the other images for clarity. The relative expression levels 
are represented by the color of the spheres. On the green-red scale, green indicates low 
expression, and red high expression. 
 
3.3.4 Importance of the activation pathway for regulating signaling 
sensitivity  
In previous work from our group, Schlee et al. used the response of the 
RET system to varying concentrations of the co-receptor GFRα3 and the ligand 
ART to distinguish between different possible mechanisms for receptor 
  
 
   
146 
activation. The results showed that distinct activation pathways would give 
different responses to varying the expression levels of the individual components 
involved (Figure 3.14) [17]. However, even in this fairly well characterized 
system, we still have little knowledge about the functional importance of the 
specific activation pathway that is employed by the receptor system.  
In the RET-GFRα3-ART system the smallest activated receptor unit 
consists of one molecule of ligand, two co-receptor molecules, and two RET 
molecules. Schlee and coworkers have shown that, in the NB41A3-GFRα3 cell 
line that they studied, the activation pathway that best described the response of 
the system to varying concentrations of ART and GFRα3 was one in which both 
GFRα3 and RET are monomeric in the absence of ligand. This, and previous 
knowledge about the molecular interactions between the different components of 
the system [3, 17], suggested that there were two orthogonal homodimerization 
events in the activation pathway, involving GFRα3 and RET, plus a 
heterodimerizion of RET with GFRα3. 
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Figure 3.3.14 Possible pathways for activation of Ret by ART and GFRa3. (A) All possible 
pathways that include sequential dimerization of Ret to form a signaling complex of composition 
ART–(GFRa3)2–(Ret)2 (models 1–4). The pathways differ in the receptor components assumed 
to be pre-associated before ART binding, the sequence of steps leading to formation of the 
signaling complex, and the composition of the non-signaling complexes that accumulate in the 
dead-end state (DE). (B) Proposed mechanism for the activation of Ret by ART and GFRa3. In 
both parts, the activated receptor complex is indicated by a red lightning bolt. (C) and (D) Global 
fits of the ART dose-response data at different cell surface GFRα3 to activation models where the 
GFRα3 is monomeric (C) or dimeric (D) in the absence of ligand. Figure reproduced from [17] 
with permission. ©2006, Rights Managed by Nature Publishing Group. 
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We wanted to test whether modifying the activation pathway of the system 
by changing the oligomeric state of either RET or GFRα3, will influence the effect 
of varying the expression levels of these components on the ART dose-
response. In the simulations described above, we showed that the expression 
levels of RET strongly affect both the amplitude and the sensitivity of the RET 
response to ART (Figure 3.2), and those of GFRα3 have a pronounced effect on 
the sensitivity of the response (Figure 3.3). Here, we wanted to test if RET and 
GFRα3 expression levels would have similar effects on the ART dose-response 
curves if the system undergoes activation through a pathway where the co-
receptor was constitutively dimeric even in in the absence of ligand (Figure 3.15).  
 
Figure 3.3.15 Hypothetical activation mechanism for RET activation, involving pre-dimerized 
GFRα3. ATR (purple) binds to pre-dimerized GFRα3 (red) and this complex sequentially recruits 
two RET molecules (blue). K1, K2, and K3 are equilibrium dissociation constants. 
 
We took the ART dose-response curves at different RET or GFRα3 
expression levels, simulated for the native activation mechanism (Figure 3.2 and 
3.3) and globally fitted the each data set to the hypothetical pathway, in which all 
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of the GFRα3 molecules exist as constitutive dimers in the absence of ART. The 
equilibrium dissociation constants K1 and K2 were allowed to vary to return the 
best fit to the data, while K3 was fixed at the value of K4 from the original 
pathway, since it describes the same binding reaction in both mechanisms. The 
concentrations of dimeric GFRα3 were adjusted, so that the total number of co-
receptors per cell was the same in both mechanisms. The results showed that 
the effect of varying RET expression levels on the ART dose-response in the 
native system was very closely mimicked in the alternative pathway that started 
with pre-dimerized GFRα3 (Figure 3.16A). This finding suggests that the 
oligomeric state of the co-receptor has little effect on how the properties of the 
system respond to varying the expression level of the RET receptor.  
However, the effect of varying GFRα3 expression levels was quite 
different for the two activation mechanisms (Figure 3.16B). Over the same range 
of GFRα3 expression levels for both mechanisms, decreasing GFRα3 expression 
had a greater effect on the maximum pRET amplitude for the mechanism in 
which the co-receptors are pre-dimerized. Also, the effect of varying GFRα3 
expression levels on the sensitivity of the pRET response to ART was 
substantially reduced for the activation mechanism involving pre-dimerized co-
receptors compared to the native mechanism (Figure 3.17). At high co-receptor 
levels, the simulation predicted that cells would show reduced sensitivity to ART 
(higher EC50), for a receptor that utilized pre-dimerized GFRa3 (Figure 3.16B, 
blue and red curves solid and dashed curves), whereas at lower co-receptor 
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levels the cells were predicted to be substantially more sensitive to ART than 
was observed for a receptor functioning by the native activation pathway (Figure 
3.16B green, purple, cyan, and orange solid and dashed curves).  
 
Figure 3.3.16 Effect of the 
resting oligomeric state of 
GFRα3 on the ART dose-
response at different 
expression levels of RET and 
GFRα3. (A) The simulated 
ART dose-responses at 
65000 GFRα3 molecules per 
cell and the indicated RET 
expression levels are shown 
by the solid lines.. The best 
fits of the data to the 
activation pathway of pre-
dimerized GFRα3 and 
monomeric RET, shown in 
Figure 3.14, are shown by the 
dashed curves. (B) The 
simulated ART dose-response 
at 6000 RET molecules per 
cell and the indicated GFRα3 
concentrations are shown by 
the solid curves. The best fits 
of the data to the activation 
pathway from Figure 3.14 are 
shown by the dashed curves. 
 
 
 
 
 
These results show that an activation mechanism that involves sequential 
recruitment of two monomeric co-receptor enables the cell to access a much 
wider range of sensitivities to ligand stimulation than is the case is activation 
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proceeds through a mechanism in which the co-receptors are pre-dimerized 
Figure 3.17). These observations suggest that the ability of the system to 
modulate the sensitivity of its pRET response to ART through regulation of the 
expression levels of GFRα3, without decreasing the maximum amplitude of the 
signal, depends on the pathway by which the activated receptor complex 
assembles, and in particular on the initial oligomeric state of the co-receptor.  
 
Figure 3.3.17 Dependence of the EC50 for the ART response on the expression level of GFRα3 
for the native activation mechanism and the hypothetical activation mechanism, which involves 
pre-dimerized GFRα3. The data for the native RET activation mechanism is shown in blue and 
those for the mechanism of pre-associated GFRα3 is in red. 
 
We also tested the effects of varying the expression levels of RET and 
GFRα3 on the pRET response when RET exists as pre-formed dimers (Figure 
3.18). We fitted the dose-response curves that we obtained from simulating the 
native RET system response to the mechanism shown in Figure 3.18. The total 
number of GFRα3 and RET molecules was kept the same between the two 
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mechanisms. The equilibrium dissociation constants K2 and K3 were allowed to 
vary and K1 was fixed to the value of K1 determined for the original mechanism, 
as this step is identical for the two mechanisms.  
 
 
Figure 3.3.18 Hypothetical activation mechanism for RET, in which the resting state of RET is 
dimeric.ART (purple) binds to monomeric GFRα3 (red), and this complex recruits an inactive RET 
dimer (blue). RET is phosphorylated when a second GFRα3 molecule binds to the ART- GFRα3-
RET2 complex.  
 
The results showed that when we varied the expression level of RET, the 
alternative activation mechanism (with pre-dimerized RET) predicted a slightly 
different maximum pRET amplitude and a higher sensitivity at low RET 
expression levels than the native pathway (Figure 3.19A). In particular, the 
predicted EC50 values are independent of RET expression levels for the 
mechanism in which RET exists as a pre-associated dimer, whereas for the 
native mechanism involving monomeric RET a decrease in RET expression 
results in a decreased sensitivity to ART stimulation. However, when we looked 
at the ART dose-responses for RET activation at varying expression levels of 
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GFRα3, we observed that modulation of GFRα3 affected the response in similar 
ways in both mechanisms. The predicted amplitude of the pRET signal for the 
pre-dimerized RET mechanism was higher for the high (Figure 3.19B blue, red 
and green solid and dashed curves) and lower for the low GFRα3 levels (Figure 
3.19B purple, cyan, and orange solid and dashed curves) compared to that 
achieved with the native activation pathway. However, at GFRα3 expression 
levels at which the co-receptor is in stoichiometric excess over RET, decreasing 
the amount of surface GFRα3 had little effect on the maximum pRET amplitude 
in either activation mechanism. Furthermore, although slight differences in the 
absolute sensitivity between the two activation pathways were evident at each 
tested expression level of GFRα3, the difference between the lowest and highest 
EC50 values was similar between the two pathways. 
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Figure 3.3.19 Effect of the 
resting oligomeric state of 
RET on the ART dose-
response at different 
expression levels of RET  
and GFRα3.(A) The 
simulated ART dose-
responses at 65000 
GFRα3 molecules per cell 
and the indicated RET 
expression levels are 
shown in the solid lines. 
The best global fit of the 
data to an activation 
pathway of pre-dimerized 
RET and monomeric 
GFRα3 molecules (Figure 
3.16) are shown by the 
dashed curves. The 
simulated ART dose-
response at 6000 RET 
molecules per cells and the 
indicated GFRα3 
concentrations are shown 
by the solid curves. The 
best fit of the data to the 
activation pathway with 
pre-dimerized RET (Figure 
3.16) are shown by the 
dashed curves. 
 
 
 
Taken together, these simulations suggest that the properties of the 
receptor system – and particularly the range of sensitivities that can be accessed 
by modulating GFRα3 expression levels – depend on the oligomerization state of 
the co-receptor in he absence of ligand, but are much less affected by whether or 
not the signaling receptor RET is pre-dimerized.  
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3.4 Conclusions and Future Directions 
The simulations described above show that involvement of a co-receptor, 
GFRα3, in the activation pathway of the RET receptor tyrosine kinase, provides 
the system with the ability to regulate the sensitivity of its response over a wide 
range of ligand concentrations, without reducing the maximum achievable 
amplitude of the signal, and that this feature is not available to a simpler 
homodimeric receptor system in which ligand binds directly to RET with no 
involvement of a co-receptor.  This effect was specific to a ligand-induced co-
receptor dimerization activation pathway, however. We observed a significant 
reduction in the sensitivity range when the system was forced to go through an 
activation pathway involving pre-formed GFRα3 dimers. In this hypothetical 
mechanism, variations in the expression of RET effectively modulated the 
magnitude of the signal, but had little effect on the sensitivity to ligand. 
For the mechanism that is believed to describe the true activation pathway 
for ART-RET-GFRa3, shown in Scheme 3.1 and in Figure 3.13B, modulating 
GFRα3 expression levels could have several different effects,, depending on its 
abundance relative to that of RET. When GFRα3 was in stoichiometric excess 
over RET, changes in GFRα3 expression levels caused significant changes in 
the sensitivity of cells to ART, but had little effect on the maximum response. In 
contrast, when the co-receptor was stoichiometrically limiting, the response of the 
system to variations in its expression levels was characterized by a strong effect 
on the maximum amplitude of the pRET signal, but not on the EC50. When 
  
 
   
156 
GFRα3 was present at levels comparable with that of RET, and variations in the 
co-receptor abundance had significantly affected both the magnitude (decreasing 
GFRα3) and sensitivity (increasing GFRα3) of the signal.  
Currently we don’t have a definitive explanation for how involvement of the 
co-receptor gives an evolutionary advantage to the RET system, or how it may 
be essential for its biological function. Our understanding is mainly limited by the 
gaps in our knowledge about the consequences of signaling of RET through its 
four different ligand/co-receptor pairs. Expression data for the three co-receptors, 
GFRα1-3 during mouse embryonic development, that we obtained from the Allen 
Brain Atlas [185], showed that some cells and tissues co-express two or three 
GFRαs at the same developmental stage, although at different levels. Examining 
the expression of GFRα3 during a given developmental stage, we also observed 
that it is present at different densities in distinct areas of the embryo. During the 
earliest tested stage, for example, there was very low detectable expression of 
the other GFRα members, suggesting that signaling was mainly mediated 
through ART/GFRα3 and that neighboring cells may experience different levels 
of ART-dependent RET signaling if exposed to similar ligand concentration, 
depending on the available surface abundance of the co-receptor. These 
observations are consistent with the idea that GFRa co-receptor levels are 
quantitatively regulated during embryonic development, in ways that are 
expected to modulate the sensitivity of RET-expressing cells to different GDNF 
family ligands as a function of location and also of time (i.e. stage of 
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development). These observations are therefore consistent with our hypothesis 
that participation of a co-receptor could serve the purpose of enabling such 
quantitative modulation of cellular response to GDNF family ligands. However, 
there is currently no direct evidence to indicate such quantitative regulation of 
signal responsiveness has significant biological consequences. Nor is there any 
evidence concerning whether or not RET can mediate a morphogenetic response 
when cells are exposed to a ligand gradient, as our simulations suggest is a 
possibility. 
Our simulations elucidate important properties of the RET system that 
could be used as starting points to design experimental systems where the 
relationships that we observed computationally can be tested. To conclusively 
establish the effect of GFRα3 expression levels for RET activation, signaling and 
function, we would have to establish an experimental system where we can 
manipulate the number of available co-receptors on the cell surface, and study 
the effects of varying its expression level. It would be very informative to have 
such a system that co-expresses at least two different GFRa co-receptors, so 
that we could study the effects of separately varying the expression level of each 
GFRα on signaling and functional responses. For such a system, it would be 
required that the signaling outcome through the different GFL/GFRα pairs is 
quantitatively characterized and distinguishable. Finally, our simulations 
suggested that the ability to regulate RET signaling by modulating co-expression 
levels depends on the pathway by which binding of ligand brings about formation 
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of the activated receptor complex. To directly test the effects of varying the 
pathway through which RET is activated would require a system where the 
dimerization of the co-receptor can be manipulated by some orthogonal means.  
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Chapter 4 Design of a GFRα3 co-receptor that can be reversibly dimerized 
by a small molecule 
 
4.1 Introduction 
The minimal composition of growth factor receptor complexes consists of 
one ligand molecule and two transmembrane receptor molecules, which can 
undergo phosphorylation on their cytoplasmic domains. However, a great 
number of receptors require the involvement of one or more membrane-anchored 
co-receptors to achieve full activation [92]. Different components of the receptor 
complex may strongly regulate distinct characteristics of the signaling response, 
such as amplitude, sensitivity to stimulus, lifetime of the activated complex, or 
subcellular compartmentalization. In addition, these regulatory effects may be 
dependent on the specific sequence of steps that leads to receptor activation. 
The possible sequence of molecular steps that determines the activation 
mechanism of a given receptor system increases proportionately with the number 
of molecules that comprise the signaling receptor complex. The mechanism, by 
which a receptor becomes activated may vary, depending on the specific cellular 
environment, for example, the local receptor expression levels, and such 
variations may be reflected in the responsiveness of the system to ligand. The 
relationship between the receptor activation pathway and the biological outcome 
of signaling through this receptor have rarely been experimentally studied, partly 
due to the technical difficulty to engineer a system that can be externally 
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manipulated to undergo activation through two or more different pathways 
without affecting the total surface levels of signaling molecules. Indeed, there are 
only few cases where the activation pathway has been characterized 
quantitatively, including the sequence of steps and their affinities [17, 31-33]. 
Schlee et al. used the RET phosphorylation response to varying concentrations 
of the co-receptor GFRα3 and the ligand ART to distinguish among the different 
possible mechanisms for receptor activation, showing that the distinct activation 
pathways would result in distinct patterns in the ART dose-response curves for 
pRET with respect to expression levels of the individual components involved 
(Figure 4.1) [17]. However, even in this fairly well characterized system, we still 
have little knowledge about the functional importance of the specific activation 
pathway that is employed by a receptor system. In other words, it is not clear to 
what extent the sequence of steps leading to receptor activation affects cellular 
responsiveness a given stimulus level.  
In the RET-GFRα3-ART system the smallest activated receptor unit is 
believed to consists of a ligand, two GFRα3 molecules, and two RET molecules 
[3, 142]. Schlee and coworkers have shown that in the cell line that they studied, 
the activation pathway that best described the response of the system to varying 
concentrations of ART and GFRα3 was one where both GFRα3 and RET were 
monomeric in the absence of ligand [17]. This and previous knowledge about the 
molecular interactions between the different components of the system 
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suggested that there were two orthogonal homodimerization events in the 
activation pathway – those of GFRα3 and RET [3]. 
 
Figure 4.1 Possible activation pathways for the RET receptor system and the pathway proposed 
for the activation of the system on NB41A3-mGFRα3. (A) Several plausible activation pathways 
for the RET receptor system proposed by Schlee et al. (B) The pathway proposed for RET 
activation by Schlee et al. that best fits the observed relationship between the effect of GFRα3 
expression levels on the ART dose-response for RET phosphorylation [17]. Figure reproduced 
from [17] with permission. ©2006, Rights Managed by Nature Publishing Group. 
 
In Chapter Three we described how we used the established activation pathway 
and the equilibrium constants obtained from this experimental system to simulate 
the response of the RET system to ART at varying GFRα3 concentrations. Our 
simulations showed that, when GFRα3 is expressed at high levels relative to 
RET, the co-receptor served to tune the system’s sensitivity to ligand over a wide 
range of EC50s, while having minimal effect on the maximum amplitude of the 
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signaling. This effect was pathway specific and the system showed a very 
different response to varying expression levels of GFRa3 when we simulated the 
response of the system to activation through an alternative pathway where the 
co-receptors were pre-dimerized. In this alternative mechanism, the range of 
sensitivities that resulted from varying the GFRa3 concentrations was narrower 
compared to that of the wild-type system and the maximum signal amplitude 
varied more at the higher GFRa3 levels tested (Figure 3.13B).  
We attempted to test experimentally whether we could observe the 
predicted differences in the dependence of the amplitude and sensitivity of the 
pRET dose-response on the expression levels of GFRα3, when the system 
selectively undergoes activation through a pathway where the resting state of 
GFRα3 is monomeric or dimeric. Also, to examine the importance and flexibility 
of the evolutionarily selected activation pathway, we wanted to see whether 
forcing the RET system to be activated through an alternative sequence of steps 
would affect the cellular response of neurite outgrowth that Li et al. had 
measured in cells expressing RET and monomeric GFRα3 upon treatment with 
ART [163]. 
To do this, we attempted to engineer an experimental RET system where 
the resting state of GFRα3 could be selectively tunes to be either monomeric or 
dimeric. Such a system had to meet several requirements for the meaningful 
comparison of cell responses to be possible: 
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1. The monomeric and dimeric forms of GFRα3 must be the same. We 
didn’t want to have a wild type and a mutant GFRα3, since we wanted to 
minimize the chance of observing a difference in signaling that was due 
to slightly different affinities of our GFRα3 variants for ART or, 
alternatively, to differences in the ability of the GFRα3/ART complex to 
bind RET. Working with the same form of GFRα3, that can be either 
monomeric or dimeric, would eliminate such potential differences in 
binding affinity/efficiency. 
2. Monomeric and dimeric GFRα3 must be co-expressed in the same 
cell line with endogenous levels of RET. To eliminate any cell line-to-
cell line variations in signaling and cellular response, we wanted both 
forms of GFRα3 to be expressed in the same cell line. The cell line used 
to determine that both GFRα3 and RET were monomeric in the absence 
of ligand expressed endogenous levels of RET and 10 times higher levels 
of GFRα3.  We wanted to replicate these characteristics as closely as 
possible to ensure that we were working with monomeric RET and were 
studying solely the effect of GFRα3 pre-dimerization.  
3. Both the monomeric and dimeric forms of GFRα3 must be 
expressed at similar levels. Since our simulations showed that the 
expression level of GFRα3 has a strong influence on the sensitivity of the 
system’s response to different levels of ART, it is important to ensure that 
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the monomeric and dimeric forms of GFRα3 are expressed at similar 
levels on the cell membrane.  
We reasoned that a system that meets all of the above requirements must have 
a form of GFRα3 that can be reversibly dimerized, for example by the addition of 
a small molecule. With such a system, we could transfect our engineered GFRα3 
into the same parental cell line, containing endogenous RET, that was used to 
determine the wild-type activation mechanism. Also, we could compare 
alternative activation pathways using cells from the same transfection batch, 
which would express the same levels of co-receptor, eliminating the problem of 
differences in receptor expression level.  
To achieve a GFRα construct with inducible dimerization we chose to use the 
iDimerize Inducible Dimerization System (Clontech). This system uses FK 
Binding Protein (FKBP), a 14-kDa ubiquitous monomeric human protein, which 
can be reversibly dimerized by the addition of a bivalent, cell permeable small 
molecule ligand, B/B (Figure 4.2). The FKBP in the Inducible Homodimerization 
System is a point mutant (F36V) of wild-type human FKBP that binds the small 
molecule dimerizer with a much higher affinity than does wild type FKBP. This 
increased affinity renders the system effective at B/B ligand concentrations that 
are low enough, so that endogenous FKBP function is not disturbed [187]. The 
iDimerize system has been successfully applied to activate proteins through 
dimerization [121, 133-135]. However, the uses of FKBP as a fusion dimerization 
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domain have only been described in intracellular systems. We aimed to test the 
applicability of this versatile system as a dimerization domain on GFRa3, which is 
expressed on the outer leaflet of the cell membrane. 
 
Figure 4.2 Crystal structure of FKBP dimer brought about by the binding a bivalent small 
molecule and the structure of a synthetic precursor of the small dimerizer B/B.Crystal structure of 
human FKBP(F36V) mutant dimerized by the small molecule FK1012, a synthetic precursor of 
B/B. The two FKBP proteins are shown in blue and red and the FK1012 molecule is in green 
[187]. (B) Chemical structure of the B/B small molecule dimerizer. 
 
One advantage of the FKBP reversible dimerization system is that it can be 
converted to function in the reverse direction. A single point mutation can convert 
the monomeric FKBP into a constitutive dimer (Figure 4.3) with a KD of 30 µM for 
the interaction in solution. This dimerization can be reversed in a few minutes by 
the addition of the monovalent small molecule ligand FK506 [188]. 
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Figure 4.3 Crystal structure of FKBP FM mutant constitutive homodimer [188].    
 
In this chapter we describe the coning and characterization of various 
FKBP-GFRα3 and FKBP-GFRα3-RET and RET-FKBP constructs. Although we 
were not, in the end, able to detect significant B/B small-molecule-dependent 
dimerization in constructs that expressed extracellular FKBP, we showed that 
when the dimerization domain was cloned C-terminal to RET, and expressed on 
the intracellular portion of the protein, we were able induce dose-dependent RET 
phosphorylation upon treatment with the B/B dimerized. Moreover, we showed 
that orthologous expression of human RET leads to constitutive activation, that 
can be toxic to the cells. Upon decreasing the RET expression levels, we were 
able to avoid the toxic effect of RET’s constitutive activation, and to measure 
ligand dependent activation. The above observations suggest that the RET 
receptor has an intrinsic affinity to self-aggregate, even in the absence of ligand 
or co-receptor, and that the extent of such self-aggregation is governed by the 
expression levels of RET. 
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4.2 Material and Methods 
4.2.1 Materials 
4.2.1.1 Plasmids, primers and cloning supplies 
The iDimerize Inducible Homodimer System was purchased from 
Clontech Laboratories, Inc (Mountain View, CA). Mouse GFRα3, β-
galactosidase, and human RET cDNA sequences was purchased from Open 
Biosystems (GE Healthcare Dharmacon, Inc) (Lafayette, CO). The mYPet and 
the Cerulean cDNA sequences were obtained from Addgene. The DNA 
sequences for FL3, FL4, HL2, HL3, HL4, and HL5 were synthesized by Genewiz, 
Inc (Cambridge, MA). All cloning and sequencing primers were purchased form 
IDT Integrated DNA Technologies, Inc (Coralville, IA). Pfu Turbo DNA 
Polymerase (M774B) was purchased form Promega Bio Sciences (San Luis 
Obispo, CA). The DNA gel extraction kit (2260250) was from Epoch Life 
Sciences (Sugar Land, TX). Xfect transfection kit (631318) was purchased from 
Clontech Laboratories and Attractene transfection reagent (301005) was from 
Qiagen (Valencia, CA). OptiMEM (31985088) and SYBR® Safe (S33102) were 
from Thermo Fisher Scientific (Waltham, MA). Miniprep (27106) and MidiPrep 
(12143) plasmid DNA purification kits were purchased from Qiagen (Hilden, 
Germany).  
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4.2.1.2 Cell culture supplies 
HEK293 (CRL-1573) and NB41A4 (CCL-147) cells were purchased from 
American Type Culture Collection (ATCC) (Manassas, VA). Both cell lines were 
cultured in DMEM (Thermo Fisher Scientific, Waltham, MA) supplemented with 
10% Fetal Bovine Serum (F6178) (SigmaAldrich, St.Louis, MO). The cells were 
passaged using standard trypsin protocol [161].  
4.2.1.3 Antibodies 
Rabbit anti-FKBP polyclonal (ab2918) and anti-FKBP monoclonal 
(ab58072) antibodies were from Abcam (Cambridge, MA). Biotimylated 
polyclonal anti-GFRα3 antibody was from R&D Systems (Minneapolis, MN).  
Alexa Fluor 488-conjugated (product number) and Alexa Fluor 647-conjugated 
(product number) polyclonal goat anti-rabbit IgGs were from Abcam. 
Phycoerythrin-conjugated streptavidin (S-21388) was from Thermo Fisher 
Scientific (Waltham, MA). HRP-conjugated goat anti-rabbit polyclonal antibody 
was from Abcam and HRP-conjugated streptavidin (N200) was from Thermo 
Fisher Scientific (Waltham, MA). Goat polyclonal anti-hemagglutinin (HA) IgG 
was from Meridian Life Science, Inc (Memphis, TN). HRP-conjugated mouse 
anti-Phosphotyrosine antibody (MA1-12445) was from Thermo Fisher Scientific. 
PathScan® Phospho-p44/42 MAPK (Thr202/Tyr204) Sandwich ELISA Antibody 
Pair (7246) was from Cell Signaling Technologies. Rabbit polyclonal anti-RET 
antibody (sc-13104) was purchased from Santa Cruz Biotechnologies (Dallas, 
TX).  
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4.2.2 Methods 
4.2.2.1 In-Fusion Cloning 
We amplified the genes that we wanted to clone into the pHom-1 plasmid 
by polymerase chain reaction (PCR). Forward and reverse primers were 
designed to have a region that is complementary to the gene of interest and to 
have 15 nucleotides (nt) sequence on the 5’ end, which was complementary to 
the DNA sequence of the pHom-1 vector, immediately following the restriction 
site used to linearize it [189]. We used Pfu Turbo DNA Polymerase (Promega Bio 
Sciences) and followed the protocol recommended by the manufacturer. The 
melting temperature of the primers was calculated based on the portion 
complementary to the gene to be amplified, and the 15 nucleotides 
complementary to the linearized pHom-1 plasmid were not considered. The 
amplified gene DNA visualized on 1% agarose gel (1% agarose, 40 mM Tris 
acetate, 1 mM ethylenediaminetetraacetic acid (EDTA), 1:10000 dilution of 
Sybr® Safe (Thermo Fisher Scientific, pH 8.2), and extracted using DNA gel 
extraction kit (Epoch Life Science). 50 ng of the purified PCR product was mixed 
with 100 ng of linearized pHom-1 plasmid DMA, and the volume was brought up 
to 8 µL with dionized water. 2 µL of In-Fusion Enzyme Premix (Clontech) was 
added, and the reaction was incubated at 50 °C for 15 min, and then placed on 
ice. The In-Fusion Enzyme mix contains a 3’ exonuclease that generates 5’ 
single stransded overhands on the linearized plasmid DNA. The 15-nt sequence, 
that is included in the amplified target gene, anneals via complementarity to 
  
 
   
170 
these exonuclease-generated single stranded DNA on the plasmid, to form the 
product of the reaction [189].  
4.2.2.2 NEB5α transformation procedure 
NEB5α cells were obtained from New England Biolabs, Inc. We followed 
the transformation protocol suggested by the manufacturer. Briefly, cells were 
thawed on ice and incubated with 5 µL of the product of our InFusion reaction for 
30 min on ice, then heat shocked for 30 sec at 42 °C. The cells were cooled on 
ice for about 10 min. 450 µL of warm Super Optimal broth with Catabolite 
repression (SOC) medium was added and the cells were incubated for 1 hour in 
an incubator at 37 °C with shaking at 250 rpm. Cells were plated overnight on 
agarose plates containing 1 µg/mL ampicillin using 100 µL of the original 
suspension or 100 µL of a 1:10 dilution of cell suspension in SOC medium. Five 
to six colonies from each plate were picked and grown overnight in 5 mL LB in an 
incubator at 37 °C with shaking at 250 rpm. 
4.2.2.3 Plasmid purification 
For Miniprep DNA purification, transformed NEB5α cells were grown in 5 
mL LB broth overnight, pelleted by centrifugation at 4200 rpm for 10 min, and 
plasmids were purified following the manufacturer’s protocol. For Midiprep 
plasmid purification, NEB5α cells were grown in 250 mL LB broth, pelleted by 
centrifugation at 4200 rpm for 10 min, and plasmids were purified using the 
manufacturer’s recommended protocol. Purified plasmids were stored in elution 
buffer at 4 or -20 °C.    
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4.2.2.4 Cloning of FKBP-GFRα3.  
We obtained the pHom-1 plasmid that encodes the human FKBP protein 
flanked by an XbaI restriction site on the 5’-end and a SpeI restriction site on the 
3’-end as part of the iDimerize Homodimerization Kit. This plasmid is a high-copy 
bacterial cloning plasmid, as well as a mammalian expression plasmid. We 
amplified the mouse GFRα3 sequence from base pair 82 to the end using In-
Fusion primers that had complementary overhangs to the SpeI cloning site of the 
pHom-1 vector. (A list of primers is included in Appendix 1). Because there was 
no signal sequence in front of the FKBP, we amplified the 81 base pairs of signal 
sequence from GFRα3 using forward and reverse primers, which had 
overhanging regions complementary to the pHom-1 plasmid around the two 
sides of the XbaI site, which would position the signal sequence N-terminal of the 
FKBP protein product. 
The cloning was performed in two steps: First, the pHom-1 plasmid was 
linearized with SpeI restriction enzyme and the GFRα3 cDNA was ligated in 
using In-Fusion cloning. The resultant plasmid was transformed and amplified 
using NEB5α cells and gel purified. Using the same procedure, the plasmid was 
digested with XbaI and the GFRα3 signal sequence was inserted. All plasmids 
were sequenced to confirm the identity of the inserted DNA fragments.  
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4.2.2.5 Cloning of FKBP-β-gal-Δα-GFRα3 and FKBP-β-gal-Δω-GFRα3 
Enzyme Complementation Pair 
4.2.2.5.1 Cloning of FKBP-β-gal-Δα-GFRα3 
The plasmid for full-length β-galactosidase (CAT # 13422). was purchased 
from Addgene (Cambridge, MA). First, we amplified the β-gal-Δ41 segments from 
the β-gal full-length cDNA sequence. Then we cloned this segment in the pHom-
1-FKBP-GFRα3 plasmid using In-Fusion cloning. To add the first 11 amino acids 
of the protein, we designed a second In-Fusion primer that contained a 5’ 
sequence complementary to the pHom-1 vector, an intervening sequence that 
corresponded to the 30 base pairs of the β-gal 1-10 amino acids, and a 3’ 
sequence that was complementary to the 5’ region of β-gal-Δ41 (Figure 4.4). 
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Figure 4.4 Schematic showing the two-step cloning process used to make the β-galΔα mutant. In 
Step I the Δ41 mutant was generated by PCR amplifying the DNA sequence starting from base 
pair 124. This sequence was cloned into the pHom-1 vector between the FKBP and GFRα3 
sequences. To add the first 30 base pairs, that code for amino acids 1-10, we used the FKBP-β-
galΔ41-GFRα3 construct as template and PCR amplified the β-gal sequence using a primer 
containing the first 30 base pairs from the full sequence of the β-gal enzyme (Step II).  The 
resulting sequence, termed β-galΔα, was ligated in the pHom-1 vector between FKBP and 
GFRα3. 
 
To insert the β-gal-Δα between FKBP and GFRα3 in pHom-1 vector, it was 
necessary to mutate the 3’ SpeI restriction sequence. QuickChange mutagenesis 
was used to change the ACT AGT SpeI sequence to GCT GGT (Ala-Gly), thus 
making the SpeI restriction site between FKBP and GFRα3 unique. Using In-
Fusion cloning we inserted the amplified β-gal-Δα in this site, resulting in a fusion 
protein of FKBP-β-gal-Δα-GFRα3. 
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4.2.2.5.2 Cloning of FKBP-β-gal-Δω-GFRα3 
To make FKBP-β-gal-Δω-GFRα3 construct we amplified the cDNA 
sequence of β-gal between base pairs 1–788. We then used In-Fusion cloning to 
insert the product between FKBP and GFRα3 in pHom-1 expression vector. 
4.2.2.5.3 Cloning of soluble FKBP-β-gal-Δα and FKBP-β-gal-Δω 
Starting with the FKBP-β-gal-Δα-GFRα3 and FKBP-β-gal-Δω-GFRα3 
clones, we PCR-amplified the β-gal-Δα and the β-gal-Δω portions of the DNA 
and cloned each one into the SpeI restriction site of an empty pHom-1 vector (C-
terminally of FKBP).  
4.2.2.6 Cloning of FKBP-mYPet-GFRα3 and FKBP-mCer-GFRα3 FRET Pair 
4.2.2.6.1 FKBP-mYPet-GFRα3 
pCEP4YPet-MAMM was a gift from Patrick Daugherty (Addgene plasmid 
# 14032) [190]. A single point A206K mutation was introduced to convert the 
protein from a weak dimer to monomer [191] by Jennifer Chow, using 
QuickChange mutagenesis. We PCR-amplified the mYPet sequence and using 
In-Fusion cloning, we inserted the mYPet DNA sequence between the FKBP and 
the GFRα3 sequences in a pHom-FKBP-GFRα3 plasmid where the SpeI 
restriction site on the 3’ end of GFRα3 was previously mutated to give an Ala-Gly 
linker. 
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4.2.2.6.2 Cloning FKBP-mCer-GFRα3 
pCEP4CyPet-MAMM plasmid was a gift from Patrick Daugherty (Addgene 
plasmid # 14033) [190]. The sequence was PCR-amplified, and inserted in the 
SpeI restriction site between the FKBP and the GFRα3 sequences in a pHom-
FKBP-GFRα3 plasmid. 
4.2.2.7 HEK293 cells transfection protocol 
4.2.2.7.1 6-well plate format transfection 
HEK293 cells were plated in 2 mL growth medium per well overnight in 6-
well tissue culture plates at a density of 6.7x105 cells per well. On the next day, 
the growth medium was aspirated and replaced with 1 mL fresh growth medium. 
For each well, 5 µg of the target plasmid DNA was diluted into 100 µL Xfect 
transfection buffer. In a second tube, 1.5 µL of Xfect transfection reagent 
(Clontech) was diluted into 100 µL of transfection buffer. The transfection reagent 
solution was added to the diluted DNA, vortexed for 10 sec, and then incubated 
at room temperature for 15 min. The resulting 200-µL solution was pipetted drop-
wise into each well and incubated with the cells for 4 hours at 37 °C.  At the end 
of the incubation period, the growth medium was aspirated and replaced with 2 
mL fresh growth medium. Protein expression was tested 48 hours post 
transfection. 
4.2.2.7.2 10-cm dish format 
The same protocol was used to transfect cells in 10-cm dishes. 4x106 cells 
were plated per dish and transfected with 30 µg DNA (unless otherwise 
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specified) and 9 µL Xfect transfection reagent diluted into 1200 µL Xfect final 
transfection buffer. After 4 hours of transfection, the cells were washed with PBS, 
lifted with trypsin, and re-plated in 24-well plates. Protein expression and function 
were tested 48 hours post transfection. 
4.2.2.8 NB41A3 cells transfection protocol 
We used Attractene transfection reagent (Qiagen) to transfect NB41A3 
cells, since Xfect did not yield good results in this cell line. The transfections were 
performed in 24-well plates. A mastermix of 0.4 µg DNA/60 µL/well was prepared 
by diluting the plasmid DNA in OptiMEM. Attractene transfection reagent was 
added to a final concentration of 1.5 µL/0.4 µg of DNA. The solution was 
vortexed and incubated at room temperature for 15 min. Meanwhile, NB41A3 
cells were lifted by incubation with trypsin for 5 min, pelleted by centrifuging at 
300g for 5 min, and resuspended in growth medium at a density of 3.2 x 105 
cells/mL. 500 µL of cell suspension was transferred to each well of a 24-well 
plate, and the DNA-Attractene transfection mixture was added drop-wise to the 
wells (60 µL/well). The cells were incubated for 24 hours in an incubator at 37 °C 
in the presence of 5% CO2, after which the growth medium was aspirated and 
replaced with 500 µL fresh growth medium. Protein expression and functional 
assays were performed 48 hours after the addition of the transfection mixture. 
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4.2.2.9 Detection of protein expression 
4.2.2.9.1 Flow Cytometry 
To test for protein expression, transiently transfected cells were detached 
48 hours post transfection, byaspiraing the growth medium and replacing it with 
300 µL pre-warmed 20 mM EDTA in PBS solution, and incubating for 5 min at 
room temperature. The cell pellets were washed with FACS buffer (PBS, 2 % 
FBS, 0.1 % BSA, 0.1% NaN) and resuspended at a density of 1 x 106 cells/mL in 
100 µL 10 µg/mL solution of biotinylated polyclonal anti-GFRα3 IgG or 10 µg/mL 
solution of polyclonal rabbit anti-FKBP IgG in FACS buffer. The samples were 
incubated for 30 min on ice. The cells were pelleted by centrifuging at 300 x g for 
5 min, and the solution was aspirated and replaced with FACS buffer. This 
washing step was repeated twice to ensure removal of unbound antibody. Cells 
were then incubated for 30 min with 100 µL of a 2.5 µg/mL solution of 
Phycoerythrin (PE)-conjugated streptavidin (for GFRα3 detection) or with 5 
µg/mL solution of Alexa Fluor 488-conjugated polyclonal goat anti-rabbit IgG (for 
FKBP detection) prepared in FACS buffer. Non-specifically bound detection 
antibodies were washed, as described above and the fluorescence intensity of 
cells was measured using FACSCalibur (BD Biosciences, Waltham, MA). The 
data were analyzed using FlowJo software (FlowJo LLC, Ashland, OR). Human 
RET ectodomain was detected using the same protocol as described for the 
detection of GFRα3 and FKBP, but using 100 µL solution of 1 µg/mL H-300 anti-
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RET primary antibody, followed by incubation with 5 µg/mL Alexa Fluor 488-
conjugated goat anti-rabbit polyclonal secondary antibody.  
4.2.2.9.2 Western blots 
Transiently transfected cells were lysed 48 hours post transfection in KIRA 
lysis buffer (10 mM Tris, 0.5% NP-40, 0.2% sodium deoxycholate, 50 mM NaF, 
0.1 mM Na3VO4, 1 mM PMSF, pH 8.0) for 30 min on ice with vigorous shaking. 
The cell lysates were cleared by centrifugation at 10000 x g for 5 min, and total 
protein concentration was measured using the PierceTM  bicinconinic acid assay 
(BCA) (Thermo Fisher Scientific (Waltham, MA). Briefly, 25 µL cell lysate was 
transferred to each well of a clear 96-well plate. 200 µL of the BCA working 
reagent, which consists of 50:1freshly prepared mixture of BCA Reagent A: BCA 
Reagent B, was added to each well. The plate was sealed with adhesive foil to 
prevent evaporation and incubated at 37 °C for 30 min. At the end of the 
incubation period, the plate was allowed to cool down to room temperature and 
the absorbance at 562 nm was measured using SpectraMax M5 microplate 
reader (Molecular Devices, Sunnyvale, CA). The total protein concentration was 
calculated based on a standard curve prepared with BSA, according to the 
manufacturer recommendation. The lysates were then diluted with deionized 
water to the concentration of the originally most dilute sample. SDS-PAGE 
samples were prepared by combining 8 µL of 6x SDS sample buffer (0.375 M 
Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 0.06% bromophenol blue) and 
40 µL diluted cell lysate. The samples were heated in a thermo cycler for 10 min 
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at 99 °C, cooled on ice for 5 min, and then loaded on a TRIS-HEPES 
polyacrylamide gel. The gels were run for 40 min at 110 V, unless otherwise 
specified. The gel was transferred to a PVDF membrane at 40 V for 1 or 4 hour. 
The membrane was blocked in 5% non-fat dry milk in TBST (for FKBP detection) 
or 5% BSA in TBST (for GFRα3 detection) solutions for 1 hour at room 
temperature with gentle shaking and subsequently incubated with 0.1 µg/mL 
primary detection antibody (anti-FKBP or anti-GFRα3) diluted in the appropriate 
blocking buffer for at least 2 hours at room temperature or overnight at 4 °C. The 
membrane was then washed in TBST three times for 15 min each, and 10 mL of 
a 1:1000 dilution of the secondary HRP-conjugated detection antibody prepared 
in blocking buffer was added and incubated for 1 hour with gentle shaking. 
Excess secondary antibody was removed by washing the membrane with TBST 
for at least one hour, and then 3 mL of ECL+ solution was added and incubated 
with the membrane for several minutes. The blot was imaged using a 
ChemiDocTM MP Imager (Bio Rad, Waltham, MA).  
4.2.2.10 RET Phosphorylation ELISA 
4.2.2.10.1 ELISA for the detection of phosphorylated endogenous mouse 
RET (Mouse pRET ELISA) 
The Mouse RET KIRA ELISA was performed as described in [163]. 
Briefly, NB41A3 cells were transfected with the indicated GFRα3 fusion 
constructs in 24-well plates. 48 hours post transfection the cells were treated with 
various concentrations of the dimerizing small molecule B/B for the indicated 
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time, followed by treatment with the indicated concentrations of ART in the 
presence of B/B. To stop the stimulation, cells were washed once with 300 µL of 
warm PBS, and then lysed with 300 µL KIRA lysis buffer (10 mM Tris, 0.5% NP-
40, 0.2% sodium deoxycholate, 50 mM NaF, 0.1 mM Na3VO4, 1 mM PMSF, pH 
8.0) for 30 min on ice with vigorous shaking. 96-well microtiter plates (Santa 
Cruz, Dallas, TX) were prepared by coating the wells overnight at 4 °C with 100 
µL of a 4.76 µg/mL solution of mAb2 capture antibody (a gift from Biogen) 
prepared in PBS. Excess capture antibody was removed by washing and the 
plate was blocked with 300 µL KIRA blocking buffer (PBS, 3% BSA, 1% FBS) per 
well for 1 hour at room temperature with constant shaking. The plate was washed 
with PBST and 250 µL of cleared lysate was added to each well. After 2 hours of 
incubation, unbound proteins were removed by washing and then the plate was 
incubated for 1.5 hours with 100 µL/well of HRP-conjugated anti-pY antibody 
diluted 1000-fold in blocking buffer. Excess detection antibody was removed by 
washing and the signal as developed by addition of 100 µL/well of the HRP 
substrate 3’,3’,5’,5’-tetramethylbezidine dihydrochloride (1-Step Ultra TMB, 
Thermo Fisher Scientific). After allowing the color to develop over a period of 
approximately 3-4 min, the reaction was quenched with 100 µL of 1 M sulfuric 
acid, and the absorbance at 450 nm was measured using a SpectraMax M5 
microplate reader (Molecular Devices, Sunnyvale, CA). 
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4.2.2.10.2 ELISA for the detection phosphorylated transfected human RET 
(Human pRET ELISA) 
HEK293 cells were transfected using the Xfect transfection protocol and 
plated in 24-well plates. 48 hours post transfection the cells were treated with 
various concentrations of B/B for the indicated time and lysed with 300 µL KIRA 
lysis buffer (10 mM Tris, 0.5% NP-40, 0.2% sodium deoxycholate, 50 mM NaF, 
0.1 mM Na3VO4, 1 mM PMSF, pH 8.0). The ELISA assay was as described for 
the mouse pRET ELISA, with the exception that the 96-well ELISA plate was 
coated with 100 µL of a 5 µg/mL solution of anti-HA antibody in PBS. 
4.2.2.11 ERK Phosphorylation ELISA 
Cells were stimulated as described above for the measurement of pRET 
levels and the ELISA was performed exactly as described in Chapter Two. 
4.2.2.12 β-galactosidase fragment complementation assay 
HEK293 cells in 6-well tissue culture plates were transfected with 2.5 µg of 
FKBP-β-galΔα-GFRα3 + 2.5 µg empty pHom-1 vector, 2.5 µg of FKBP-β-galΔω-
GFRα3 + 2.5 µg empty pHom-1 vector, or 2.5 µg of FKBP-β-galΔα-GFRα3 + 
FKBP-β-galΔω-GFRα3. After incubating the cells with the transfection mixture for 
4 hours, the cells were lifted using trypsin and re-plated in phenol red-free growth 
medium in 96-well plates (one well from the 6-well plate was divided in 16 wells 
from the 96 well plate). 48 hours post transfection, the growth medium was 
removed by aspiration and replaced with growth medium containing 0.155 or 
1.55 mM chlorophenol red-β-D-galactopyranoside (CPRG) and the cells were 
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incubated for the specified time. At the end of the incubation, period the 
absorbance at 575 nm was measured using a SpectraMax M5 microplate reader 
(Molecular Devices, Sunnyvale, CA).  
4.3 Results and Discussion 
4.3.1 Cloning, expression, activity, and dimerization of FKBP-GFRα3 
construct 
 First, we attempted to express an FKBP-GFRα3 fusion protein without 
introducing any additional modifications to the construct. Since the co-receptor is 
expressed on the outer leaflet of the cell membrane, we cloned GFRα3 C-
terminal to FKBP. To direct the expression of the fusion protein to the cell 
membrane, we cloned the GFRα3 signal sequence N-terminal to FKBP. We 
preserved the SpeI cloning site between FKBP and GFRα3, which allowed us to 
modify the linker region between the two proteins. In the current construct the 
SpeI DNA sequence (5’-ACTAGT-3’) would translate into a two-residue 
Threonine-Serine linker (Figure 4.5). 
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Figure 4.5 Schematic showing the FKBP-GFRα3 fusion construct. The GFRα3 signal sequence 
of (grey rectangle) was cloned N-terminally to FKBP (green rectangle) to direct the trafficking of 
the protein to the cell membrane. In wild type GFRα3 the signal sequence is cleaved off in the 
mature protein, however we don’t know if this happens in our construct. The SpeI restriction site 
(ACTAGT) was retained between the DNA sequences of FKBP (green) and GFRα3 (blue 
rectangle), resulting in a Threonine-Serine linker between the two components of the fusion 
protein.   
 
We successfully cloned the construct shown in Figure 4.5 and expressed it in 
NB41A3 mouse neuroblastoma cells that endogenously express mouse RET, as 
described in Materials and Methods. As an alternative expression system, we 
also used HEK293 cells. Because higher levels of expression were achieved in 
these cells, we used them for the initial characterization of our constructs. We 
used flow cytometry to measure the expression of our FKBP-GFRα3 fusion 
protein. To ensure that the intact fusion protein was expressed we detected both 
the GFRα3 and the FKBP components (Figure 4.6).  
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Figure 4.6 Expression of FKBP-GFRα3 measured by flow cytometry. HEK293 (A and B) and 
NB41A3 (C) cells were transfected with pHom-1-FKBP-GFRα3 (blue and red histograms) or 
empty pHom-1 (black histograms). 48 hours post transfection the cell surface expression of 
GFRα3 (A and C) or FKBP (B) was measured. 
 
 We tested if our construct was active in NB41A3 cells that expressed 
endogenous mouse RET. Cells transfected with FKBP-GFRα3 or with unmodified 
pHom-1 vector (mock), were stimulated for 10 min with various concentrations of 
ART in 300 µL DMEM, and then pRET levels were measured by Mouse pRET 
ELISA (Figure 4.7). Figure 4.7A shows that FKBP-GFRα3 was able to support 
dose-dependent ART signaling. The lack of any detectable RET activation in the 
mock-transfected control cells showed that the RET phosphorylation that we 
observed upon ART stimulation was not due to endogenous expression of 
GFRα3 in this cell line. 
Next, we wanted to test if pre-treatment of the cells with B/B dimerizer 
would cause any differences in the ART-induced pRET dose-response profile. 
We transfected NB41A3 cells with FKBP-GFRα3 plasmid or with empty pHom-1 
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plasmid, and 48 hours post transfection we treated the cells with 200 nM B/B for 
30 min to form FKBP-GFRα3 dimers, or with assay buffer alone. We then 
incubated the cells with various concentrations of ART for 10 min, lysed the cells, 
and measured the relative amount of phosphorylated RET in the cell lysates 
using the mouse pRET ELISA (Figure 4.7B).  
 
Figure 4.7 ART dose-response for RET activation in the presence or abcense of B/B dimerizer. 
(A) Ability of the FKBP-GFRα3 protein to mediate RET activation upon ART stimulation. NB41A3, 
transiently transfected with FKBP-GFRα3 or empty pHom-1 (mock), were incubated with different 
concentrations of ART for 10 min and the pRET levels were measured by ELISA. (B) Effect of 
B/B on RET activation. Transfected NB41A3 cells were incubated with 0 or 200 nM B/B for 30 
min before ART was added for 10 min. Cells were lysed and relative pRET levels were measured 
by ELISA.   
 
The results showed that pre-treating cells with the small molecule dimerizer had 
no significant effect on the extent of RET activation (Figure 7B). We also tested 
50 and 100 nM B/B, but didn’t see any effect on the ART dose-response (data 
not shown).  
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A possible explanation for the failure to observe any effect of the B/B 
dimerizer on the RET phosphorylation was that we did not achieve the 
dimerization of GFRα3 that we assumed. Since a dimerization event produces no 
measureable signal by itself, we attempted to look for the extent of GFRα3 
dimerization by capturing the dimers using chemical crosslinking, and visualizing 
them by Western blot. Since we were interested to see only dimerization that 
happens on the cell surface, and not intracellularly, we chose 
bis(sulfosuccinimidyl)suberate (BS3) and ethylene 
glycolbis(sulfosuccinimidylsuccinate) (Sulfo-EGS) (Thermo Fisher Scientific) as 
the chemical crosslinkers (Figure 4.8).  
 
Figure 4.8 Structure of the amine-to-amine reactive cell-impermeable crosslinkers used to 
capture FKBP-GFRα3 dimers. (A) BS3 and (B) Sulfo-EGS.  
 
Both compounds are water-soluble, cell membrane impermeable amine-
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to-amine crosslinkers, but the linker separating the two reactive groups in BS3 is 
11.4 Å, while in Sulfo-EGS it is 16 Å.  We performed the crosslinking under 
several conditions, including at different cross-linker concentrations (0.25, 0.5, 1, 
2, and 3 mM), incubation times (10, 30, and 60 min), pH values (6, 7, and 8), and 
temperatures (4, 20, and 37 °C) (Figure 4.9). However, under all conditions we 
found that we were able to capture very little dimerization of FKBP-GFRα3 that 
was induced by B/B binding. 
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Figure 4.9 Chemical cross-linking of B/B-induced FKBP-GFRα3 dimers under different 
experimental conditions. (A) HEK293 cells were transfected with FKBP-GFRα3 plasmid DNA. 48 
hours post transfection cells were treated with 50 nM B/B, washed once with PBS, and incubated 
with the indicated concentration of the chemical cross-linker BS3 for 10, 30 or 60 min at room 
temperature. The cross-linker solutions were removed by aspiration and the cells were lysed 
using KIRA lysis buffer. Proteins from he cell lysates were separated by SDS-PAGE, under 
reducing conditions. Proteins were transferred to PVDF membranes, and visualized using anti-
GFRα3 antibody. (B) Transfected HEK293 cells were treated with 50 nM B/B for 30 min, washed, 
and incubated in PBS (pH 7) or in 1 mM BS3, prepared in PBS at pH 6, 7, or 8, for 30 min. Cell 
lysis and Western blot analysis were performed as described in A. (C) HEK293 cells, transfected 
with FKBP-GFRα3 plasmid DNA, were incubated with the indicated concentration of B/B for 30 
min, washed, and incubated with 1 mM Sulfo-EGS for 30 min at 4, 20, or 37 °C. Cell lysis and 
Western blot analysis were performed as described in A. 
 
We considered the possibility that under some of the tested dimerization 
crosslinking conditions, we successfully captured the B/B-induced dimers, but the 
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chemical modification of the proteins made them undetectable by the antibodies 
that we used for our Western blot analysis. To test if visualizing the cross-linked 
dimers was impeded, we transfected cells with the pHom-1 vector that encodes 
for soluble intracellular FKBP, which has been shown to be efficiently dimerized 
by B/B3. 48 hours post transfection, we incubated the cells with 200 nM B/B and 
used EGS – a variant of Sulfo-EGS that is cell membrane permeable, to capture 
dimeric FKBP. We observed that there was significant B/B-dependent 
enrichment in the band corresponding to the FKBP dimer (Figure 4.10), which 
suggested that the small molecule dimerizer was indeed able to bind to the 
soluble FKBP protein and achieve dimerization, and that the EGS chemical 
crosslinker was able to capture this interaction by trapping the dimer as a 
covalent complex.  
 
Figure 4.10 Detection of B/B-dependent dimerization of soluble intracellular FKBP by Western 
blot. HEK293 cells transfected with pHom-1 vector were treated with 200 nM B/B, crosslinked 
with 1 mM EGS for 30 min, and lysed.  Proteins from lysates were separated on an SDS-PAGE 
gel and transferred to a PVDF membrane. FKBP bands were detected with anti-FKBP antibody. 
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4.3.2 Effect of cloning linkers between FKBP and GFRα3 on the ability to 
form B/B-induced dimers  
 The detection of significant levels of B/B-dependent dimerization for the 
soluble FKBP, but not for the membrane-tethered FKBP-GFRα3 protein, 
suggested that the latter might be sterically hindered from forming a B/B-induced 
dimer. To make the construct more flexible and thus increase the likelihood that 
the FKBP domains are dimerized by B/B, we engineered linkers of various 
lengths and structures between FKBP and GFRα3 (Table 4.1).  
Table 4.1 Linkers between FKBP and GFRα3. 
 
 With the linkers that adopted a defined secondary structure (the helical linkers in 
Table 1), we could also explore the relative orientation of the B/B binding site on 
the FKBP and the ART binding site on the GFRα3 molecules within our 
constructs. We hypothesized that when the constructs were pre-dimerized with 
the B/B small molecules, activation by ART would only be possible if the ART-
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binding sites on the two GFRα3 molecules within a dimer are positioned in way 
that permits the binding of one ART to both GFRα3 molecules simultaneously. 
Since the linkers were too long to be inserted using regular one-step 
mutagenesis, we had them synthesized by an external vendor. The only 
restriction site between FKBP and GFRα3 in our construct was SpeI, but 
following the addition of the GFRα3 gene, it was also present at the 3’-end of the 
GFRα3 sequence. We therefore used QuickChange mutagenesis to mutate the 
SpeI restriction site sequence that was on the 3’-end of GFRα3, from ACTAGT to 
GCTGGT, which was not recognized by the SpeI restriction endonuclease. We 
amplified the DNA sequences for each linker, with SpeI restriction sites on both 
the 5’- and the 3’-ends, and inserted them into SpeI-linearized pHom-FKBP-
GFRα3 vector using In-Fusion cloning. We cloned all listed linkers between the 
FKBP and GFRα3 in our construct, and got viable bacterial colonies upon 
transformation of NEB5α cells with the resultant plasmids. However, because the 
linker DNA sequences had a very high GC content, we were able to successfully 
confirm the identity of only two linkers – FL14 and HL2, by sequencing. Because 
they were representatives of both classes of linker that we wanted to test, we 
proceeded to characterize the dimerization of the resulting two FKBP-linker-
GFRα3 fusion proteins upon treatment with B/B.  
The expression of each construct in HEK293 cells was confirmed using 
flow cytometry, by staining transfected cells for GFRα3 expression (Figure 4.11). 
We cross-linked the proteins expressed on the membrane of HEK293 cells, after 
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treatment with 1 nM B/B, using either EGS or Sulfo-EGS and detected GFRα3 or 
FKBP on western blots (Figure 4.12). We saw no crosslinking with either cross-
linker.  
 
Figure 4.11 Expression of FKBP-HL2-GFRα3 and FKBP-FL14-GFRα3 on HEK293 cells. HEK293 
cells were transfected with FKBP-HL2-GFRα3 (blue histogram), FKBP-FL14-GFRα3 (red 
histogram) or empty pHom-1 plasmid DNA (black histogram). 48 hours after transfection cell 
surface protein expression was measured using flow cytometry. All samples were stained with 
anti-GFRα3 polyclonal antibody. 
 
Additionally, NB41A3 cells were transfected with either construct, and the 
ability of the GFRα3 fusion proteins to activate RET in the presence of ART was 
tested using ELISA. Although both constructs were active in NB41A3 cells, pre-
incubation with B/B did not show significant effect on the extent of RET 
phosphorylation (data not shown).  
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Figure 4.12 Detection of B/B-dependent dimerization of FKBP-FL14-GFRα3 and FKBP-HL2-
GFRα3 by Western blot. HEK293 cells transfected with the indicated constructs were treated with 
1 mM B/B and crosslinked with 1 mM EGS or Sulfo-EGS for 30 min at r.t. Cell lysates containing 
equal amount of protein were run on an 8% TRIS-HEPES gel under reducing conditions and 
transferred to a PVDF membrane. Protein bands were detected using anti-GFRα3 (A and C) or 
anti-FKBP (B) antibodies. 
 
4.3.3 Mutating Valine36 on FKBP to Methionine to produce ligand-
reversible constitutive dimers of FKBP-GFRα3 on the cell membrane  
 A single point mutation in FKBP protein (Valine36 to Methionine) converts 
it into a constitutive dimer [188]. We introduced this mutation into our FKBP-
linker-GFRα3 constructs, to use them as positive controls for dimerization and to 
test the efficiency of chemical crosslinking for detection of the dimers. We tested 
various concentrations of BS3, Sulfo-EGS, and EGS to see if they could capture 
the resulting constitutive FKBP(V36M)-GFRα3 dimers. Even with the 
constitutively dimeric mutants we were able to detect only a very small fraction of 
dimeric protein by chemical crosslinking. 
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 When we tested different concentrations of the EGS cross-linker to 
capture the FKBP-GFRα3 dimers, we noticed that increasing concentrations of 
cross-linker caused the protein bands, corresponding to the monomeric protein to 
become fainter, without a concomitant increase in the intensity of the bands that 
corresponded to the dimeric species (Figure 4.13). High concentrations of the 
BS3 and Sulfo-EGS had similar effect on the detection, especially when we used 
the anti-FKBP antibody for detection of the Western blot bands.  This result 
suggested that chemically modifying the protein with this cross-linker could 
render it undetectable in our Western blot experiments, by disrupting the epitope 
that the antibodies recognize. 
 
Figure 4.13 Effect of EGS on the detection of FKBP protein by Western blot using anti-FKBP 
antibody. HEK293 cells transfected with FKBP(V36M)-GFRα3 were cross-linked for 30 min at 
room temperature using the indicated concentrations of EGS. Cell lysates containing equal 
amount of protein were run on an 8% TRIS-HEPES gel under reducing conditions and transferred 
to a PVDF membrane. Protein bands were detected using an anti-FKBP antibody. 
 
To address this possibility, we took two approaches to make FKBP-GFRα3 
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constructs that can be detected upon dimerization without the need for chemical 
crosslinking. 
4.3.4 Mutating Cysteine 55 to Serine to prevent the formation of covalent 
disulfide-linked FKBP dimers on the membrane  
 When SDS-PAGE samples were prepared under denaturing, but non-
reducing conditions, a large fraction of the FKBP-GFRα3 protein was dimeric, 
even without chemically crosslinking the cell surface proteins (Figure 4.14).  
This result suggested that the two FKBPs on adjacent proteins might be disulfide 
linked. Numerous sources have reported that FKBP is monomeric in the reducing 
environment of the cytosol [187, 188, 192], but there is one report of the 
formation of disulfide bonds between Cys55 in FKBP when cells were lysed for 
the purpose of protein purification [193].  
 
Figure 4.14 Evidence for the formation of disulfide-linked FKBP(V36M)-GFRα3 dimers on the 
membrane of untreated cells. HEK293 cells transfected with FKBP(V36M)-GFRα3 were lysed 
and run on a gel under non-reducing conditions. The proteins were transferred to a PVDF 
membrane and protein bands were detected with anti-FKBP antibody.  
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We reasoned that since we are expressing the protein extracellularly, it might 
experience more oxidizing conditions that may favor the formation of a disulfide-
linked dimer. If this was the case we couldn’t interpret out functional experiments 
as tests for the effect of dimerization of GFRα3 with B/B, since considerable 
dimerization was detected in samples that were not treated with the small 
molecule.  
To reduce the possibility of disulfide dimer formation on the cell surface, 
we mutated Cysteine 55 to Serine using QuickChange mutagenesis. The 
mutation didn’t affect the expression of the proteins in NB41A3 cells, or disrupt 
the recognition site for our anti-FKBP antibody, indicated by the comparable 
levels of expression of the FKBP(C55S)-HL2-GFRα3 and the FKBP-HL2-GFRα3 
constructs (Figure 4.15).  
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Figure 4.15 Expression of FKBP(C55S)-HL2-GFRα3 on NB41A3 cells. NB41A3 cells were 
transfected with FKBP(C55S)-HL2-GFRα3 (red histogram) or FKBP-HL2-GFRα3 (blue 
histogram). 48 hours post transfection cell surface expression of GFRα3 was detected using flow 
cytometry. The black histogram represents untransfected cells stained with anti-GFRα3 primary 
and secondary antibodies. 
 
We tested whether the FKBP(C55S)-HL2-GFRα3 was able to mediate ART 
activation of RET, and whether pre-incubation with B/B dimerizer would affect the 
extent of RET activation. The cells were incubated with 2.4 nM B/B or 10 nM 
FK506 in DMEM for 30 min, followed by stimulation with various concentrations 
of ART for 10 min. The 2.4 nM B/B concentration was chosen based on a B/B 
dose response that suggested that such low concentration might be more 
effective at inducing dimerization between FKBP(C55S)-HL2-GFRα3 molecules 
than a higher dose of the small molecules (data not shown). The FK506 
treatment was used as a negative control, rather than 0 nM B/B, since it has 
been shown that it binds to and dissociates noncovalent FKBP dimers [188]. 
Thus, even in the event that we have B/B-independent dimerization due to weak 
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self-association of FKBPs, treatment with FK506 will ensure that, upon ART 
stimulation, these potential interactions are reversed. At the end of the 
stimulation period, the cells were lysed, and we measured the level of ERK 
phosphorylation using pERK ELISA. Because the response in our mouse pRET 
ELISA was very low, we chose pERK as the readout for RET activation, since 
this assay is more sensitive and gives larger signal amplitude than the pRET 
ELISA. However, the results of this experiment showed identical responses for 
samples treated with dimerizer B/B and the monovalent molecule FK506 (Figure 
4.16). 
 
Figure 4.16 Effect of B/B pre-incubation on the ART-dependent ERK activation in NB41A3 cells 
transfected with FKBP-HL2- GFRα3. NB41A3 cells, transiently expressing FKBP(C55S)-HL2-
GFRα3, were incubated with 2.4 or 10 nM FK506 for 30 min and then stimulated with various 
concentrations of ART for 10 min. Cells were lysed and the relative levels of pERK were 
measured using pERK ELISA. 
 
This outcome of this experiment indicated that pre-treatment of cells with B/B did 
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not have an effect on the extent of ERK activation upon stimulation of cells with 
various concentrations of ART, even when we ensured that B/B-untreated cells 
had monomeric GFRα3 proteins. To interpret the results, however, it was 
necessary that we confirmed the formation of FKBP-GFRα3 dimers upon 
treatment of cells with B/B. To that end, we engineered an FKBP-GFRα3 fusion 
proteins that can generate signal upon dimerization.   
4.3.5 Engineering of FKBP-β-gal-GFRα3 enzyme fragment complementation 
assay to directly detect B/B-induced dimers 
β-Galactosidase (β-gal) is a hydrolase that catalyzes the conversion of β-
galactosides into monosaccharides, and is encoded by the Lac Z gene in the lac 
operon in E. Coli. β-gal is a tetrameric enzyme, consisting of four identical 
subunits that each contains 1021 amino acids. The monomers have 5 domains 
with about 50 residues on the N-terminus, which are extended and contribute to 
the active site of the enzyme [194]. β-gal complementation has been widely used 
in bacterial cloning (blue-white colony selection) where an inactive truncated β-
gal is expressed by the host bacterium and the enzymatic activity can be 
restored by a complementing peptide encoded by a transfected vector, if that 
sequence has not been interrupted by a cloned gene. Based on the same 
principle, the β-gal fragment complementation has been successfully used in 
mammalian cells, where three different fragments can be used: Δα is similar to 
the fragment used in bacterial cloning and is characterized by a deletion of amino 
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acids 11 – 41 in the N-terminal region of the protein, Δω lacks the C-terminal 
amino acids after position 787, and Δµ has a deletion in the middle of the protein 
(amino acids 49 – 601). Each of the three truncation mutants is inactive, but 
enzymatic activity can be restored when any two mutants are brought together. 
We chose Δα and Δω mutants for our experiments (Figure 4.17), because this 
complementary pair was reported to have the lowest extent of self-association 
[195]. Enzyme fragment self-association would be a source of background signal 
that is undesirable in our assay, since the only dimerization that we want to 
detect is B/B-mediated FKBP dimerization.  
 
Figure 4.17 Schematic of the FKBP-β-galΔα-GFRα3 and FKBP-β-galΔω-GFRα3 enzyme 
fragment complementation pair. The signal sequence is shown in grey, FKBP is in green, β-gal is 
in purple and GFRα3 is in dark blue. The deletion mutations in the β-gal enzyme are represented 
by the blank/white regions in the shapes.   
  
In other studies, researchers have interpreted positive signals from such β-gal 
complementation assays as evidence of dimerization [196-198]. However, wild 
type β-gal functions as a tetramer, and it is unclear if in these assay systems the 
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signal comes from a single complementation event (dimerization of target 
proteins), or from tetramerization of complementary pairs of subunits, which 
would require 8 target proteins to associate together [199]. 
There are multiple commercially available substrates for detection of β-gal 
activity that allow colorimetric, fluorescent, or chemiluminescent readouts. For 
our assays we chose the substrate chlorophenol red-β-D-galactopyranoside 
(CPRG) (Figure 4.18), which allows colorimetric detection of β-gal activity and is 
highly sensitive. 
 
Figure 4.18 β-galactosidase (β-gal) catalyzed hydrolysis of Chlorophenol red-β-D-
galactopyranoside (CPRG) to chlorophenol red and glucose. 
 
The β-gal complementation assays system has been previously used for 
detection of protein-protein interactions in membrane-bound receptors [196, 200-
202] however, none of these studies involved using the enzyme fragment pair 
extracellularly. Since we wanted to fuse the β-gal fragments to GFRα3, which 
has no cytoplasmic domain, in our system the enzyme had to be positioned on 
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the N-terminus of the protein, and thus be expressed extracellularly.  
We cloned the constructs FKBP(C55S)-β-galΔα-GFRα3 and FKBP(C55S)-β-
galΔω-GFRα3 in separate pHom-1 vectors, and transfected HEK293 cells to test 
for their expression on the cell membrane. We confirmed that both proteins were 
expressed on the cell surface using flow cytometry (Figure 4.19), although the 
expression was lower than that observed for the FKBP-GFRα3 constructs (Figure 
4.6). We proceeded to test if we could measure β-gal activity when the two 
constructs were co-expressed in HEK293 cells. β-gal has only been used as an 
intracellular protein, whereas in our system we expressed it in the extracellular 
portion of a cell surface protein. We, therefore, needed to modify the existing 
 
Figure 4.19 FKBP(C55S)-β-galΔα-GFRα3 and FKBP(C55S)-β-galΔω-GFRα3 expression in 
HEK293 cells. HEK293 cells were transfected with FKBP(C55S)-β-galΔα-GFRα3 (blue 
histogram), FKBP(C55S)-β-galΔω-GFRα3 (red histogram) or both (green histogram) and the cell 
surface expression of GFRα3 (A) and FKBP (B) was measured 48 hours post transfection using 
flow cytometry. 
 
protocol for monitoring β-gal activity. The β-gal substrate, CPRG, which we used, 
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is not cell permeable, which served our purposes of not detecting any residual 
activity from improperly trafficked β-gal that is retained in the cytosol. However, 
the general protocol suggested by the manufacturer required incubating cell 
lysates diluted into PBS containing Mg2+, with CPRG for up to 24 hours. In our 
system, however, we needed to assay β-gal activity in intact cells, since we were 
only interested in measuring the signal coming from cell-membrane expressed 
comlexes. For that reason, we could not incubate the cells with substrate diluted 
in PBS, since the cells would most probably start to die after a few hours. Thus, 
we tested the reaction in DMEM free of phenol red (which had the same spectral 
characteristics as the product of CPRG hydrolysis that we measure in the β-gal 
assay), supplemented with 10% FBS. As a positive control we also included PBS 
supplemented with 1 µM Mg2+. We used purified wild type β-gal enzyme at a 
concentration of 25 U and incubated it with 0.155 mM CPRG – the manufacturer 
recommended concentration – and let the reaction proceed for 24 hour at 37 °C. 
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Figure 4.20 CPRG hydrolysis catalyzed by full-length β-galactosidase in PBS or phenol red-free 
growth medium (GM). 25 U of full-length β-gal was added to 100 µL of 0.155 mM CPRG 
substrate in the indicated diluent, for 24 hours, in a 96-well plate. The enzymatic activity was 
measured by the absorption of the reaction product at 575 nm.  Plotted are the results from a 
single experiment. 
 
The signal was lower when DMEM was used as the diluent instead of PBS 
(Figure 4.20). However, even in DMEM the reaction produced a strong signal, 
and we proceeded to test if we can measure B/B-dependent β-gal 
complementation in cells. For our pilot experiments we chose HEK293 cells, 
since this cell line is easier to transfect and usually showed enhanced expression 
of the constructs. HEK293 cells were transfected with 2.5 µg β-galΔα + 2.5 µg 
pHom-1 vector (β-galΔα only), 2.5 µg β-galΔω + 2.5 µg pHom-1 vector (β-galΔω 
only), or with 2.5 µg β-galΔα + 2.5 µg β-galΔω (β-galΔα and β-galΔω). 48 hours 
post transfection, cells were treated with 0.155 or 1.55 CPRG solution containing 
5 nM B/B or an equivalent volume of ethanol as vehicle control, for 24 hour at 37 
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°C. We also included the control condition where the CPRG ± 5 nM B/B solutions 
were prepared in PBS supplemented with 1 µM Mg2+. Figure 4.21A and B shows 
that there was very little background signal seen in cells transfected with either of 
the two β-gal deletion mutants alone, and that  we could observe enzymatic 
activity when the two complementary mutants were expressed together. This 
result suggested that our constructs were functional. The signals were very low 
when we used 0.155 mM CPRG substrate (Figure 4.21A and C), but was 
significantly higher when we increased the concentration 10-fold, to 1.55 mM 
(Figure 4.21B and D). However, the signal due to B/B-independent association 
was relatively high (Figure 4.21, black bars).  
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Figure 4.21 β-galactosidase fragment complementation assay in transfected HEK293 cells, 24 
hours after the addition of CPRG substrate. HEK293 cells transfected with FKBP(C55S)-β-galΔα-
GFRα3, FKBP(C55S)-β-galΔω-GFRα3 or both were plated in 96-well plates, and 48 hours post 
transfection were incubated for 24 hours with 0.155 (A and C) or 1.55 (B and D) mM CPRG and 5 
nM (patterned bars) or 0 nM (black bars) B/B prepared in PBS, supplemented with 1µM Mg2+ (A 
and B) or phenol red-free growth medium (C and D). Plotted is the raw absorbance at 575 nm 
from a single experiment. 
 
In the cell samples that were treated in phenol red-free growth medium we 
noticed only a slight difference in signal upon addition of 5 nM B/B, compared to 
the 0 nM B/B control (Figure 4.21C and D). This effect, however, was not present 
in the samples treated in PBS (Figure 4.21A and B). The signal there was about 
2-fold higher than that measured in the samples incubated in growth medium, 
consistent with what we observed in our preliminary experiments with purified 
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full-length β-gal. However, in PBS it appeared that treatment with B/B caused a 
slight decrease in the enzymatic activity, rather than increase. This signal was 
most probably not due to β-gal activity that was restricted to the outer side of the 
cell membrane, since we could expect cells incubated in PBS for 24 hours to be 
necrotic and that their membrane would be compromised, allowing the CPRG to 
be accessible to intracellular proteins. 
We also let the reaction done in growth medium run for 48 hours, to test if 
doubling the incubation time would increase the sensitivity of our system. The 
signal from all samples was higher at 48 hours of incubation, and the difference 
between 5 and 0 nM B/B doubled (Figure 4.22).  
 
Figure 4.22 4 β-galactosidase fragment complementation assay in transfected HEK293 cells, 24 
hours after the addition of CPRG substrate HEK293 cells transfected with FKBP(C55S)-β-galΔα-
GFRα3, FKBP(C55S)-β-galΔω-GFRα3 or both were plated in 96-well plates. 48 hours post 
transfection, cells were incubated for 48 hours with 0.155 (A) or 1.55 (B) mM CPRG and 5 nM 
(patterned bars) or 0 nM (black bars) B/B prepared in phenol red-free growth medium. Plotted is 
the raw absorbance at 575 nm from a single experiment. 
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 Using the same transfection conditions as before, we performed the 
enzyme complementation assay using 0.155 and 0.775 mM CPRG substrate and 
various concentrations of B/B to test if we could measure a dose-dependent 
ligand-induced dimerization. In our experiment using 0.155 mM CPRG we 
included treatments with various concentrations of ART as a positive control for 
dimerization. We did not observe ligand-induced β-gal enzymatic activity with B/B 
or ART (Figure 4.23).  
 
Figure 4.23 B/B- and ART-induced dimerization of FKBP(C55S)-β-galΔα-GFRα3, and 
FKBP(C55S)-β-galΔω-GFRα3 measured by β-galactosidase activity after incubation of cells for 
24 hours with the CPRG substrate. HEK293 cells transfected with FKBP(C55S)-β-galΔα-GFRα3 
(blue), FKBP(C55S)-β-galΔω-GFRα3 (red) or both (green) were plated in 96-well plates, and 48 
hours post transfection, were incubated for 24 hours with 0.155 (A and B) or 0.775 (C) mM CPRG 
and various concentrations of B/B (A and C) or ART (B) prepared in phenol red-free growth 
medium. 
 
The individually transfected β-gal mutants were inactive (shown in panel C) and 
when they were co-transfected in the same cells, we observed a significantly 
higher signal. However it seemed that the enzyme fragments associated 
independently and not in response to stimulation with either B/B or ART.  
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To see if longer incubation with the ligand would reveal B/B- or ART-
dependent association of FKBP-β-gal-GFRα3 constructs, we measured the B/B 
and ART dose-response β-gal activation incubating the cells with 0.155 mM 
CPRG substrate for 96 hours (Figure 4.24).  As expected, the measured signal 
increased for all samples. There was also a slight increase in enzymatic activity 
upon incubation with B/B, suggesting that we might be observing FKBP-mediated 
dimerization. However, the high background also suggested that the effect of 
ligand stimulation was very small and did not represent complete dimerization of 
the FKBP-tagged proteins on the cell surface.  
 
Figure 4.24 B/B- and ART-induced dimerization of FKBP-β-galΔα-GFRα3 and FKBP-β-galΔω-
GFRα3 measured by β-galactosidase activity after incubation of cells with CPRG substrate for 96 
hours. HEK293 cells transfected with FKBP(C55S)-β-galΔα-GFRα3 (blue), FKBP(C55S)-β-
galΔω-GFRα3 (red) or both (green) were plated in 96-well plates, and 48 hours post transfection, 
were incubated for 96 hours with 0.155 mM CPRG and various concentrations of B/B (A) or ART 
(B) prepared in phenol red-free growth medium. 
 
We reasoned that one possibility for why we observed such high levels of ligand-
independent association was that, when proteins are constrained to the cell 
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membrane, their effective local concentration is greatly increased, and even low 
affinity for self-association could drive efficient dimer formation. Since GFRα3 
has a GPI-anchor, and is therefore enriched in lipid rafts on the cell membrane8, 
this effect may be even more pronounced in our system due to the high 
concentration of proteins localized in these membrane microdomains. In an 
attempt to lower the ligand-independent protein association, we first tried to 
disrupt the lipid rafts by depleting the cell membrane of cholesterol. We 
transfected HEK293 cells with FKBP-β-galΔα-GFRα3 alone, or co-transfected 
them with FKBP-β-galΔα-GFRα3 and FKBP-β-galΔω-GFRα3, and let them grow 
for 72 hours in growth medium containing 5 µM Lovastatin [203, 204], an 
approved drug that lowers cholesterol and is not toxic for long-term use in tissue 
culture. We then added B/B and 0.155 mM CPRG and incubated the cells for 24 
hours. Depleting the cholesterol did not decrease the background β-gal activity 
(Figure 4.25A), which suggested that segregation of the FKBP-β-gal-GFRα3 
proteins in lipid rafts is not the cause of the spontaneous self-association. We 
also considered the possibility that localizing the β-gal constructs on the cell 
membrane enhances their, otherwise, weak self-association, which results in 
high constitutive background β-gal activity. We tested whether expressing the β-
gal constructs as soluble proteins would decrease the ligand-independent signal.  
To do this, we engineered a soluble FKBP-β-gal-Δα (sFKBP-β-gal-Δα) and 
FKBP-β-gal-Δω (sFKBP-β-gal-Δω) fragment complementation pair that, due to 
the lack of membrane translocation sequence, is retained in the cytoplasm. 
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Transfected HEK293 cells were incubated for 24 hours with various 
concentrations of B/B and 0.155 mM CPRG prepared in lysis buffer (Figure 
4.25B). 
  
Figure 4.25 Effect of lovastatin on B/B-dependent dimerization of membrane-tethered FKBP-β-
galΔα-GFRα3 and FKBP-β-galΔω-GFRα3, and B/B-dependent dimerization of soluble cytosolic 
FKBP-β-galΔα and FKBP-β-galΔω, measured by β-gal enzyme fragment complementation 
assay. (A) HEK239 cells were transfected with FKBP-β-galΔα-GFRα3 (blue), or with FKBP-β-
galΔα-GFRα3 and FKBP-β-galΔω-GFRα3 (green and purple) and incubated for 72 hours with 5 
µM (blue and green) or 0 µM (purple) lovastatin. Various concentrations of B/B were added 
together with 0.155 mM CPRG in the presence or absence of lovastatin. β-gal activity was 
measured 24 hours later.  (B) HEK293 cells were transfected with sFKBP-β-galΔα-GFRα3, 
sFKBP-β-galΔω or both. 48 hours post transfection various concentrations of B/B and 0.155 mM 
CPRG were added to the cells in lysis buffer and the absorbance at 575 nm was measured 24 
hours later. 
 
The absorbance that we measured for the soluble proteins was several-fold 
higher than for the membrane-tethered constructs This result suggested either 
that when expressed on the membrane the β-gal enzyme was mostly inactive, or 
when two proteins containing two complementary β-gal fragments dimerized, the 
orientation was not optimal for enzyme complementation. 
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4.3.6 Design, cloning, and activity of FKBP-GFRα3-FRET pair  
Another approach that we took to directly observe FKBP-GFRα3 dimerization 
was to fuse our chimeric protein to a Förster resonance energy transfer (FRET) 
pair of monomeric Yellow Fluorescent Protein (mYPet) and monomeric Cerulean 
(mCerulean) proteins. YPet is a variant of the Enhanced Yellow Fluorescent 
Protein (EYFP) that was mutated so that the resultant protein is monomeric and 
has brighter spectral characteristics [190]. An additional point mutation, A120K, 
was introduced to make the protein monomeric (mYPet) [191]. mCerulean is a 
mutant of the Cyan Fluorescent Protein (CFP) [190, 205] that has a single point 
mutation, A120K, that makes it monomeric . 
We created two new constructs containing mCerulean or mYPet inserted 
between FKBP and GFRα3, starting from our original construct, and co-
expressed them in NB41A3 cells and HEK293 cells. HEK293 cells were 
transfected with 5 µg of plasmid DNA (in 6-well plates), for single construct 
transfections and with 2.5 µg plasmid DNA of each construct for co-expression, 
using X-fect transfection reagent and the vendor recommended protocol. 
NB41A3 cells were transfected with 0.2 µg of plasmid DNA for individual 
expression, and with 0.1 µg of each plasmid DNA for co-transfection of both 
constructs, using Attractene transfection reagent and following the 
manufacturer’s protocol. To check for expression of all three components of our 
chimeric protein, we detected each one individually in the same sample of 
transfected cells 48 hours after transfection. We measured the fluorescence 
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mYPet when it was excited with the 488 nm laser. At the same time we detected 
FKBP and GFRα3 with polyclonal antibodies that were detected with a secondary 
IgG conjugated to a fluorophore. We confirmed our FACS results with Western 
blot experiments that detected both the GFRα3 and the FKBP portions of the 
chimeric proteins (Figure 4.26).  
 
Figure 4.26 Expression of FKBP-mCer-GFRα3 and FKBP-mYPet-GFRα3 in NB41A3 cells 
measured by flow cytometry. (A and B) Detection of FKBP (A) and GFRα3 (B) in NB41A3 cells 
transfected with FKBP-mCer-GFRα3 (blue), FKBP-mYPet-GFRα3 (red), or both (green), using 
flow cytometry. (C and D) Analysis of cell lysates from NB41A3 cells transfected with the 
indicated plasmid DNAs detected by Western blot, detected using antibodies against FKBP (C) 
and GFRα3 (D). Arrows show the expected molecular weight for full-length FKBP-mCer-GFRα3 
and FKBP-mYPet-GFR3. 
 
 Both of our constructs expressed well in HEK293 cells (Figure 4.26). Next, 
we used FKBP-mYpet-GFRα3 to test the construct’s activity to activate RET in 
the presence of ART.  We transfected NB41A3 cells using Attractene transfection 
reagent and, 48 hours post transfection, treated cells with various concentrations 
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of ART for 10 min. At the end of the stimulation the cells were lysed, and 
phosphorylation of RET, ERK and Akt were measured using the appropriate 
ELISA. Figure 4.27 shows that there was dose-dependent ART activation of 
RET, which suggested that the transfected FKBP-mYPet-GFRα3 was functional. 
Next, we tested whether pre-incubation of cells with B/B dimerizer resulted in an 
observable difference in the pRET ART dose-response. NB41A3 cells were 
transiently transfected with FKBP-mYPet-GFRα3 construct and, 48 hours later, 
the cells were incubated with 100 nM B/B for 40 min, followed by a 10-min 
stimulation with various concentrations of ART. At the end of the incubation 
period cells were lysed, and the lysates analyzed for pRET using mouse pRET 
ELISA. Figure 4.27 shows that pre-treatment with B/B did not alter the response 
of cells to ART. 
 
Figure 4.27 Effect of pre-incubation of cells with B/B on the level of ART-dependent RET 
phosphorylation. NB41A3 cells were transiently transfected with FKBP-mYPet-GFRα3. 48 hours 
post transfection cells were sequentially incubated with 100 or 0 nM B/B for 40 min, followed by 
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various concentrations of ART for 10 min. pRET levels in cell lysates were measured using the 
mouse pRET ELISA. 
 
 Because we didn’t observe any significant difference in the 
phosphorylation response of RET to ART when cells were pre-treated with 100 
nM B/B (Figure 4.27), we did not proceed to measure the FRET signal in cells 
co-transfected with FKBP-mYPet-GFRα3 and FKBP-mCerulean-GFRα3. We 
hypothesized that the lack of effect of pre-treating cells with B/B on the amplitude 
of the ART-dependent pRET response could be attributed to the inefficient 
dimerization. Thus, we tried to improve the efficiency of B/B-dependent 
oligomerization of FKBP-GFRα3 proteins by adding more FKBP domains to the 
existing construct.  
4.3.7 Cloning, expression and B/B-dependent dimerization of a 3xFKBP-
GFRα3 construct 
We engineered a construct that had three consecutive FKBP(C55S) 
domains fused N-terminal to GFRα3 in attempt to induce a more stable B/B-
mediated oligomer on the cell surface. The usage of multiple FKBP domains has 
been reported to achieve better results for small molecule-induced protein 
oligomerization and activation than a single FKBP fused to the same proteins 
[188, 206].  Additional B/B binding sites would make the FKBP-small molecule 
binding stronger by adding avidity to the interaction. Also, this situation can result 
in higher-order oligomerization of the GFRα3s, since the FKBP domains from 
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one protein have the capacity to dimerize with FKBP domains on multiple other 
proteins (Figure 4.28). Thus, with the 3xFKBP-GFRα3 construct we could test if 
higher-order clustering of GFRα3 had an effect on the ART-dependent RET 
phosphorylation. 
 
Figure 4.28 Schematic of B/B-induced dimerization and oligomerization of membrane-tethered 
3xFKBP-GFRα3. (A) Multiple FKBP domains may increase the stability of the dimer by providing 
more binding sites for B/B. (B) FKBP domains within the same protein may form B/B-induced 
dimers with FKBP domains on two or more other proteins. 
 
We generated a new construct in which we inserted two additional 
FKBP(C55S) proteins between the FKBP(C55S) and GFRα3 proteins in 
FKBP(C55S)-GFRα3 construct. For initial characterization, we expressed the 
new construct, designated as 3xFKBP(C55S)-GFRα3, in HEK293 cells and 
detected the relative expression of GFRα3 on the cell surface using flow 
cytometry (Figure 4.29). 
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Figure 4.29 3xFKBP(C55S)-GFRα3 expression in HEK293 cells measured by flow cytometry. 
HEK293 cells were transfected with 3xFKBP(C55S)-GFRα3 or with empty pHom-1 vector. 48 
hours post transfection GFRα3 expression was measured using flow cytometry. 
 
However, the shift in fluorescence brightness relative to the mock-transfected 
cells was lower than that for the single FKBP-GFRα3 chimera (Figure 4.5A), 
suggesting that the bigger protein, containing three copies of FKBP, was 
expressed poorly. To test if we could capture protein dimers or oligomers, we 
treated cells with 0, 50 or 100 nM B/B for 30 min and then crosslinked the 
extracellular proteins by treating the cells with 0, 1 or 5 mM BS3 for 30 min. Equal 
amounts of cell lysates were loaded onto a 6% Tris-HEPES polyacrylamide gel, 
and the separated proteins were transferred to a PVSF membrane and stained 
for GFRα3 (Figure 4.30). 
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Figure 4.30 B/B-induced dimerization of 3xFKBP(C55S)-GFRα3 on the surface of HEK293 cells 
detected by Western blot. HEK293 cells were transfected with 3xFKBP(C55S)-GFRα3. 48 hours 
post transfection cells were treated with 0, 50, or 100 nM B/B for 30 min and then cross-linked 
with 0, 1, or 5 mM EGS for 30 min. Cell lysates containing equal amounts of total protein were 
separated on a 6% Tris-HEPES gel and transferred to a PVDF membrane. Protein bands were 
detected with anti-GFRα3 antibody. 
 
For all tested B/B treatments we observed that increasing concentrations of 
chemical cross-linker caused the disappearance of the otherwise thick band 
corresponding to the monomeric 3xFKBP(C55S)-GFRα3 protein. When cells 
were cross-linked with 1 mM EGS, there was a faint band at the molecular weight 
where we expected to see a dimer. However, the major species that was 
detected was a protein of molecular weight that agreed with the predicted size of 
the monomeric protein 3xFKBP-GFRα3. Neither protein band was visible in the 
samples that were treated with 5 mM EGS, which agreed with our previous 
observation that high concentration of crossinker made the proteins undetectable 
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by our antibodies.  
These results show that, even with the multiple FKBP domain protein, we 
were unable to capture B/B-induced dimerization. Possible explanations for this 
result are that FKBP was not functional when expressed as an extracellular 
protein or, alternatively, that chemical crosslinking is not an appropriate method 
to capture the interaction.     
4.3.8 Design and B/B-induced activation of FKBP-GFRα3-RET(TM-KD) and 
RET-FKBP 
Another approach that we took to detecting GFRα3 dimers, without the 
need to chemically crosslink the proteins, was to engineer a construct that had 
GFRα3 expressed on the cell surface, but instead of being GPI-linked to the 
outer leaflet of the membrane, it was fused to the transmembrane and kinase 
domains (TM/KD) of RET, followed by FKBP and an HA tag at the C-terminus of 
the protein. This approach was based on the hypothesis that, upon dimerization 
with B/B, the kinase domains within a dimer would autophosphorylate, and we 
could detect this by ELISA. Another benefit of this class of constructs was to 
place FKBP inside the cell, obviating concerns that this cytosolic protein might 
not be functional when exposed on the extracellular side of the plasma 
membrane. 
We first cloned the mouse GFRα3 sequence up to amino acid 369 into the 
pHom-1 vector, using the unique XbaI restriction site in the plasmid. The 
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resultant construct comprised 5’-GFRα3-XbaI-FKBP, and we cloned the RET 
transmembrane (TM) and kinase domains (KD) between the GFRα3 and FKBP 
proteins.  We designed 5 variants of the RET-TM/KD that differed in their 
membrane-proximal (MP) N-terminal amino acids (Figure 4.31). The 
transmembrane domain of RET is a single alpha helix that extends into the 
membrane-proximal (MP) part of the extracellular domain [207, 208]. It has been 
shown that the length (number of helical turns) of the transmembrane domain 
may affect the relative orientation of the kinase domains within a homodimer 
upon ligand-induced dimerization [88]. We therefore reasoned, that constructs 
that differed in the number of membrane-proximal helix residues, could be 
activated to different extent by dimerization with ART or B/B.  
 
Figure 4.31 Schematic representation of the GFRα3-RET(TM/KD)-FKBP constructs. Mouse 
GFRα3 (dark blue rectangle) was cloned N-terminal to FKBP. The signal sequence was retained, 
targeting the resulting protein for extracellular transport. We excluded amino acids after 369, to 
eliminate post-translational modifications that would localize the protein into lipid rafts. Human 
RET transmembrane (green) and kinase domains (purple) were cloned between GFRα3 and 
FKBP. Different amino acid from the membrane-proximal (MP) portion of the extracellular domain 
(teal) were retained, to allow a range of possible relative orientation of the kinase domains within 
dimers formed upon treatment with B/B small molecule dimerizer. 
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 We successfully cloned constructs B, C, D, and E. However, all viable cell 
colonies that we obtained from transforming NEB5α cells with plasmid containing 
construct A were missing the entire RET TM/KD portion, with the exception of 
one plasmid that had only the first 16 amino acids of the RET transmembrane 
domain. We transfected HEK293 cells to test the expression of all variants, 
including variant A that had a small portion of transmembrane domain. All 
variants were detected on the cell surface including variant A, which suggested 
that even the small portion of the RET transmembrane domain was enough to 
position the rest of the protein into the cell membrane (Figure 4.32). We also 
used one of the A constructs that was missing its entire transmembrane domain 
and our flow cytometry analysis confirmed that no GFRα3 expression was 
detected on the cell surface (not shown).  
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Figure 4.32 Expression of GFRα3-RET(TM/KD)-FKBP variants in HEK293 cells measured by 
flow cytometry. HEK293 cells were transfected with one of the five GFRα3-RET(TM/KD)-FKBP 
variants. 48 hours post transfection protein expression was measured by flow cytometry using 
anti-GFRα3 antibody. The different constructs are labeled by the letter code given in Figure 4.29. 
 
 Next, we proceeded to test for ART- or B/B-dependent RET kinase 
activation upon stimulation of cells transfected with GFRα3-RET(TM/KD)-FKBP 
constructs.  Constructs B, C, D and E, as well as the variant of A (A*) that lacked 
the RET kinase domain, were transiently expressed into HEK293 cells. 48 hours 
post transfection, the cells were treated for 10 min with 10 nM ART, 50 nM B/B or 
assay buffer containing the same amount of ethanol as the B/B sample. At the 
end of the treatment cells were lysed with KIRA or ERK lysis buffer, and the 
relative amounts of pRET and pERK were measured using the human pRET or 
ERK ELISAs, respectively.  The results showed that there was significant ligand-
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independent RET phosphorylation in all of the functional constructs. ART or B/B 
treatment had no significant additional effect on the RET phosphorylation levels 
measured in these samples. Treatment with B/B did not induce ERK 
phosphorylation; however, there was a small increase in the pERK levels upon 
treatment with ART (Figure 4.33). 
 
Figure 4.33 B/B- and ART-dependent RET and ERK phosphorylation in HEK293 cells expressing 
GFRα3-RET(TM/KD)-FKBP constructs. HEK293 cells transfected with A, C, D, E, or B* 
constructs were treated for 10 min with 10 nM ART (grey bars), 50 nM B/B (black bars), or assay 
buffer (patterned bars), and pRET or pERK levels were measured using ELISA. 
 
 The significant ligand-independent activation in the GFRα3-RET(TM/KD)-
FKBP and in the FKBP-β-gal-GFRα3 constructs pointed to the possibility that 
ligand-independent dimerization in these constructs may be driven by self-
association of the GFRα3 domains. This hypothesis was also supported by the 
spontaneous formation of disulfide-linked dimers between FKBP-GFRα3 
molecules, described in Section 4.3.4.  To eliminate the possibility that 
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overexpression of GFRα3 drives self-association in the protein we engineered a 
human RET-FKBP construct that could be activated by the binding of B/B. With 
this protein we were also able to test if co-expression of the RET receptor with 
one of its co-receptors can lower the constitutive activation that we observed for 
the GFRα3-RET(TM/KD)-FKBP chimera [169]. 
We cloned full-length human RET into the pHom-1 vector using the XbaI 
cloning site, positioning RET N-terminal to the FKBP fragment. HEK293 cells 
were transfected with the construct and the expression was confirmed using flow 
cytometry (Figure 4.34). 
  
Figure 4.34 RET-FKBP expression in HEK293 cells measured by flow cytometry. HEK293 cells 
were transfected with RET-FKBP or empty pHom-1 plasmid DNA. The expression of RET on the 
cell surface was measured with anti-human RET IgG. 
 
 When we transfected HEK293 cells using Xfect, with the optimal amount 
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of DNA recommended by the manufacturer (30 µg of plasmid DNA per 10-cm 
plate), the cells were not viable 48 hours after transfection. Lowering the amount 
of DNA used for the transfection to 15 µg per 10-cm plate helped with cell 
viability. However, when we measured RET activation using our human pRET 
ELISA, the results showed that RET was constitutively active and its 
phosphorylation was not affected by incubation with B/B (data not shown). 
Further lowering the amount of DNA used to 10.2 µg per 10-cm dish for cell 
transfection allowed us to measure B/B-dependent activation of RET and ERK 
(Figure 4.35). The higher pRET signal of untreated cells compared to the 
negative controls in the human pRET ELISA suggested that B/B independent 
RET activation was still present. However, treatment of transfected cells with B/B 
showed a dose-dependent increase in pRET levels, suggesting that at these low 
levels of expression, a significant fraction of the receptors remained monomeric 
and available for B/B-induced activation.  
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Figure 4.35 B/B-dependent activation of RET-FKBP on the surface of HEK293 cells. HEK293 
cells transfected with RET-FKBP plasmid DNA were treated with various concentrations of B/B 
for 10 (blue), 30 (red) or 40 min (green). At the end of the stimulation cells were lysed with KIRA 
or ERK lysis buffer and the relative amounts of pRET (A) and pERK (B) were measured using the 
appropriate ELISA. 
 
 These results showed that B/B was, in fact, able to bind to two FKBP 
proteins from our RET-FKBP construct and trigger dimerization. However, 
because the basal level of RET phosphorylation was high, the B/B-dependent 
increase in signal was relatively small. In an attempt to reduce the background 
RET phosphorylation, we co-transfected HEK293 cells with RET-FKBP plus full-
length mouse GFRα3. The signal that we measured for RET phosphorylation, 
however, was unchanged in both basal level and amplitude upon stimulation with 
B/B (Figure 4.36). 
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Figure 4.36 B/B-dependent RET activation of RET-FKBP co-transfected with mGFRα3 in 
HEK239 cells. HEK293 cells were transfected with the indicated combinations of plasmid DNA in 
6-well plates. 48 hours after transfection the cells were treated with various concentrations of B/B 
for 10 min and lysed with KIRA buffer. pRET levels were measured using KIRA ELISA and the 
A450 was adjusted according to the total protein content in the lysates. 
 
4.4 Conclusions and Future Directions 
We were able to successfully clone and express a number of GFRα3 
fusion proteins in order to study the effect of the resting oligomerization state of 
the co-receptor on the extent of RET activation upon stimulation with various 
concentrations of ART. The lack of a direct signal in response to GFRα3 
dimerization proved to be a challenging aspect of this project, since chemical 
crosslinking of the resultant dimers was inefficient and seemed to interfere with 
the detection of the proteins in Western blots. Our analysis of the response of 
cells expressing different variant of the FKBP-GFRα3 fusion protein to pre-
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incubation with the small molecule FKBP dimerizer, B/B, was hindered by the 
fact that we observed a large fraction of co-receptors that were covalent dimers 
when the FKBP fusion protein was expressed on the cell surface. The β-
galactosidase enzyme fragment complementation assay that we designed wasn’t 
able to measure the B/B-induced dimerization, possibly because it wasn’t 
sensitive enough to detect the small differences in signal between treated and 
untreated cells. We haven’t yet tested our FKBP-GFR3 FRET pair and it could 
prove to be a successful way of detecting dimerization.  
We saw low, but clearly different, response of cells expression RET-FKBP 
to stimulation with various concentrations of B/B, indicating that when expressed 
intracellularly the FKBP is active and can be dimerized with the small molecule 
dimerizer B/B. However, with these constructs we relied on detection of RET 
phosphorylation as a readout for protein dimerization, and the constitutive RET 
activation that we observed made the results difficult to interpret conclusively. 
However, based on the results that we collected we could conclude that if FKBP 
was to be used for GFRα3 reversible dimerization, it should be cloned so that the 
it is expressed on the cytoplasmic side of the plasma membrane, since only the 
constructs that had intracellular FKBP showed B/B-mediated dimerization. This 
means that GFRα3 has to be modified to be a transmembrane rather than GPI-
anchored protein, as we did for our GFRα3-RET(TM/KD)-FKBP constructs. A 
similar construct that has a different mode of detection than the RET kinase 
domain might prove to be more useful in this case. The RET kinase domain may 
  
 
   
229 
contribute to the constitutive dimerization of the construct when it is expressed at 
high levels and substituting it with another signal-generating protein, which has 
lower affinity for self-aggregation, might be advantageous. One possibility is to 
clone the β-gal enzyme fragments C-terminal to a transmembrane domain that 
follows GFRα3. 
 We showed that the expression of human RET-FKPB in HEK293 cells led 
to constitutive activation of the receptor. Cells expressing (presumably) very high 
levels of RET died 48 hours post transfection, and the control experiments, in 
which the same amount of plasmid DNA that does not encode RET, confirmed 
that the cytotoxic effect was RET-dependent. It was necessary to decrease the 
expression levels of RET below the detection threshold for our flow cytometry 
assay, to avoid cell toxicity and to measure B/B-dependent RET phosphorylation.  
These observations suggest that RET has an intrinsic affinity to self-aggregate 
and become activated, even in the absence of ligand. The reason why such 
constitutive activation is not observed in the NB41A3 cell line that expresses 
endogenous RET, is probably because the endogenous expression levels of the 
receptor are low compared with the KD for the self-aggregation interaction. Such 
self-aggregation is not common for all receptor tyrosine kinases. For example, 
the epidermal growth factor receptor (EGFR) is expressed at densities ranging 
from 4 x 103 to 1 x 105 molecules per cell in different strains of human fibroblasts 
[209]. However, in the human epidermoid carcinoma cell line, A431, the 
expression level of EGFR is 1.2 x 106 [210], and there is no significant level of 
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ligand-independent receptor activation. Thus, it is possible that the intrinsic self-
aggregation that we observed for RET could play a role in the activation pathway 
of the receptor. Indeed, in Chapter 2, we showed that such receptor-mediated 
oligomerization may play a role in the activation of RET by agonist monoclonal 
antibodies.  
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Appendix 1. List of primers used for cloning 
Construct Use Direction Sequence 
FKBP-GFRα3 cloning Forward AAAACTGGAAACTAGTATGGGGCTCTCCTG
GAGCCCG 
 Reverse CGTACGGATAACTAGTCTACCAGAGGGTC
TGCAGCAGAATCAA 
GFRα3 signal 
sequence 
cloning  Forward CACCATGGCTTCTAGAGGGCTCTCCTGGA
GCC 
 Reverse CCTGCACTCCTCTAGATCCTGCTCCAAGT
GGCAG 
FKBP(V36M) Mutation Forward TGCTTGAAGATGGAAAGAAAATGGATTCC
TCCCGGGACAGAAA 
V36M Reverse TTTCTGTCCCGGGAGGAATCCATTTTCTTT
CCATCTTCAAGCA 
FKBP(C55S) Mutation Forward TCCCCAAGCGCGGCCAGACCAGCGTGGT
GCACTACACCGGG 
C55S Reverse CCCGGTGTAGTGCACCACGCTGGTCTGG
CCGCGCTTGGGGA 
FKBP-mYPet-
GFRα3 
Cloning Forward AAAACTGGAAACTAGTGTGAGCAAAGGCG
AAGAGC 
 Reverse CAAGGGAGTTACTAGTCTTATAGAGCTCG
TTCATGCCCT 
FKBP-mCerulean-
GFRα3 
Cloning Forward AAAACTGGAAACTAGTGTGAGCAAGGGCG
AGG 
 Reverse CAAGGGAGTTACTAGTGTACAGCTCGTCC
ATGCC 
GFRα3 
Ectodomain 
Cloning Forward CACCATGGCTGCTGGAGGGCTCTCCTGG
AGC 
 Reverse CCTGCACTCCTCTAGAGCTGTTCTGCTGC
TGC 
RET TM and KD 
Variant A 
Cloning Forward GCAGAACAGCTCTAGAGCTGTCCTCTTCT
CCTTCAT 
 Reverse CCTGCACTCCTCTAGAGAATCTAGTAAAT
GCATGGGAAATTCTACC 
RET TM and KD 
Variant B 
Cloning Forward GCAGAACAGCTCTAGAATCCAGGATCCAC
TGTGC 
 Reverse CCTGCACTCCTCTAGAGAATCTAGTAAAT
GCATGGGAAATTCTACC 
RET TM and KD 
Variant C 
Cloning Forward GCAGAACAGCTCTAGACCACTGTGCGACG
AGC 
 Reverse CCTGCACTCCTCTAGAGAATCTAGTAAAT
GCATGGGAAATTCTACC 
RET TM and KD 
Variant D 
Cloning Forward GCAGAACAGCTCTAGATGCGACGAGCTGT
GC 
 Reverse CCTGCACTCCTCTAGAGAATCTAGTAAAT
GCATGGGAAATTCTACC 
RET TM and KD  
Variant E 
Cloning Forward GCAGAACAGCTCTAGATCCGACGAGCTGT
CCCG 
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 Reverse CCTGCACTCCTCTAGAGAATCTAGTAAAT
GCATGGGAAATTCTACC 
FKBP Cloning Forward AAAACTGGAAGCTGGTGCTTCTAGAGGAG
TGCAGG 
 Reverse CGTACGGATAACTAGTTTCCAGTTTTAGAA
GCTCCACATC 
soluble  
FKBP-β-galΔα 
Cloning Forward AAAACTGGAAACTAGTACCATGATTACGG
ATTCTCTGGCC 
 Reverse CGTACGGATAACTAGTTTATTTTTGACACC
AGACCAACTGGTAATGG 
soluble  
FKBP-β-galΔω 
Cloning Forward AAAACTGGAAACTAGTACCATGATTACGG
ATTCTCTGGCC 
 Reverse CGTACGGATAACTAGTTAATTCAATTCGCG
CGTCCCG 
β-galΔ41 (between 
FKBP and GFRα3) 
Cloning Forward AAAACTGGAAACTAGTGAAGAGGCCCGCA
C 
 Reverse CAAGGGAGTTACTAGTTTTTTGACACCAG
ACCAACTG 
β-galΔα (between 
FKBP and GFRα3) 
Cloning Forward AAAACTGGAAACTAGTACCATGATTACGG
ATTCTCTGGCCGTCGTTGAAGAGGCCCGC
AC 
 Reverse CAAGGGAGTTACTAGTTTTTTGACACCAG
ACCAACTG 
β-galΔω (between 
FKBP and GFRα3) 
Cloning Forward AAAACTGGAAACTAGTACCATGATTACGG
ATTCTCTGGCCGTCGTTTTACAA 
 Reverse CAAGGGAGTTACCAGCATTCAATTCGCGC
GTCC 
RET-FKBP Cloning Forward CACCATGGCTTCTAGAGCGAAGGCGACGT
C 
 Reverse CCTGCACTCCTCTAGAGAATCTAGTAAAT
GCATGGGAAATTCTA 
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Appendix 2. DNA sequences 
pHom-1 plasmid DNA 
ACGCGTTCGAGCTCGCCCCGTTACATAACTTACGGTAAATGGCCCGCCTGG
CTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCC
CATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTA
CGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACG
CCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAG
TACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCAT
CGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATA
GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGG
GAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAAC
TCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTA
TATAAGCAGAGCTCGTTTAGTGAACCGATCCACGCTGTTTTGACCTCCATAG
AAGACACCGGGACCGATCCAGCCTCCGGGGGATCTTGGTGGCGTGAAACT
CCCGCACCTCTTCGGCCAGCGAATTCCAGAAGCCGCCACCATGGCTTCTAG
AGGAGTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCA
AGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGA
AAGAAAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAG
GCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGT
GTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCC
ACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTG
GAGCTTCTAAAACTGGAAACTAGTTATCCGTACGACGTACCAGACTACGCAT
AAGAAAAGTGAGGATCCTGAGAACTTCAGGGTGAGTTTGGGGACCCTTGAT
TGTTCTTTCTTTTTCGCTATTGTAAAATTCATGTTATATGGAGGGGGCAAAGT
TTTCAGGGTGTTGTTTAGAATGGGAAGATGTCCCTTGTATCACCATGGACCC
TCATGATAATTTTGTTTCTTTCACTTTCTACTCTGTTGACAACCATTGTCTCCT
CTTATTTTCTTTTCATTTTCTGTAACTTTTTCGTTAAACTTTAGCTTGCATTTGT
AACGAATTTTTAAATTCACTTTTGTTTATTTGTCAGATTGTAAGTACTTTCTCT
AATCACTTTTTTTTCAAGGCAATCAGGGTATATTATATTGTACTTCAGCACAG
TTTTAGAGAACAATTGTTATAATTAAATGATAAGGTAGAATATTTCTGCATATA
AATTCTGGCTGGCGTGGAAATATTCTTATTGGTAGAAACAACTACATCCTGG
TCATCATCCTGCCTTTCTCTTTATGGTTACAATGATATACACTGTTTGAGATG
AGGATAAAATACTCTGAGTCCAAACCGGGCCCCTCTGCTAACCATGTTCATG
CCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCTGTC
TCATCATTTTGGCAAAGGATTCACTCCTCAGGTGCAGGCTGCCTATCAGAAG
GTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGATCTT
TTTCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGA
CTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTT
TTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTAAAACATC
AGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCCATATGCTGGCTGCC
ATGAACAAAGGTGGCTATAAAGAGGTCATCAGTATATGAAACAGCCCCCTG
CTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGATTTTTTTT
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ATATTTTGTTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACATG
TTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTC
CCTCTTCTCTTATGAAGATCCCTCGAGGAGCTTTTTGCAAAAGCCCTAGGCC
TCCAAAAAAGCCTCTTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCGGC
CTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATG
GGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGG
GACTATGGTTGCTGACTAATTGCTGCATTAATGAATCGGCCAACGCGCGGG
GAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTC
GCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGG
CGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGT
GAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTG
GCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGC
TCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACC
GGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGC
TCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGC
TGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAAC
TATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCA
GCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGA
GTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCT
TGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAG
CAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTT
CTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGG
TCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGA
AGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCA
ATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCC
ATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTA
CCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGC
TCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAA
GTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGA
AGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATT
GCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGC
TCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAA
AAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCC
GCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCA
TGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATT
CTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACG
GGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGCCACC
TCCACCTGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTG
TTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCAT
CTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGC
CGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTT
  
 
   
235 
CCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGAT
ACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTT
CCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAA
CCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTG
ATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTT
GTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGC
GGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGA
TTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAA
GGAGAAAATACCGCATCAGGAAATTGTAAACGTTAATATTTTGTTAAAATTCG
CGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGC
AAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTC
CAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAG
GGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCT
AATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA
AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGA
GAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAG
TGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGC
CGCTACAGGGCGCGTCGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGG
GAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGG
GGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTC
ACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTATAGG 
 
Mouse GFRα3 (signal sequences) 
GGGCTCTCCTGGAGCCCGCGACCTCCACTGCTGATGATCCTGCTACTGGTG
CTGTCGTTGTGGCTGCCACTTGGAGCAGGAAACTCCCTTGCCACAGAGAAC
AGGTTTGTGAACAGCTGTACCCAGGCCAGAAAGAAATGCGAGGCTAATCCC
GCTTGCAAGGCTGCCTACCAGCACCTGGGCTCCTGCACCTCCAGTTTAAGC
AGGCCGCTGCCCTTAGAGGAGTCTGCCATGTCTGCAGACTGCCTAGAGGC
AGCAGAACAACTCAGGAACAGCTCTCTGATAGACTGCAGGTGCCATCGGCG
CATGAAGCACCAAGCTACCTGTCTGGACATTTATTGGACCGTTCACCCTGCC
CGAAGCCTTGGTGACTACGAGTTGGATGTCTCACCCTATGAAGACACAGTG
ACCAGCAAACCCTGGAAAATGAATCTTAGCAAGTTGAACATGCTCAAACCAG
ACTCGGACCTCTGCCTCAAATTTGCTATGCTGTGTACTCTTCACGACAAGTG
TGACCGCCTGCGCAAGGCCTACGGGGAGGCATGCTCAGGGATCCGCTGCC
AGCGCCACCTCTGCCTAGCCCAGCTGCGCTCCTTCTTTGAGAAGGCAGCAG
AGTCCCACGCTCAGGGTCTGCTGCTGTGTCCCTGTGCACCAGAAGATGCG
GGCTGTGGGGAGAGGCGGCGTAACACCATCGCCCCCAGTTGCGCCCTGCC
TTCTGTAACCCCCAATTGCCTGGATCTGCGGAGCTTCTGCCGTGCGGACCC
TTTGTGCAGATCACGCCTGATGGACTTCCAGACCCACTGTCATCCTATGGAC
ATCCTTGGGACTTGTGCAACTGAGCAGTCCAGATGTCTGCGGGCATACCTG
GGGCTGATTGGGACTGCCATGACCCCAAACTTCATCAGCAAGGTCAACACT
ACTGTTGCCTTAAGCTGCTCCTGCCGAGGCAGCGGCAACCTACAGGACGA
GTGTGAACAGCTGGAAAGGTCCTTCTCCCAGAACCCCTGCCTCGTGGAGG
  
 
   
236 
CCATTGCAGCTAAGATGCGTTTCCACAGACAGCTCTTCTCCCAGGACTGGG
CAGACTCTACTTTTTCAGTGGTGCAGCAGCAGAACAGC 
 
FKBP-GFRα3 
ATGGCTTCTAGAGGGCTCTCCTGGAGCCCGCGACCTCCACTGCTGATGATC
CTGCTACTGGTGCTGTCGTTGTGGCTGCCACTTGGAGCAGGATCTAGAGGA
GTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCG
CGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGA
AAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAA
GCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGG
GTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTG
GGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGC
TTCTAAAACTGGAAACTAGTAACTCCCTTGCCACAGAGAACAGGTTTGTGAA
CAGCTGTACCCAGGCCAGAAAGAAATGCGAGGCTAATCCCGCTTGCAAGG
CTGCCTACCAGCACCTGGGCTCCTGCACCTCCAGTTTAAGCAGGCCGCTGC
CCTTAGAGGAGTCTGCCATGTCTGCAGACTGCCTAGAGGCAGCAGAACAAC
TCAGGAACAGCTCTCTGATAGACTGCAGGTGCCATCGGCGCATGAAGCACC
AAGCTACCTGTCTGGACATTTATTGGACCGTTCACCCTGCCCGAAGCCTTG
GTGACTACGAGTTGGATGTCTCACCCTATGAAGACACAGTGACCAGCAAAC
CCTGGAAAATGAATCTTAGCAAGTTGAACATGCTCAAACCAGACTCGGACCT
CTGCCTCAAATTTGCTATGCTGTGTACTCTTCACGACAAGTGTGACCGCCTG
CGCAAGGCCTACGGGGAGGCATGCTCAGGGATCCGCTGCCAGCGCCACCT
CTGCCTAGCCCAGCTGCGCTCCTTCTTTGAGAAGGCAGCAGAGTCCCACGC
TCAGGGTCTGCTGCTGTGTCCCTGTGCACCAGAAGATGCGGGCTGTGGGG
AGAGGCGGCGTAACACCATCGCCCCCAGTTGCGCCCTGCCTTCTGTAACCC
CCAATTGCCTGGATCTGCGGAGCTTCTGCCGTGCGGACCCTTTGTGCAGAT
CACGCCTGATGGACTTCCAGACCCACTGTCATCCTATGGACATCCTTGGGA
CTTGTGCAACTGAGCAGTCCAGATGTCTGCGGGCATACCTGGGGCTGATTG
GGACTGCCATGACCCCAAACTTCATCAGCAAGGTCAACACTACTGTTGCCTT
AAGCTGCTCCTGCCGAGGCAGCGGCAACCTACAGGACGAGTGTGAACAGC
TGGAAAGGTCCTTCTCCCAGAACCCCTGCCTCGTGGAGGCCATTGCAGCTA
AGATGCGTTTCCACAGACAGCTCTTCTCCCAGGACTGGGCAGACTCTACTTT
TTCAGTGGTGCAGCAGCAGAACAGCAACCCTGCTCTGAGACTGCAGCCCA
GGCTACCCATTCTTTCTTTCTCCATCCTTCCCTTGATTCTGCTGCAGACCCT
CTGGTAG 
FKBP-FL14-GFRα3 
ATGGCTTCTAGAGGGCTCTCCTGGAGCCCGCGACCTCCACTGCTGATGATC
CTGCTACTGGTGCTGTCGTTGTGGCTGCCACTTGGAGCAGGATCTAGAGGA
GTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCG
CGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGA
AAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAA
GCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGG
GTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTG
  
 
   
237 
GGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGC
TTCTAAAACTGGAAACTAGTCTTAGCGGCGGCGGCGGCAGCGGCGGCGGC
GGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGCCGCCGCCACT
AGTAACTCCCTTGCCACAGAGAACAGGTTTGTGAACAGCTGTACCCAGGCC
AGAAAGAAATGCGAGGCTAATCCCGCTTGCAAGGCTGCCTACCAGCACCTG
GGCTCCTGCACCTCCAGTTTAAGCAGGCCGCTGCCCTTAGAGGAGTCTGCC
ATGTCTGCAGACTGCCTAGAGGCAGCAGAACAACTCAGGAACAGCTCTCTG
ATAGACTGCAGGTGCCATCGGCGCATGAAGCACCAAGCTACCTGTCTGGAC
ATTTATTGGACCGTTCACCCTGCCCGAAGCCTTGGTGACTACGAGTTGGAT
GTCTCACCCTATGAAGACACAGTGACCAGCAAACCCTGGAAAATGAATCTTA
GCAAGTTGAACATGCTCAAACCAGACTCGGACCTCTGCCTCAAATTTGCTAT
GCTGTGTACTCTTCACGACAAGTGTGACCGCCTGCGCAAGGCCTACGGGG
AGGCATGCTCAGGGATCCGCTGCCAGCGCCACCTCTGCCTAGCCCAGCTG
CGCTCCTTCTTTGAGAAGGCAGCAGAGTCCCACGCTCAGGGTCTGCTGCTG
TGTCCCTGTGCACCAGAAGATGCGGGCTGTGGGGAGAGGCGGCGTAACAC
CATCGCCCCCAGTTGCGCCCTGCCTTCTGTAACCCCCAATTGCCTGGATCT
GCGGAGCTTCTGCCGTGCGGACCCTTTGTGCAGATCACGCCTGATGGACTT
CCAGACCCACTGTCATCCTATGGACATCCTTGGGACTTGTGCAACTGAGCA
GTCCAGATGTCTGCGGGCATACCTGGGGCTGATTGGGACTGCCATGACCC
CAAACTTCATCAGCAAGGTCAACACTACTGTTGCCTTAAGCTGCTCCTGCCG
AGGCAGCGGCAACCTACAGGACGAGTGTGAACAGCTGGAAAGGTCCTTCT
CCCAGAACCCCTGCCTCGTGGAGGCCATTGCAGCTAAGATGCGTTTCCACA
GACAGCTCTTCTCCCAGGACTGGGCAGACTCTACTTTTTCAGTGGTGCAGC
AGCAGAACAGCAACCCTGCTCTGAGACTGCAGCCCAGGCTACCCATTCTTT
CTTTCTCCATCCTTCCCTTGATTCTGCTGCAGACCCTCTGGTAG 
 
FKPB-HL2-GFRα3 
ATGGCTTCTAGAGGGCTCTCCTGGAGCCCGCGACCTCCACTGCTGATGATC
CTGCTACTGGTGCTGTCGTTGTGGCTGCCACTTGGAGCAGGATCTAGAGGA
GTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCG
CGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGA
AAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAA
GCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGG
GTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTG
GGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGC
TTCTAAAACTGGAAACTAGTCTTGCCGAAGCCGCCGCCAAGGAAGCCGCCG
CCAAGGCCGCCGCCACTAGTAACTCCCTTGCCACAGAGAACAGGTTTGTGA
ACAGCTGTACCCAGGCCAGAAAGAAATGCGAGGCTAATCCCGCTTGCAAGG
CTGCCTACCAGCACCTGGGCTCCTGCACCTCCAGTTTAAGCAGGCCGCTGC
CCTTAGAGGAGTCTGCCATGTCTGCAGACTGCCTAGAGGCAGCAGAACAAC
TCAGGAACAGCTCTCTGATAGACTGCAGGTGCCATCGGCGCATGAAGCACC
AAGCTACCTGTCTGGACATTTATTGGACCGTTCACCCTGCCCGAAGCCTTG
GTGACTACGAGTTGGATGTCTCACCCTATGAAGACACAGTGACCAGCAAAC
  
 
   
238 
CCTGGAAAATGAATCTTAGCAAGTTGAACATGCTCAAACCAGACTCGGACCT
CTGCCTCAAATTTGCTATGCTGTGTACTCTTCACGACAAGTGTGACCGCCTG
CGCAAGGCCTACGGGGAGGCATGCTCAGGGATCCGCTGCCAGCGCCACCT
CTGCCTAGCCCAGCTGCGCTCCTTCTTTGAGAAGGCAGCAGAGTCCCACGC
TCAGGGTCTGCTGCTGTGTCCCTGTGCACCAGAAGATGCGGGCTGTGGGG
AGAGGCGGCGTAACACCATCGCCCCCAGTTGCGCCCTGCCTTCTGTAACCC
CCAATTGCCTGGATCTGCGGAGCTTCTGCCGTGCGGACCCTTTGTGCAGAT
CACGCCTGATGGACTTCCAGACCCACTGTCATCCTATGGACATCCTTGGGA
CTTGTGCAACTGAGCAGTCCAGATGTCTGCGGGCATACCTGGGGCTGATTG
GGACTGCCATGACCCCAAACTTCATCAGCAAGGTCAACACTACTGTTGCCTT
AAGCTGCTCCTGCCGAGGCAGCGGCAACCTACAGGACGAGTGTGAACAGC
TGGAAAGGTCCTTCTCCCAGAACCCCTGCCTCGTGGAGGCCATTGCAGCTA
AGATGCGTTTCCACAGACAGCTCTTCTCCCAGGACTGGGCAGACTCTACTTT
TTCAGTGGTGCAGCAGCAGAACAGCAACCCTGCTCTGAGACTGCAGCCCA
GGCTACCCATTCTTTCTTTCTCCATCCTTCCCTTGATTCTGCTGCAGACCCT
CTGGTAG 
 
mYPet 
GTGAGCAAAGGCGAAGAGCTGTTCACCGGCGTGGTGCCCATCCTGGTGGA
GCTGGACGGCGACGTGAACGGCCACAAGTTCAGCGTGAGCGGCGAGGGC
GAGGGCGACGCCACCTACGGCAAGCTGACCCTGAAGCTGCTGTGCACCAC
CGGCAAGCTGCCCGTGCCCTGGCCCACCCTGGTGACCACCCTGGGCTACG
GCGTGCAGTGCTTCGCCCGGTACCCCGACCACATGAAGCAGCACGACTTC
TTCAAGAGCGCCATGCCCGAGGGCTACGTGCAGGAGCGGACCATCTTCTT
CAAGGACGACGGCAACTACAAGACCCGGGCCGAGGTGAAGTTCGAGGGCG
ACACCCTGGTGAACCGGATCGAGCTGAAGGGCATCGACTTCAAGGAGGAC
GGCAACATCCTGGGCCACAAGCTGGAGTACAACTACAACAGCCACAACGTG
TACATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATC
CGGCACAACATCGAGGACGGCGGCGTGCAGCTGGCCGACCACTACCAGCA
GAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACC
TGAGCTACCAGAGCAAGCTGTTCAAGGACCCCAACGAGAAGCGGGACCAC
ATGGTGCTGCTGGAGTTCCTGACCGCCGCCGGCATCACCGAGGGCATGAA
CGAGCTCTATAAGTAA 
 
mCerulean 
GTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGA
GCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGC
GAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCAC
CGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTGGG
GCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCT
TCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCA
AGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGAC
ACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGG
  
 
   
239 
CAACATCCTGGGGCACAAGCTGGAGTACAACGCCATCAGCGACAACGTCTA
TATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCG
CCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGA
ACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTG
AGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGATCACAT
GGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACG
AGCTGTACAAGT 
 
Full-length β-gal 
ATGACCATGATTACGGATTCTCTGGCCGTCGTTTTACAACGTCGTGACTGGG
AAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGC
CAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGT
TGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGGTTTCCGGCACCAGAA
GCGGTGCCGGAAAGCTGGCTGGAGTGCGATCTTCCTGAGGCCGATACTGT
CGTCGTCCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATCTACAC
CAACGTAACCTATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAAT
CCGACGGGTTGTTACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGG
AAGGCCAGACGCGAATTATTTTTGATGGCGTTAACTCGGCGTTTCATCTGTG
GTGCAACGGGCGCTGGGTCGGTTACGGCCAGGACAGTCGTTTGCCGTCTG
AATTTGACCTGAGCGCATTTTTACGCGCCGGAGAAAACCGCCTCGCGGTGA
TGGTGCTGCGTTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATGTGGC
GGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACAC
AAATCAGCGATTTCCATGTTGCCACTCGCTTTAATGATGATTTCAGCCGCGC
TGTACTGGAGGCTGAAGTTCAGATGTGCGGCGAGTTGCGTGACTACCTACG
GGTAACAGTTTCTTTATGGCAGGGTGAAACGCAGGTCGCCAGCGGCACCG
CGCCTTTCGGCGGTGAAATTATCGATGAGCGTGGTGGTTATGCCGATCGCG
TCACACTACGTCTGAACGTCGAAAACCCGAAACTGTGGAGCGCCGAAATCC
CGAATCTCTATCGTGCGGTGGTTGAACTGCACACCGCCGACGGCACGCTG
ATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGAGGTGCGGATTGAAAAT
GGTCTGCTGCTGCTGAACGGCAAGCCGTTGCTGATTCGAGGCGTTAACCGT
CACGAGCATCATCCTCTGCATGGTCAGGTCATGGATGAGCAGACGATGGTG
CAGGATATCCTGCTGATGAAGCAGAACAACTTTAACGCCGTGCGCTGTTCG
CATTATCCGAACCATCCGCTGTGGTACACGCTGTGCGACCGCTACGGCCTG
TATGTGGTGGATGAAGCCAATATTGAAACCCACGGCATGGTGCCAATGAAT
CGTCTGACCGATGATCCGCGCTGGCTACCGGCGATGAGCGAACGCGTAAC
GCGAATGGTGCAGCGCGATCGTAATCACCCGAGTGTGATCATCTGGTCGCT
GGGGAATGAATCAGGCCACGGCGCTAATCACGACGCGCTGTATCGCTGGA
TCAAATCTGTCGATCCTTCCCGCCCGGTGCAGTATGAAGGCGGCGGAGCC
GACACCACGGCCACCGATATTATTTGCCCGATGTACGCGCGCGTGGATGAA
GACCAGCCCTTCCCGGCTGTGCCGAAATGGTCCATCAAAAAATGGCTTTCG
CTACCTGGAGAGACGCGCCCGCTGATCCTTTGCGAATACGCCCACGCGAT
GGGTAACAGTCTTGGCGGTTTCGCTAAATACTGGCAGGCGTTTCGTCAGTA
TCCCCGTTTACAGGGCGGCTTCGTCTGGGACTGGGTGGATCAGTCGCTGAT
  
 
   
240 
TAAATATGATGAAAACGGCAACCCGTGGTCGGCTTACGGCGGTGATTTTGG
CGATACGCCGAACGATCGCCAGTTCTGTATGAACGGTCTGGTCTTTGCCGA
CCGCACGCCGCATCCAGCGCTGACGGAAGCAAAACACCAGCAGCAGTTTTT
CCAGTTCCGTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATACCTGTT
CCGTCATAGCGATAACGAGCTCCTGCACTGGATGGTGGCGCTGGATGGTAA
GCCGCTGGCAAGCGGTGAAGTGCCTCTGGATGTCGCTCCACAAGGTAAAC
AGTTGATTGAACTGCCTGAACTACCGCAGCCGGAGAGCGCCGGGCAACTC
TGGCTCACAGTACGCGTAGTGCAACCGAACGCGACCGCATGGTCAGAAGC
CGGGCACATCAGCGCCTGGCAGCAGTGGCGTCTGGCGGAAAACCTCAGTG
TGACGCTCCCCGCCGCGTCCCACGCCATCCCGCATCTGACCACCAGCGAA
ATGGATTTTTGCATCGAGCTGGGTAATAAGCGTTGGCAATTTAACCGCCAGT
CAGGCTTTCTTTCACAGATGTGGATTGGCGATAAAAAACAACTGCTGACGCC
GCTGCGCGATCAGTTCACCCGTGCACCGCTGGATAACGACATTGGCGTAAG
TGAAGCGACCCGCATTGACCCTAACGCCTGGGTCGAACGCTGGAAGGCGG
CGGGCCATTACCAGGCCGAAGCAGCGTTGTTGCAGTGCACGGCAGATACA
CTTGCTGATGCGGTGCTGATTACGACCGCTCACGCGTGGCAGCATCAGGG
GAAAACCTTATTTATCAGCCGGAAAACCTACCGGATTGATGGTAGTGGTCAA
ATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGATACACCGCATCCGGCG
CGGATTGGCCTGAACTGCCAGCTGGCGCAGGTAGCAGAGCGGGTAAACTG
GCTCGGATTAGGGCCGCAAGAAAACTATCCCGACCGCCTTACTGCCGCCTG
TTTTGACCGCTGGGATCTGCCATTGTCAGACATGTATACCCCGTACGTCTTC
CCGAGCGAAAACGGTCTGCGCTGCGGGACGCGCGAATTGAATTATGGCCC
ACACCAGTGGCGCGGCGACTTCCAGTTCAACATCAGCCGCTACAGTCAACA
GCAACTGATGGAAACCAGCCATCGCCATCTGCTGCACGCGGAAGAAGGCA
CATGGCTGAATATCGACGGTTTCCATATGGGGATTGGTGGCGACGACTCCT
GGAGCCCGTCAGTATCGGCGGAATTACAGCTGAGCGCCGGTCGCTACCAT
TACCAGTTGGTCTGGTGTCAAAAATAA 
 
FKBP-β-galΔα-GFRα3 
ATGGCTTCTAGAGGGCTCTCCTGGAGCCCGCGACCTCCACTGCTGATGATC
CTGCTACTGGTGCTGTCGTTGTGGCTGCCACTTGGAGCAGGATCTAGAGGA
GTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCG
CGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGA
AAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAA
GCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGG
GTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTG
GGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGC
TTCTAAAACTGGAAACTAGTACCATGATTACGGATTCTCTGGCCGTCGTTGA
AGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCG
AATGGCGCTTTGCCTGGTTTCCGGCACCAGAAGCGGTGCCGGAAAGCTGG
CTGGAGTGCGATCTTCCTGAGGCCGATACTGTCGTCGTCCCCTCAAACTGG
CAGATGCACGGTTACGATGCGCCCATCTACACCAACGTAACCTATCCCATTA
CGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTTGTTACTCGC
  
 
   
241 
TCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTAT
TTTTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGGGT
CGGTTACGGCCAGGACAGTCGTTTGCCGTCTGAATTTGACCTGAGCGCATT
TTTACGCGCCGGAGAAAACCGCCTCGCGGTGATGGTGCTGCGTTGGAGTG
ACGGCAGTTATCTGGAAGATCAGGATATGTGGCGGATGAGCGGCATTTTCC
GTGACGTCTCGTTGCTGCATAAACCGACTACACAAATCAGCGATTTCCATGT
TGCCACTCGCTTTAATGATGATTTCAGCCGCGCTGTACTGGAGGCTGAAGTT
CAGATGTGCGGCGAGTTGCGTGACTACCTACGGGTAACAGTTTCTTTATGG
CAGGGTGAAACGCAGGTCGCCAGCGGCACCGCGCCTTTCGGCGGTGAAAT
TATCGATGAGCGTGGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGT
CGAAAACCCGAAACTGTGGAGCGCCGAAATCCCGAATCTCTATCGTGCGGT
GGTTGAACTGCACACCGCCGACGGCACGCTGATTGAAGCAGAAGCCTGCG
ATGTCGGTTTCCGCGAGGTGCGGATTGAAAATGGTCTGCTGCTGCTGAACG
GCAAGCCGTTGCTGATTCGAGGCGTTAACCGTCACGAGCATCATCCTCTGC
ATGGTCAGGTCATGGATGAGCAGACGATGGTGCAGGATATCCTGCTGATGA
AGCAGAACAACTTTAACGCCGTGCGCTGTTCGCATTATCCGAACCATCCGC
TGTGGTACACGCTGTGCGACCGCTACGGCCTGTATGTGGTGGATGAAGCCA
ATATTGAAACCCACGGCATGGTGCCAATGAATCGTCTGACCGATGATCCGC
GCTGGCTACCGGCGATGAGCGAACGCGTAACGCGAATGGTGCAGCGCGAT
CGTAATCACCCGAGTGTGATCATCTGGTCGCTGGGGAATGAATCAGGCCAC
GGCGCTAATCACGACGCGCTGTATCGCTGGATCAAATCTGTCGATCCTTCC
CGCCCGGTGCAGTATGAAGGCGGCGGAGCCGACACCACGGCCACCGATAT
TATTTGCCCGATGTACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGT
GCCGAAATGGTCCATCAAAAAATGGCTTTCGCTACCTGGAGAGACGCGCCC
GCTGATCCTTTGCGAATACGCCCACGCGATGGGTAACAGTCTTGGCGGTTT
CGCTAAATACTGGCAGGCGTTTCGTCAGTATCCCCGTTTACAGGGCGGCTT
CGTCTGGGACTGGGTGGATCAGTCGCTGATTAAATATGATGAAAACGGCAA
CCCGTGGTCGGCTTACGGCGGTGATTTTGGCGATACGCCGAACGATCGCC
AGTTCTGTATGAACGGTCTGGTCTTTGCCGACCGCACGCCGCATCCAGCGC
TGACGGAAGCAAAACACCAGCAGCAGTTTTTCCAGTTCCGTTTATCCGGGC
AAACCATCGAAGTGACCAGCGAATACCTGTTCCGTCATAGCGATAACGAGC
TCCTGCACTGGATGGTGGCGCTGGATGGTAAGCCGCTGGCAAGCGGTGAA
GTGCCTCTGGATGTCGCTCCACAAGGTAAACAGTTGATTGAACTGCCTGAA
CTACCGCAGCCGGAGAGCGCCGGGCAACTCTGGCTCACAGTACGCGTAGT
GCAACCGAACGCGACCGCATGGTCAGAAGCCGGGCACATCAGCGCCTGGC
AGCAGTGGCGTCTGGCGGAAAACCTCAGTGTGACGCTCCCCGCCGCGTCC
CACGCCATCCCGCATCTGACCACCAGCGAAATGGATTTTTGCATCGAGCTG
GGTAATAAGCGTTGGCAATTTAACCGCCAGTCAGGCTTTCTTTCACAGATGT
GGATTGGCGATAAAAAACAACTGCTGACGCCGCTGCGCGATCAGTTCACCC
GTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGCATTGACC
CTAACGCCTGGGTCGAACGCTGGAAGGCGGCGGGCCATTACCAGGCCGAA
GCAGCGTTGTTGCAGTGCACGGCAGATACACTTGCTGATGCGGTGCTGATT
ACGACCGCTCACGCGTGGCAGCATCAGGGGAAAACCTTATTTATCAGCCGG
  
 
   
242 
AAAACCTACCGGATTGATGGTAGTGGTCAAATGGCGATTACCGTTGATGTTG
AAGTGGCGAGCGATACACCGCATCCGGCGCGGATTGGCCTGAACTGCCAG
CTGGCGCAGGTAGCAGAGCGGGTAAACTGGCTCGGATTAGGGCCGCAAGA
AAACTATCCCGACCGCCTTACTGCCGCCTGTTTTGACCGCTGGGATCTGCC
ATTGTCAGACATGTATACCCCGTACGTCTTCCCGAGCGAAAACGGTCTGCG
CTGCGGGACGCGCGAATTGAATTATGGCCCACACCAGTGGCGCGGCGACT
TCCAGTTCAACATCAGCCGCTACAGTCAACAGCAACTGATGGAAACCAGCC
ATCGCCATCTGCTGCACGCGGAAGAAGGCACATGGCTGAATATCGACGGTT
TCCATATGGGGATTGGTGGCGACGACTCCTGGAGCCCGTCAGTATCGGCG
GAATTACAGCTGAGCGCCGGTCGCTACCATTACCAGTTGGTCTGGTGTCAA
AAAACTAGTAACTCCCTTGCCACAGAGAACAGGTTTGTGAACAGCTGTACCC
AGGCCAGAAAGAAATGCGAGGCTAATCCCGCTTGCAAGGCTGCCTACCAG
CACCTGGGCTCCTGCACCTCCAGTTTAAGCAGGCCGCTGCCCTTAGAGGAG
TCTGCCATGTCTGCAGACTGCCTAGAGGCAGCAGAACAACTCAGGAACAGC
TCTCTGATAGACTGCAGGTGCCATCGGCGCATGAAGCACCAAGCTACCTGT
CTGGACATTTATTGGACCGTTCACCCTGCCCGAAGCCTTGGTGACTACGAG
TTGGATGTCTCACCCTATGAAGACACAGTGACCAGCAAACCCTGGAAAATG
AATCTTAGCAAGTTGAACATGCTCAAACCAGACTCGGACCTCTGCCTCAAAT
TTGCTATGCTGTGTACTCTTCACGACAAGTGTGACCGCCTGCGCAAGGCCT
ACGGGGAGGCATGCTCAGGGATCCGCTGCCAGCGCCACCTCTGCCTAGCC
CAGCTGCGCTCCTTCTTTGAGAAGGCAGCAGAGTCCCACGCTCAGGGTCTG
CTGCTGTGTCCCTGTGCACCAGAAGATGCGGGCTGTGGGGAGAGGCGGCG
TAACACCATCGCCCCCAGTTGCGCCCTGCCTTCTGTAACCCCCAATTGCCT
GGATCTGCGGAGCTTCTGCCGTGCGGACCCTTTGTGCAGATCACGCCTGAT
GGACTTCCAGACCCACTGTCATCCTATGGACATCCTTGGGACTTGTGCAACT
GAGCAGTCCAGATGTCTGCGGGCATACCTGGGGCTGATTGGGACTGCCAT
GACCCCAAACTTCATCAGCAAGGTCAACACTACTGTTGCCTTAAGCTGCTCC
TGCCGAGGCAGCGGCAACCTACAGGACGAGTGTGAACAGCTGGAAAGGTC
CTTCTCCCAGAACCCCTGCCTCGTGGAGGCCATTGCAGCTAAGATGCGTTT
CCACAGACAGCTCTTCTCCCAGGACTGGGCAGACTCTACTTTTTCAGTGGT
GCAGCAGCAGAACAGCAACCCTGCTCTGAGACTGCAGCCCAGGCTACCCA
TTCTTTCTTTCTCCATCCTTCCCTTGATTCTGCTGCAGACCCTCTGGTAG 
 
FKBP-β-galΔω-GFRα3 
ATGGCTTCTAGAGGGCTCTCCTGGAGCCCGCGACCTCCACTGCTGATGATC
CTGCTACTGGTGCTGTCGTTGTGGCTGCCACTTGGAGCAGGATCTAGAGGA
GTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCG
CGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGA
AAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAA
GCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGG
GTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTG
GGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGC
TTCTAAAACTGGAAACTAGTACCATGATTACGGATTCTCTGGCCGTCGTTTT
  
 
   
243 
ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGC
AGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCG
ATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCT
GGTTTCCGGCACCAGAAGCGGTGCCGGAAAGCTGGCTGGAGTGCGATCTT
CCTGAGGCCGATACTGTCGTCGTCCCCTCAAACTGGCAGATGCACGGTTAC
GATGCGCCCATCTACACCAACGTAACCTATCCCATTACGGTCAATCCGCCG
TTTGTTCCCACGGAGAATCCGACGGGTTGTTACTCGCTCACATTTAATGTTG
ATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTATTTTTGATGGCGTTA
ACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGGGTCGGTTACGGCCAG
GACAGTCGTTTGCCGTCTGAATTTGACCTGAGCGCATTTTTACGCGCCGGA
GAAAACCGCCTCGCGGTGATGGTGCTGCGTTGGAGTGACGGCAGTTATCT
GGAAGATCAGGATATGTGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTT
GCTGCATAAACCGACTACACAAATCAGCGATTTCCATGTTGCCACTCGCTTT
AATGATGATTTCAGCCGCGCTGTACTGGAGGCTGAAGTTCAGATGTGCGGC
GAGTTGCGTGACTACCTACGGGTAACAGTTTCTTTATGGCAGGGTGAAACG
CAGGTCGCCAGCGGCACCGCGCCTTTCGGCGGTGAAATTATCGATGAGCG
TGGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGTCGAAAACCCGAA
ACTGTGGAGCGCCGAAATCCCGAATCTCTATCGTGCGGTGGTTGAACTGCA
CACCGCCGACGGCACGCTGATTGAAGCAGAAGCCTGCGATGTCGGTTTCC
GCGAGGTGCGGATTGAAAATGGTCTGCTGCTGCTGAACGGCAAGCCGTTG
CTGATTCGAGGCGTTAACCGTCACGAGCATCATCCTCTGCATGGTCAGGTC
ATGGATGAGCAGACGATGGTGCAGGATATCCTGCTGATGAAGCAGAACAAC
TTTAACGCCGTGCGCTGTTCGCATTATCCGAACCATCCGCTGTGGTACACG
CTGTGCGACCGCTACGGCCTGTATGTGGTGGATGAAGCCAATATTGAAACC
CACGGCATGGTGCCAATGAATCGTCTGACCGATGATCCGCGCTGGCTACC
GGCGATGAGCGAACGCGTAACGCGAATGGTGCAGCGCGATCGTAATCACC
CGAGTGTGATCATCTGGTCGCTGGGGAATGAATCAGGCCACGGCGCTAATC
ACGACGCGCTGTATCGCTGGATCAAATCTGTCGATCCTTCCCGCCCGGTGC
AGTATGAAGGCGGCGGAGCCGACACCACGGCCACCGATATTATTTGCCCG
ATGTACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGTGCCGAAATG
GTCCATCAAAAAATGGCTTTCGCTACCTGGAGAGACGCGCCCGCTGATCCT
TTGCGAATACGCCCACGCGATGGGTAACAGTCTTGGCGGTTTCGCTAAATA
CTGGCAGGCGTTTCGTCAGTATCCCCGTTTACAGGGCGGCTTCGTCTGGGA
CTGGGTGGATCAGTCGCTGATTAAATATGATGAAAACGGCAACCCGTGGTC
GGCTTACGGCGGTGATTTTGGCGATACGCCGAACGATCGCCAGTTCTGTAT
GAACGGTCTGGTCTTTGCCGACCGCACGCCGCATCCAGCGCTGACGGAAG
CAAAACACCAGCAGCAGTTTTTCCAGTTCCGTTTATCCGGGCAAACCATCGA
AGTGACCAGCGAATACCTGTTCCGTCATAGCGATAACGAGCTCCTGCACTG
GATGGTGGCGCTGGATGGTAAGCCGCTGGCAAGCGGTGAAGTGCCTCTGG
ATGTCGCTCCACAAGGTAAACAGTTGATTGAACTGCCTGAACTACCGCAGC
CGGAGAGCGCCGGGCAACTCTGGCTCACAGTACGCGTAGTGCAACCGAAC
GCGACCGCATGGTCAGAAGCCGGGCACATCAGCGCCTGGCAGCAGTGGC
GTCTGGCGGAAAACCTCAGTGTGACGCTCCCCGCCGCGTCCCACGCCATC
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CCGCATCTGACCACCAGCGAAATGGATTTTTGCATCGAGCTGGGTAATAAG
CGTTGGCAATTTAACCGCCAGTCAGGCTTTCTTTCACAGATGTGGATTGGCG
ATAAAAAACAACTGCTGACGCCGCTGCGCGATCAGTTCACCCGTGCACCGC
TGGATAACGACATTGGCGTAAGTGAAGCGACCCGCATTGACCCTAACGCCT
GGGTCGAACGCTGGAAGGCGGCGGGCCATTACCAGGCCGAAGCAGCGTT
GTTGCAGTGCACGGCAGATACACTTGCTGATGCGGTGCTGATTACGACCGC
TCACGCGTGGCAGCATCAGGGGAAAACCTTATTTATCAGCCGGAAAACCTA
CCGGATTGATGGTAGTGGTCAAATGGCGATTACCGTTGATGTTGAAGTGGC
GAGCGATACACCGCATCCGGCGCGGATTGGCCTGAACTGCCAGCTGGCGC
AGGTAGCAGAGCGGGTAAACTGGCTCGGATTAGGGCCGCAAGAAAACTAT
CCCGACCGCCTTACTGCCGCCTGTTTTGACCGCTGGGATCTGCCATTGTCA
GACATGTATACCCCGTACGTCTTCCCGAGCGAAAACGGTCTGCGCTGCGG
GACGCGCGAATTGAATACTAGTAACTCCCTTGCCACAGAGAACAGGTTTGT
GAACAGCTGTACCCAGGCCAGAAAGAAATGCGAGGCTAATCCCGCTTGCAA
GGCTGCCTACCAGCACCTGGGCTCCTGCACCTCCAGTTTAAGCAGGCCGCT
GCCCTTAGAGGAGTCTGCCATGTCTGCAGACTGCCTAGAGGCAGCAGAACA
ACTCAGGAACAGCTCTCTGATAGACTGCAGGTGCCATCGGCGCATGAAGCA
CCAAGCTACCTGTCTGGACATTTATTGGACCGTTCACCCTGCCCGAAGCCTT
GGTGACTACGAGTTGGATGTCTCACCCTATGAAGACACAGTGACCAGCAAA
CCCTGGAAAATGAATCTTAGCAAGTTGAACATGCTCAAACCAGACTCGGAC
CTCTGCCTCAAATTTGCTATGCTGTGTACTCTTCACGACAAGTGTGACCGCC
TGCGCAAGGCCTACGGGGAGGCATGCTCAGGGATCCGCTGCCAGCGCCAC
CTCTGCCTAGCCCAGCTGCGCTCCTTCTTTGAGAAGGCAGCAGAGTCCCAC
GCTCAGGGTCTGCTGCTGTGTCCCTGTGCACCAGAAGATGCGGGCTGTGG
GGAGAGGCGGCGTAACACCATCGCCCCCAGTTGCGCCCTGCCTTCTGTAA
CCCCCAATTGCCTGGATCTGCGGAGCTTCTGCCGTGCGGACCCTTTGTGCA
GATCACGCCTGATGGACTTCCAGACCCACTGTCATCCTATGGACATCCTTG
GGACTTGTGCAACTGAGCAGTCCAGATGTCTGCGGGCATACCTGGGGCTG
ATTGGGACTGCCATGACCCCAAACTTCATCAGCAAGGTCAACACTACTGTTG
CCTTAAGCTGCTCCTGCCGAGGCAGCGGCAACCTACAGGACGAGTGTGAA
CAGCTGGAAAGGTCCTTCTCCCAGAACCCCTGCCTCGTGGAGGCCATTGCA
GCTAAGATGCGTTTCCACAGACAGCTCTTCTCCCAGGACTGGGCAGACTCT
ACTTTTTCAGTGGTGCAGCAGCAGAACAGCAACCCTGCTCTGAGACTGCAG
CCCAGGCTACCCATTCTTTCTTTCTCCATCCTTCCCTTGATTCTGCTGCAGA
CCCTCTGGTAG 
 
FKBP-mCerulean-GFRα3 
ATGGCTTCTAGAGGGCTCTCCTGGAGCCCGCGACCTCCACTGCTGATGATC
CTGCTACTGGTGCTGTCGTTGTGGCTGCCACTTGGAGCAGGATCTAGAGGA
GTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCG
CGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGA
AAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAA
GCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGG
  
 
   
245 
GTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTG
GGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGC
TTCTAAAACTGGAAACTAGTGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCC
TGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC
GTGACCACCCTGACCTGGGGCGTGCAGTGCTTCGCCCGCTACCCCGACCA
CATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
CGCCATCAGCGACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCAT
CAAGGCCAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGC
TCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTG
CTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCC
AACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGG
GATCACTCTCGGCATGGACGAGCTGTACACTAGTAACTCCCTTGCCACAGA
GAACAGGTTTGTGAACAGCTGTACCCAGGCCAGAAAGAAATGCGAGGCTAA
TCCCGCTTGCAAGGCTGCCTACCAGCACCTGGGCTCCTGCACCTCCAGTTT
AAGCAGGCCGCTGCCCTTAGAGGAGTCTGCCATGTCTGCAGACTGCCTAGA
GGCAGCAGAACAACTCAGGAACAGCTCTCTGATAGACTGCAGGTGCCATCG
GCGCATGAAGCACCAAGCTACCTGTCTGGACATTTATTGGACCGTTCACCC
TGCCCGAAGCCTTGGTGACTACGAGTTGGATGTCTCACCCTATGAAGACAC
AGTGACCAGCAAACCCTGGAAAATGAATCTTAGCAAGTTGAACATGCTCAAA
CCAGACTCGGACCTCTGCCTCAAATTTGCTATGCTGTGTACTCTTCACGACA
AGTGTGACCGCCTGCGCAAGGCCTACGGGGAGGCATGCTCAGGGATCCGC
TGCCAGCGCCACCTCTGCCTAGCCCAGCTGCGCTCCTTCTTTGAGAAGGCA
GCAGAGTCCCACGCTCAGGGTCTGCTGCTGTGTCCCTGTGCACCAGAAGAT
GCGGGCTGTGGGGAGAGGCGGCGTAACACCATCGCCCCCAGTTGCGCCC
TGCCTTCTGTAACCCCCAATTGCCTGGATCTGCGGAGCTTCTGCCGTGCGG
ACCCTTTGTGCAGATCACGCCTGATGGACTTCCAGACCCACTGTCATCCTAT
GGACATCCTTGGGACTTGTGCAACTGAGCAGTCCAGATGTCTGCGGGCATA
CCTGGGGCTGATTGGGACTGCCATGACCCCAAACTTCATCAGCAAGGTCAA
CACTACTGTTGCCTTAAGCTGCTCCTGCCGAGGCAGCGGCAACCTACAGGA
CGAGTGTGAACAGCTGGAAAGGTCCTTCTCCCAGAACCCCTGCCTCGTGGA
GGCCATTGCAGCTAAGATGCGTTTCCACAGACAGCTCTTCTCCCAGGACTG
GGCAGACTCTACTTTTTCAGTGGTGCAGCAGCAGAACAGCAACCCTGCTCT
GAGACTGCAGCCCAGGCTACCCATTCTTTCTTTCTCCATCCTTCCCTTGATT
CTGCTGCAGACCCTCTGGTAG 
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FKBP-mYPet-GFRα3 
ATGGCTTCTAGAGGGCTCTCCTGGAGCCCGCGACCTCCACTGCTGATGATC
CTGCTACTGGTGCTGTCGTTGTGGCTGCCACTTGGAGCAGGATCTAGAGGA
GTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCG
CGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGA
AAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAA
GCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGG
GTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTG
GGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGC
TTCTAAAACTGGAAACTAGTGTGAGCAAAGGCGAAGAGCTGTTCACCGGCG
TGGTGCCCATCCTGGTGGAGCTGGACGGCGACGTGAACGGCCACAAGTTC
AGCGTGAGCGGCGAGGGCGAGGGCGACGCCACCTACGGCAAGCTGACCC
TGAAGCTGCTGTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTG
GTGACCACCCTGGGCTACGGCGTGCAGTGCTTCGCCCGGTACCCCGACCA
CATGAAGCAGCACGACTTCTTCAAGAGCGCCATGCCCGAGGGCTACGTGC
AGGAGCGGACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGGGCC
GAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGGATCGAGCTGAAGGG
CATCGACTTCAAGGAGGACGGCAACATCCTGGGCCACAAGCTGGAGTACAA
CTACAACAGCCACAACGTGTACATCACCGCCGACAAGCAGAAGAACGGCAT
CAAGGCCAACTTCAAGATCCGGCACAACATCGAGGACGGCGGCGTGCAGC
TGGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTG
CTGCCCGACAACCACTACCTGAGCTACCAGAGCAAGCTGTTCAAGGACCCC
AACGAGAAGCGGGACCACATGGTGCTGCTGGAGTTCCTGACCGCCGCCGG
CATCACCGAGGGCATGAACGAGCTCTATAAGACTAGTAACTCCCTTGCCAC
AGAGAACAGGTTTGTGAACAGCTGTACCCAGGCCAGAAAGAAATGCGAGGC
TAATCCCGCTTGCAAGGCTGCCTACCAGCACCTGGGCTCCTGCACCTCCAG
TTTAAGCAGGCCGCTGCCCTTAGAGGAGTCTGCCATGTCTGCAGACTGCCT
AGAGGCAGCAGAACAACTCAGGAACAGCTCTCTGATAGACTGCAGGTGCCA
TCGGCGCATGAAGCACCAAGCTACCTGTCTGGACATTTATTGGACCGTTCA
CCCTGCCCGAAGCCTTGGTGACTACGAGTTGGATGTCTCACCCTATGAAGA
CACAGTGACCAGCAAACCCTGGAAAATGAATCTTAGCAAGTTGAACATGCTC
AAACCAGACTCGGACCTCTGCCTCAAATTTGCTATGCTGTGTACTCTTCACG
ACAAGTGTGACCGCCTGCGCAAGGCCTACGGGGAGGCATGCTCAGGGATC
CGCTGCCAGCGCCACCTCTGCCTAGCCCAGCTGCGCTCCTTCTTTGAGAAG
GCAGCAGAGTCCCACGCTCAGGGTCTGCTGCTGTGTCCCTGTGCACCAGA
AGATGCGGGCTGTGGGGAGAGGCGGCGTAACACCATCGCCCCCAGTTGCG
CCCTGCCTTCTGTAACCCCCAATTGCCTGGATCTGCGGAGCTTCTGCCGTG
CGGACCCTTTGTGCAGATCACGCCTGATGGACTTCCAGACCCACTGTCATC
CTATGGACATCCTTGGGACTTGTGCAACTGAGCAGTCCAGATGTCTGCGGG
CATACCTGGGGCTGATTGGGACTGCCATGACCCCAAACTTCATCAGCAAGG
TCAACACTACTGTTGCCTTAAGCTGCTCCTGCCGAGGCAGCGGCAACCTAC
AGGACGAGTGTGAACAGCTGGAAAGGTCCTTCTCCCAGAACCCCTGCCTCG
TGGAGGCCATTGCAGCTAAGATGCGTTTCCACAGACAGCTCTTCTCCCAGG
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ACTGGGCAGACTCTACTTTTTCAGTGGTGCAGCAGCAGAACAGCAACCCTG
CTCTGAGACTGCAGCCCAGGCTACCCATTCTTTCTTTCTCCATCCTTCCCTT
GATTCTGCTGCAGACCCTCTGGTAG 
 
Human RET-FKBP 
ATGGCTTCTAGAGCGAAGGCGACGTCCGGTGCCGCGGGGCTGCGTCTGCT
GTTGCTGCTGCTGCTGCCGCTGCTAGGCAAAGTGGCATTGGGCCTCTACTT
CTCGAGGGATGCTTACTGGGAGAAGCTGTATGTGGACCAGGCGGCCGGCA
CGCCCTTGCTGTACGTCCATGCCCTGCGGGACGCCCCTGAGGAGGTGCCC
AGCTTCCGCCTGGGCCAGCATCTCTACGGCACGTACCGCACACGGCTGCA
TGAGAACAACTGGATCTGCATCCAGGAGGACACCGGCCTCCTCTACCTTAA
CCGGAGCCTGGACCATAGCTCCTGGGAGAAGCTCAGTGTCCGCAACCGCG
GCTTTCCCCTGCTCACCGTCTACCTCAAGGTCTTCCTGTCACCCACATCCCT
TCGTGAGGGCGAGTGCCAGTGGCCAGGCTGTGCCCGCGTATACTTCTCCTT
CTTCAACACCTCCTTTCCAGCCTGCAGCTCCCTCAAGCCCCGGGAGCTCTG
CTTCCCAGAGACAAGGCCCTCCTTCCGCATTCGGGAGAACCGACCCCCAG
GCACCTTCCACCAGTTCCGCCTGCTGCCTGTGCAGTTCTTGTGCCCCAACA
TCAGCGTGGCCTACAGGCTCCTGGAGGGTGAGGGTCTGCCCTTCCGCTGC
GCCCCGGACAGCCTGGAGGTGAGCACGCGCTGGGCCCTGGACCGCGAGC
AGCGGGAGAAGTACGAGCTGGTGGCCGTGTGCACCGTGCACGCCGGCGC
GCGCGAGGAGGTGGTGATGGTGCCCTTCCCGGTGACCGTGTACGACGAGG
ACGACTCGGCGCCCACCTTCCCCGCGGGCGTCGACACCGCCAGCGCCGT
GGTGGAGTTCAAGCGGAAGGAGGACACCGTGGTGGCCACGCTGCGTGTCT
TCGATGCAGACGTGGTACCTGCATCAGGGGAGCTGGTGAGGCGGTACACA
AGCACGCTGCTCCCCGGGGACACCTGGGCCCAGCAGACCTTCCGGGTGGA
ACACTGGCCCAACGAGACCTCGGTCCAGGCCAACGGCAGCTTCGTGCGGG
CGACCGTACATGACTATAGGCTGGTTCTCAACCGGAACCTCTCCATCTCGG
AGAACCGCACCATGCAGCTGGCGGTGCTGGTCAATGACTCAGACTTCCAG
GGCCCAGGAGCGGGCGTCCTCTTGCTCCACTTCAACGTGTCGGTGCTGCC
GGTCAGCCTGCACCTGCCCAGTACCTACTCCCTCTCCGTGAGCAGGAGGG
CTCGCCGATTTGCCCAGATCGGGAAAGTCTGTGTGGAAAACTGCCAGGCAT
TCAGTGGCATCAACGTCCAGTACAAGCTGCATTCCTCTGGTGCCAACTGCA
GCACGCTAGGGGTGGTCACCTCAGCCGAGGACACCTCGGGGATCCTGTTT
GTGAATGACACCAAGGCCCTGCGGCGGCCCAAGTGTGCCGAACTTCACTA
CATGGTGGTGGCCACCGACCAGCAGACCTCTAGGCAGGCCCAGGCCCAGC
TGCTTGTAACAGTGGAGGGGTCATATGTGGCCGAGGAGGCGGGCTGCCCC
CTGTCCTGTGCAGTCAGCAAGAGACGGCTGGAGTGTGAGGAGTGTGGCGG
CCTGGGCTCCCCAACAGGCAGGTGTGAGTGGAGGCAAGGAGATGGCAAAG
GGATCACCAGGAACTTCTCCACCTGCTCTCCCAGCACCAAGACCTGCCCCG
ACGGCCACTGCGATGTTGTGGAGACCCAAGACATCAACATTTGCCCTCAGG
ACTGCCTCCGGGGCAGCATTGTTGGGGGACACGAGCCTGGGGAGCCCCG
GGGGATTAAAGCTGGCTATGGCACCTGCAACTGCTTCCCTGAGGAGGAGAA
GTGCTTCTGCGAGCCCGAAGACATCCAGGATCCACTGTGCGACGAGCTGT
  
 
   
248 
GCCGCACGGTGATCGCAGCCGCTGTCCTCTTCTCCTTCATCGTCTCGGTGC
TGCTGTCTGCCTTCTGCATCCACTGCTACCACAAGTTTGCCCACAAGCCACC
CATCTCCTCAGCTGAGATGACCTTCCGGAGGCCCGCCCAGGCCTTCCCGG
TCAGCTACTCCTCTTCCAGTGCCCGCCGGCCCTCGCTGGACTCCATGGAGA
ACCAGGTCTCCGTGGATGCCTTCAAGATCCTGGAGGATCCAAAGTGGGAAT
TCCCTCGGAAGAACTTGGTTCTTGGAAAAACTCTAGGAGAAGGCGAATTTG
GAAAAGTGGTCAAGGCAACGGCCTTCCATCTGAAAGGCAGAGCAGGGTAC
ACCACGGTGGCCGTGAAGATGCTGAAAGAGAACGCCTCCCCGAGTGAGCT
TCGAGACCTGCTGTCAGAGTTCAACGTCCTGAAGCAGGTCAACCACCCACA
TGTCATCAAATTGTATGGGGCCTGCAGCCAGGATGGCCCGCTCCTCCTCAT
CGTGGAGTACGCCAAATACGGCTCCCTGCGGGGCTTCCTCCGCGAGAGCC
GCAAAGTGGGGCCTGGCTACCTGGGCAGTGGAGGCAGCCGCAACTCCAGC
TCCCTGGACCACCCGGATGAGCGGGCCCTCACCATGGGCGACCTCATCTC
ATTTGCCTGGCAGATCTCACAGGGGATGCAGTATCTGGCCGAGATGAAGCT
CGTTCATCGGGACTTGGCAGCCAGAAACATCCTGGTAGCTGAGGGGCGGA
AGATGAAGATTTCGGATTTCGGCTTGTCCCGAGATGTTTATGAAGAGGATTC
GTACGTGAAGAGGAGCCAGGGTCGGATTCCAGTTAAATGGATGGCAATTGA
ATCCCTTTTTGATCATATCTACACCACGCAAAGTGATGTATGGTCTTTTGGTG
TCCTGCTGTGGGAGATCGTGACCCTAGGGGGAAACCCCTATCCTGGGATTC
CTCCTGAGCGGCTCTTCAACCTTCTGAAGACCGGCCACCGGATGGAGAGG
CCAGACAACTGCAGCGAGGAGATGTACTGCCTGATGCTGCAATGCTGGAAG
CAGGAGCCGGACAAAAGGCCGGTGTTTGCGGACATCAGCAAAGACCTGGA
GAAGATGATGGTTAAGAGGAGAGACTACTTGGACCTTGCGGCGTCCACTCC
ATCTGACTCCCTGATTTATGACGACGGCCTCTCAGAGGAGGAGACACCGCT
GGTGGACTGTAATAATGCCCCCCTCCCTCGAGCCCTCCCTTCCACATGGAT
TGAAAACAAACTCTATGGTAGAATTTCCCATGCATTTACTAGATTCTCTAGAG
GAGTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCAAG
CGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAA
GAAAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGC
AAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGT
GGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCAC
TGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGA
GCTTCTAAAACTGGAAACTAGTTATCCGTACGACGTACCAGACTACGCATAA 
 
GFRα3-RET(TM/KD)-FKBP Variant A 
ATGGCTTGTGGAGGGCTCTCCTGGAGCCCGCGACCTCCACTGCTGATGATC
CTGCTACTGGTGCTGTCGTTGTGGCTGCCACTTGGAGCAGGAAACTCCCTT
GCCACAGAGAACAGGTTTGTGAACAGCTGTACCCAGGCCAGAAAGAAATGC
GAGGCTAATCCCGCTTGCAAGGCTGCCTACCAGCACCTGGGCTCCTGCAC
CTCCAGTTTAAGCAGGCCGCTGCCCTTAGAGGAGTCTGCCATGTCTGCAGA
CTGCCTAGAGGCAGCAGAACAACTCAGGAACAGCTCTCTGATAGACTGCAG
GTGCCATCGGCGCATGAAGCACCAAGCTACCTGTCTGGACATTTATTGGAC
CGTTCACCCTGCCCGAAGCCTTGGTGACTACGAGTTGGATGTCTCACCCTA
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TGAAGACACAGTGACCAGCAAACCCTGGAAAATGAATCTTAGCAAGTTGAA
CATGCTCAAACCAGACTCGGACCTCTGCCTCAAATTTGCTATGCTGTGTACT
CTTCACGACAAGTGTGACCGCCTGCGCAAGGCCTACGGGGAGGCATGCTC
AGGGATCCGCTGCCAGCGCCACCTCTGCCTAGCCCAGCTGCGCTCCTTCTT
TGAGAAGGCAGCAGAGTCCCACGCTCAGGGTCTGCTGCTGTGTCCCTGTG
CACCAGAAGATGCGGGCTGTGGGGAGAGGCGGCGTAACACCATCGCCCCC
AGTTGCGCCCTGCCTTCTGTAACCCCCAATTGCCTGGATCTGCGGAGCTTC
TGCCGTGCGGACCCTTTGTGCAGATCACGCCTGATGGACTTCCAGACCCAC
TGTCATCCTATGGACATCCTTGGGACTTGTGCAACTGAGCAGTCCAGATGTC
TGCGGGCATACCTGGGGCTGATTGGGACTGCCATGACCCCAAACTTCATCA
GCAAGGTCAACACTACTGTTGCCTTAAGCTGCTCCTGCCGAGGCAGCGGCA
ACCTACAGGACGAGTGTGAACAGCTGGAAAGGTCCTTCTCCCAGAACCCCT
GCCTCGTGGAGGCCATTGCAGCTAAGATGCGTTTCCACAGACAGCTCTTCT
CCCAGGACTGGGCAGACTCTACTTTTTCAGTGGTGCAGCAGCAGAACAGCT
CTAGAACGGTGATCGCAGCCGCTGTCCTCTTCTCCTTCATCGTCTCGGTGC
TGCTGTCTGCCTTCTGCATCCACTGCTACCACAAGTTTGCCCACAAGCCACC
CATCTCCTCAGCTGAGATGACCTTCCGGAGGCCCGCCCAGGCCTTCCCGG
TCAGCTACTCCTCTTCCAGTGCCCGCCGGCCCTCGCTGGACTCCATGGAGA
ACCAGGTCTCCGTGGATGCCTTCAAGATCCTGGAGGATCCAAAGTGGGAAT
TCCCTCGGAAGAACTTGGTTCTTGGAAAAACTCTAGGAGAAGGCGAATTTG
GAAAAGTGGTCAAGGCAACGGCCTTCCATCTGAAAGGCAGAGCAGGGTAC
ACCACGGTGGCCGTGAAGATGCTGAAAGAGAACGCCTCCCCGAGTGAGCT
TCGAGACCTGCTGTCAGAGTTCAACGTCCTGAAGCAGGTCAACCACCCACA
TGTCATCAAATTGTATGGGGCCTGCAGCCAGGATGGCCCGCTCCTCCTCAT
CGTGGAGTACGCCAAATACGGCTCCCTGCGGGGCTTCCTCCGCGAGAGCC
GCAAAGTGGGGCCTGGCTACCTGGGCAGTGGAGGCAGCCGCAACTCCAGC
TCCCTGGACCACCCGGATGAGCGGGCCCTCACCATGGGCGACCTCATCTC
ATTTGCCTGGCAGATCTCACAGGGGATGCAGTATCTGGCCGAGATGAAGCT
CGTTCATCGGGACTTGGCAGCCAGAAACATCCTGGTAGCTGAGGGGCGGA
AGATGAAGATTTCGGATTTCGGCTTGTCCCGAGATGTTTATGAAGAGGATTC
GTACGTGAAGAGGAGCCAGGGTCGGATTCCAGTTAAATGGATGGCAATTGA
ATCCCTTTTTGATCATATCTACACCACGCAAAGTGATGTATGGTCTTTTGGTG
TCCTGCTGTGGGAGATCGTGACCCTAGGGGGAAACCCCTATCCTGGGATTC
CTCCTGAGCGGCTCTTCAACCTTCTGAAGACCGGCCACCGGATGGAGAGG
CCAGACAACTGCAGCGAGGAGATGTACTGCCTGATGCTGCAATGCTGGAAG
CAGGAGCCGGACAAAAGGCCGGTGTTTGCGGACATCAGCAAAGACCTGGA
GAAGATGATGGTTAAGAGGAGAGACTACTTGGACCTTGCGGCGTCCACTCC
ATCTGACTCCCTGATTTATGACGACGGCCTCTCAGAGGAGGAGACACCGCT
GGTGGACTGTAATAATGCCCCCCTCCCTCGAGCCCTCCCTTCCACATGGAT
TGAAAACAAACTCTATGGTAGAATTTCCCATGCATTTACTAGATTCTCTAGAG
GAGTGCAGGTGGAGACTATCTCCCCAGGAGACGGGCGCACCTTCCCCAAG
CGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAA
GAAAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGC
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AAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGT
GGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCAC
TGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGA
GCTTCTAAAACTGGAAACTAGTTATCCGACCTTCCCCAAGCGCGGCCAGAC
CT 
Variants B, C, D, and E share the same sequence as Variant A, but have the 
following additional nucleotides positioned between the two AA nucleotides of 
Variant A highlighted in cyan: 
 
ATCCAGGATCCACTGTGCGACGAGCTGTGCCGC – Variant B 
CCACTGTGCGACGAGCTGTGCCGC – Variant C 
TGCGACGAGCTGTGCCGC - Variant D 
TCCGACGAGCTGTCCCGC – Variant E 
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Appendix 3. DynaFit scripts 
 
1. Global fitting of the mAb2 binding to the two-step kinetic binding 
mechanism from Figure 2.7. (See Chapter 2, Section 2.3.3) 
 
[task] 
task = fit  
data = progress 
 
[mechanism] 
M + R <-> MR :  k1 k2            
MR + R <-> MRR : k3 k4           
 
[constants] 
k1 = 0.00316 ? 
k2 = 18 * k1  
k3 = 1000 ? 
k4 = 1 * k2  
 
[concentrations] 
R = 0.01 
 
[responses] 
MR = 10000 ? 
MRR = 20000 ? 
 
[data] 
variable time 
directory ./Ret/mAb2_10_60_binding/ 
file 0nM.txt | concentration M = 0                   
file 0.015nM.txt | concentration M = 0.015 
file 0.046nM.txt | concentration M = 0.046 
file 0.137nM.txt | concentration M = 0.137 
file 0.41nM.txt | concentration M = 0.41 
file 1.23nM.txt | concentration M = 1.23 
file 3.7nM.txt | concentration M = 3.7 
file 11.1nM.txt | concentration M = 11.1 
file 33.3nM.txt | concentration M = 33.3 
file 100nM.txt | concentration M = 100 
file 300nM.txt | concentration M = 300 
[output] 
   directory ./mAb_Time-course 
[end]  
M = mAb2 
R = RET 
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2. Simulations of the time-course for total mAb2 binding (monovalent and 
bivalent) (See Chapter 2, Section 2.3.3) 
 
[task] 
task = simulate  
data = progress 
 
[mechanism] 
M + R <-> MR :  k1 k2 
M + MR <-> MRR : k3 k4 
 
[constants] 
k1 = 0.07 
k2 = 18 * k1 
k3 = 290000 
k4 = 1 * k2 
 
[concentrations] 
R = 0.01 
M = 300 
 
[responses] 
MRR = 20000 
MR = 10000 
 
[data] 
variable time 
mesh from 1 to 60 step 1 
directory ./mAb_Simulations 
file 1.txt  
   
[output] 
   directory ./mAb_Simulations 
[end] 
  
Using the same script, and changing 
the concentration of mAb2 (M), we 
performed the same simulations for a 
[mAb2] in the range between 0.046 and 
7.29 x 104 nM 
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3. Simulations of the time-course for bivalent binding of mAb2 (See 
Chapter 2, Section 2.3.3) 
 
[task] 
task = simulate  
data = progress 
 
[mechanism] 
M + R <-> MR :  k1 k2 
M + MR <-> MRR : k3 k4 
 
[constants] 
k1 = 0.07 
k2 = 18 * k1 
k3 = 290000 
k4 = 1 * k2 
 
[concentrations] 
R = 0.01 
M = 300 
 
[responses] 
MRR = 20000 
 
[data] 
variable time 
mesh from 1 to 60 step 1 
directory ./mAb_Simulations 
file 1.txt  
   
[output] 
   directory ./mAb_Simulations 
[end] 
  
Using the same script, and changing 
the concentration of mAb2 (M), we 
performed the same simulations for a 
[mAb2] in the range between 0.046 and 
7.29 x 104 nM 
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4. Simulations of the time-course for monovalently bound mAb2 (See 
Chapter 2, Section 2.3.3) 
 
[task] 
task = simulate  
data = progress 
 
[mechanism] 
M + R <-> MR :  k1 k2 
M + MR <-> MRR : k3 k4 
 
[constants] 
k1 = 0.07 
k2 = 18 * k1 
k3 = 290000 
k4 = 1 * k2 
 
[concentrations] 
R = 0.01 
M = 300 
 
[responses] 
MR = 10000 
 
[data] 
variable time 
mesh from 1 to 60 step 1 
directory ./mAb_Simulations 
file 1.txt  
   
[output] 
   directory ./mAb_Simulations 
[end] 
  
Using the same script, and changing 
the concentration of mAb2 (M), we 
performed the same simulations for a 
[mAb2] in the range between 0.046 and 
7.29 x 104 nM 
M = mAb2 
R = RET 
  
 
   
255 
5. Simulations of the ART dose-response for RET activation at varying 
expression levels of RET (See Chapter 3, Section 3.3.1) 
 
[task] 
task = simulate     
data = equilibria  
  
[mechanism] 
L + G <-> LG : K1 diss 
LG + R <-> LGR : K2 diss 
LGR + L <-> LGRL : K3 diss 
LGRL + R <-> LGRLR : K4 diss 
 
[constants]  
K1 = 417 
K2 = 0.015 
K3 = 0.1 
K4 = 0.00022 
 
[concentrations] 
L = 0.2 
 
[responses] 
LGRLR = 58000 
[data] 
variable G 
plot logarithmic 
mesh  from 0.001 to 100 step 0.1 
directory ./simulationoutput/07281015/RETSYS 
 
file  0.0256RET.txt |concentration R = 0.0256  
file  0.017RET.txt |concentration R = 0.017   
file  0.0114RET.txt |concentration R = 0.01138  
file  0.00759RET.txt |concentration R = 0.00759   
file  0.00506RET.txt |concentration R = 0.00506  
file  0.00338RET.txt |concentration R = 0.00338  
file  0.00225RET.txt |concentration R = 0.00225 
file  0.0015RET.txt |concentration R = 0.0015 
file  0.001RET.txt |concentration R = 0.001 
 
[output] 
   directory ./simulationoutput/07282015/RETSYS 
[end]  
G = ART 
L = GFRα3 
R = RET 
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6. Simulations of the ART dose-response for RET activation at varying 
expression levels of GFRα3 (See Chapter 3, Section 3.3.1) 
 
[task] 
task = simulate     
data = equilibria  
  
[mechanism] 
L + G <-> LG : K1 diss 
LG + R <-> LGR : K2 diss 
LGR + L <-> LGRL : K3 diss 
LGRL + R <-> LGRLR : K4 diss 
 
[constants]  
K1 = 417 
K2 = 0.015 
K3 = 0.1 
K4 = 0.00022 
 
[concentrations] 
R = 0.02 
 
[responses] 
LGRLR = 58000 
[data] 
variable G 
plot logarithmic 
mesh  from 0.001 to 100 step 0.1 
directory ./simulationoutput/07281015/RETSYS 
 
file 1.txt | concentration L = 0.9 
file 2.txt | concentration L = 0.3 
file 3.txt | concentration L = 0.1 
file 4.txt | concentration L = 0.033 
file 5.txt | concentration L = 0.011 
file 6.txt | concentration L = 0.0037    
 
[output] 
directory ./simulationoutput/07282015/RETSYS 
 
[end] 
  
G = ART 
L = GFRα3 
R = RET 
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7. Global fitting of the simulated RET response to varying expression levels 
of RET, obtained with the native RET activation mechanism, to a 
hypothetical homodimeric receptor activation mechanism (See Chapter 3, 
Section 3.3.2) 
 
[task] 
task = fit     
data = equilibria 
   
[mechanism] 
G + R <-> GR : K1 diss           
GR + R <-> RGR : K2 diss 
 
[constants] 
K1 = 16 ? 
K2 = 0.00022 ? 
 
[responses] 
RGR = 58000 
 
[data] 
plot logarithmic 
variable G 
directory ./Ret/RETsim_VaryRET/ 
     
file  0.0256RET.txt |concentration R = 0.0256  
file  0.017RET.txt |concentration R = 0.017   
file  0.0114RET.txt |concentration R = 0.01138  
file  0.00759RET.txt |concentration R = 0.00759   
file  0.00506RET.txt |concentration R = 0.00506  
file  0.00338RET.txt |concentration R = 0.00338  
file  0.00225RET.txt |concentration R = 0.00225 
file  0.0015RET.txt |concentration R = 0.0015 
file  0.001RET.txt |concentration R = 0.001 
 
[output]  ./output/07222015 
[end] 
  
G = ART 
R = RET 
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8. Global fitting of the simulated RET response to varying expression levels 
of GFRα3, obtained with the native RET activation mechanism, to a 
hypothetical homodimeric receptor activation mechanism (See Chapter 3, 
Section 3.3.2) 
 
[task] 
task = fit     
data = equilibria 
   
[mechanism] 
G + R <-> GR : K1 diss           
GR + R <-> RGR : K2 diss 
 
[constants] 
K1 = 16 ? 
K2 = 0.00022 ? 
 
[responses] 
RGR = 58000 
 
[data] 
plot logarithmic 
variable G 
directory ./Ret/RETsim_VaryL_evenly/ 
     
file  0.9L.txt | R = 0.9 ? 
file  0.3L.txt | R = 0.3 ?  
file  0.1L.txt | R = 0.1 ? 
file  0.033L.txt  | R = 0.033 ? 
file  0.011L.txt | R = 0.011 ? 
file  0.0037L.txt  | R = 0.0037 ? 
 
[output]  ./output/07222015 
[end] 
  
G = ART 
R = RET 
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9. Global fit of the simulated RET response for the native activation 
pathway to a mechanism of pre-associated GFRα3 (See Chapter 3, Section 
3.3.4) 
 
[task] 
task = fit     
data = equilibria   
[mechanism] 
 
LL + G <=> LLG : K1 diss 
LLG + R <=> LLGR : K2 diss 
LLGR + R <=> LLGRR : K3 diss 
 
[constants] 
K1 = 6 ?  
K2 = 0.015 ? 
K3 = 0.00022  
 
[concentrations] 
LL = 0.1 
 
[responses] 
LLGRR = 58000  
 
[data] 
plot logarithmic 
variable G 
   directory ./Ret/RET_1.5_fold/ 
      
file  0.0256RET.txt |concentration R = 0.0256  
file  0.017RET.txt |concentration R = 0.017   
file  0.0114RET.txt |concentration R = 0.01138  
file  0.00759RET.txt |concentration R = 0.00759   
file  0.00506RET.txt |concentration R = 0.00506  
file  0.00338RET.txt |concentration R = 0.00338  
file  0.00225RET.txt |concentration R = 0.00225 
file  0.0015RET.txt |concentration R = 0.0015 
file  0.001RET.txt |concentration R = 0.001 
 
[output]  ./output/07222015 
[end] 
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10. Global fit of the simulated RET response for the native activation 
pathway to a mechanism involving pre-associated RET (See Chapter 3, 
Section 3.3.4) 
 
[task] 
task = fit     
data = equilibria 
   
[mechanism] 
L + G <=> LG : K1 diss 
LG + RR <=> LGRR : K2 diss 
LGRR + L <=> LLGRR : K3 diss 
 
[constants] 
K1 = 417    
K2 = 0.015 ? 
K3 = 0.00022 ? 
 
[concentrations] 
L = 0.2  
 
[responses] 
LLGRR = 58000  
 
[data] 
plot logarithmic 
variable G 
directory ./Ret/RLR_FIT_RET_1.5/ 
 
file  0.0256RET.txt |concentration RR = 0.0128  
file  0.017RET.txt |concentration RR = 0.00853   
file  0.0114RET.txt |concentration RR = 0.00569  
file  0.00759RET.txt |concentration RR = 0.00379   
file  0.00506RET.txt |concentration RR = 0.00253  
file  0.00338RET.txt |concentration RR = 0.00169 
file  0.00225RET.txt | concentration RR = 0.00112  
  
[output]  ./output/07222015 
[end] 
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